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1 Abstract 
Prevalence of mutations and deregulated gene expression has resulted in a wide variety of 
tumor antigens which can be targeted for immunotherapy. NY-BR-1 is a breast cancer 
associated differentiation antigen which is overexpressed in more than 60% of breast 
cancers. In this study we established the first NY-BR-1 expressing transplantable tumor 
model using the murine mammary adenocarcinoma cell line EO771 as parental cells  for the 
generation of NY-BR-1-expressing transfectants (EONY cells) which are compatible for 
transplantation into HLA-DRB1*0401tg mice. Since NY-BR-1 is not endogenously expressed 
in these mice, transplantation of NY-BR-1 expressing tumors led to the induction of CD4+ and 
CD8+ T cells specific for HLA-DR*0401- and H2-Db-restcried NY-BR-1 epitopes, respectively, 
previously identified in our lab. We also generated MHC I knockout cell lines with the aim of 
using them to study NK cell responses or as parental lines for transection of human MHC I 
molecules. Since several HLA-restricted NY-BR-1-specific T cell epitopes have been 
described, these cells could serve as an important tool to study the efficacy of using the 
epitopes as peptide vaccines and studying the synergistic effect of induced CD8+ and CD4+ T 
cells in HLA-transgenic mice co-expressing human MHC I and MHC II molecules. 
Additionally, we also confirmed that previously identified H2-Db-restrcited epitope was indeed 
naturally processed based on detection of CD8+ T cells which specifically recognized this 
epitope in mice following transplantation of NY-BR-1 expressing tumors or upon 
immunization with global NY-BR-1 antigen. We also observed that immunization with Ad.NY-
BR-1 was more suitable for generating a NY-BR-1 specific CD8+ T cell line compared to 
immunization with nonameric peptide. We also obtained evidence suggesting that the H2-Db-
restricted CTL epitope might actually be identical to the core sequence of one of the 
previously identified HLA-DRB1*0301-restricted CD4
+
 T cell epitopes. Thus binding of the 
CTL epitope to HLA-DRB1*0301 molecules on feeder cells might have resulted in 
predominant restimulation of HLA-DR3B1*0401-restricted CD4+ T cells in vitro. Cancer 
immunotherapy involving T cells have focused primarily on cytotoxic CD8+ T cells. However, 
a body of evidence has emerged in the recent past that argues for including CD4
+
 T cells 
because they not only eliminate tumor cells directly but also greatly enhance the outcome of 
cancer immunotherapy by various ways. One of the mechanisms by which CD4+ T cells can 
contribute to successful immunotherapy is by repolarizing tumor associated macrophages 
(TAMs) into a less immunosuppressive phenotype in an antigen dependent fashion. In this 
study we could demonstrate that NY-BR-1 specific CD4+ T cells could repolarize M2-like 
macrophages towards an M1-like phenotype upon antigen specific interaction. However, the 
majority of the CD4+ T cells infiltrating the EONY tumors appeared to have tumor promoting 
functions as depletion of CD4+ T cells resulted in delayed tumor growth and was 
accompanied by switch in the polarization status of TAMs towards an  
M-1like phenotype. Though Ad.NY-BR-1 immunization resulted in induction of NY-BR-1 
specific CD4+ T cells and slight changes in polarization of intra-tumoral macrophages; it did 
not seem to drastically change the proportion of tumor-promoting CD4+ T cells in the tumor 
since the protective effect and switch in TAM phenotype was observed in both control virus 
and Ad.NY-BR-1 immunized mice. Therefore, antigen-specific instruction of TAMs by NY-
BR-1-specific CD4+ T cells could not be demonstrated in vivo, possibly due to the prevalence 
of tumor infiltrating CD4+ T cells with a tumor promoting phenotype occurring in the 
EO771/NY-BR-1 model established within this thesis. 
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2 Zusammenfassung 
Häufig auftretende Mutationen sowie eine deregulierte Genexpression haben zur Entstehung 
einer Vielzahl von Tumorantigenen geführt, die als Zielstrukturen in der Immuntherapie 
eingesetzt werden können. NY-BR-1 stellt ein Brustkrebs-assoziiertes 
Differenzierungsantigen dar, das in über 60% aller Brusttumoren über-exprimiert wird. Unter 
Verwendung der murinen Mammakarzinomlinie EO771 als parentale Zelllinie für die 
Herstellung NY-BR-1-exprmierender Transfektanten (EONY) sowie des HLA-DRB1*0401 
transgenen Mausstammes, konnte in der vorliegenden Arbeit erstmals ein transplantierbares 
NY-BR-1exprimierendes Tumormodell etabliert werden. Da NY-BR-1 in diesen Tieren nicht 
endogen exprimiert wird, führte die Transplantation von NY-BR-1-exprimierenden 
Tumorzellen zur Induktion von CD8+ und CD4+ T Zellantworten gegen HLA-DR4- bzw. H2-Db 
restringierte T-Zellepitope, die bereits in früheren Studien unseres Labors identifiziert worden 
waren. Darüber hinaus wurden MHC I knock out Zelllinien hergestellt, die für die 
Untersuchung von NK- Zellantworten oder als parentale Ausgangslinien für die Etablierung 
von HLA-exprimierenden Transfektanten verwendet werden können. Nachdem mehrere 
HLA-restringierte, NY-BR-1-spezifische T Zellepitope beschrieben worden sind, könnten 
diese MHC I knock out Zelllinien als wichtiges Werkzeug dienen, um die Effizienz dieser 
Epitope als Peptid basierte Vakzine zu prüfen und dabei den synergistischen Effekt der CD8+ 
und CD4+ T Zellen in HLA-transgenen Mäusen zu untersuchen. Darüber hinaus konnte 
bestätigt werden, dass es sich bei dem bereits früher identifizierten H2-Db-restringierten CTL 
Epitop tatsächlich um ein natürliches Prozessierungsprodukt handelt, da CD8+ T Zellen mit 
einer spezifischen Reaktivität gegen dieses Epitop nur in Mäusen detektiert wurden, die mit 
NY-BR-1 exprimierenden Tumoren transplantiert oder mit globalem NY-BR-1 Antigen 
immunisiert worden waren. Wir konnten außerdem zeigen, dass sich die Immunisierung mit 
Ad.NY-BR-1, im Vergleich zur Immunisierung mit dem nonameren Peptid, besser für die 
Generierung einer NY-BR-1-spezifischen CD8+ T Zelllinie eignet. Darüber hinaus deuten 
unsere Ergebnisse darauf hin, dass das H2-Db-restringierte CTL Epitop identisch mit der 
Kernsequenz eines bereits zuvor identifizierten HLA-DRB1*0301- restringierten CD4
+
 T 
Zellepitops ist, und die Bindung des CTL Epitopes an HLA-DRB1*0301 Moleküle auf den 
Feederzellen zu einer bevorzugten Restimulierung von HLA-DRB1*0301-restringierten CD4+ 
T-Zellen in vitro führen kann. Immuntherapeutische Verfahren zur Krebsbehandlung, die T 
Zellen beinhalten, fokussierten sich bisher in erster Linie auf CD8+ T Zellen. Inzwischen 
häufen sich jedoch Hinweise, die für eine Miteinbeziehung von CD4+ Zellen sprechen, da 
diese Zellen nicht nur in der Lage sind, Tumorzellen direkt zu eliminieren, sondern den Erfolg 
einer Tumortherapie auf verschiedene Art und Weise verbessern können. Ein Mechanismus 
über den CD4+ T Zellen zu einer erfolgreichen Immuntherapie beitragen können, besteht in 
einer Antigen-abhängigen Re-Polarisierung von Tumor-assoziierten Makrophagen (TAMs) in 
Richtung eines weniger immunsuppressiven Phänotyps. In der vorliegenden Arbeit konnten 
wir zeigen, dass NY-BR-1-spezifische CD4+ T Zellen mittels Antigen-spezifischer 
Stimulierung in der Lage sind, M2-artige Makrophagen in Richtung eines M1-Phänotyps zu 
re-polarisieren. Allerdings schien die Mehrzahl der EONY-Tumor infiltrierenden CD4+ T 
Zellen einen Tumor-fördernden Effekt aufzuweisen, da die Depletion der CD4+ T Zellen zu 
einer Verzögerung des Tumorwachstums führte und von einem Wechsel des 
Polarisierungsstatus der TAMs in Richtung eines M1-artigen Phänotyps begleitet wurde. 
Obwohl die Immunisierung mit Ad.NY-BR-1 zu einer Induktion NY-BR-1-spezifischer CD4+ T-
Zellen führte und leichte Veränderungen in der Polarisierung intratumoraler Makrophagen 
auslöste, schien sie sich auf den Anteil Tumor-fördernder CD4+ T-Zellen im Tumor kaum 
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auszuwirken, da der protektive Effekt und der Wechsel des TAM Phänotyps sowohl in den 
Kontrolltieren als auch in Mäusen, die mit Ad.NY-BR-1 immunisiert worden waren 
beobachtet wurde. Somit konnte die Antigen-spezifische Instruktion von TAMs durch NY-BR-
1-spezifische CD4+ T Zellen in vivo nicht gezeigt werden - möglicherweise aufgrund des 
hohen intratumoralen Anteils von Tumor fördernden CD4+ T Zellen, der sich in dem NY-BR-1 
exprimierenden Tumormodell, das im Rahmen dieser Arbeit etabliert wurde, bildet. 
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3 Introduction 
3.1 Cancer 
Cancer is defined as a collection of many diseases that are characterized by uncontrolled 
proliferation of aberrant cells. Cancer cells arise due to alterations at the genetic level (i.e. 
mutations, translocations etc.) or at the epigenetic level both of which result in deregulated 
cell growth. These abnormal cells compete for nutrients and outgrow healthy cells causing 
fatal organ failures. Cancer cells can arise from any tissue and based on the tissue of origin 
they are classified into four main categories viz. carcinomas, sarcomas, hematopoietic 
cancers and neuroectodermal tumors. Carcinomas arise from cells of epithelial origin present 
in the skin, the gastrointestinal tract, mammary gland, pancreas, liver etc. Sarcomas on the 
other hand are cancers affecting mesenchymal cells like fibroblasts and connective tissues 
like bone, cartilage, fat, muscle and blood vessels. Hematopoietic cancers include leukemia, 
lymphomas and myelomas. Leukemia is characterized by rapidly proliferating immature white 
blood cells that are in the circulation whereas lymphoma results in solid tumors derived from 
cells of lymphoid origins like T and B lymphocytes. Conversely, myeloma is the cancer of 
plasma cells, another type of white blood cell which produces antibodies. Cancers arising in 
the brain, spinal cord and the peripheral nervous system are classified as neuroectodermal 
cancers and they include gliomas, glioblastomas, neuroblastomas etc. Irrespective of the 
tissue of origin all cancer cells are characterized by genetic instabilities and mutations(1). 
Mutations in cancer cells can be caused by a wide variety of mutagens which can be mainly 
categorized as physical, chemical or biological agents. Physical noxae like radiation (UV 
rays, X-rays, γ-rays etc.) and chemical agents like 3-methylcholanthrene, benzo[a]pyrene, 
dibenz[a,h]anthracene etc. can result in mutations in the DNA either by inducing DNA 
damage which cannot be effectively repaired or by intercalating into DNA. Biological agents 
like viruses can also result in the introduction of oncogenes that drive uncontrolled cell 
proliferation (1). Genetic instability can be caused due to errors at various steps of DNA 
replication or faulty DNA damage response (2). Besides mutations, other genetic alterations 
like gross chromosomal rearrangements including gene amplifications and translocations  
can result in either activation of oncogenes or inactivation of tumor suppressor genes(2). 
The cumulative effect of these mutations or gene alterations is that the growth of cancer cells 
is no longer regulated like that of normal cells. These cells have acquired increased 
proliferative capacity and show reduced cell death. This can be due to various reasons. The 
cancer cells can become independent of mitogenic signals either by producing their own 
growth factors or by stimulating their neighboring stromal cells to produce growth factors. 
They can also survive with low amounts of growth factors by upregulating their cognate 
receptors. Various signaling pathways rely on conformational changes of the signaling 
molecule to switch between active and inactive state. Some mutations in cancer cells give 
rise to an altered protein which cannot switch back to the inactive state thus resulting in the 
constitutive activation of the signaling pathway. Additionally, mutations of the receptors can 
lead to their activation independent of ligand binding. Cancer cells do not undergo apoptosis 
like normal cells in response to various stress factors. They can evade apoptosis by 
deregulating the balance between the pro-apoptotic and anti-apoptotic factors. Moreover, 
they can acquire endless replicative potential by upregulating telomerase which enables 
them to avoid telomere shortening that accompanies normal cell division.    
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The cancer cells not only proliferate endlessly but they can also alter the tumor 
microenvironment for their own benefit. As a tumor grows in size the available nutrients and 
oxygen become limiting. In order to circumvent this they can promote neo-angiogenesis by 
secreting factors like vascular endothelial growth factor (VEGF) or by recruiting macrophages 
which can do so as well. It is known that the immune system can eradicate aberrant cancer 
cells, however a growing tumor manages to escape being killed by the host immune system 
by various ways (discussed in more detail in Section 3.4). Several of the features described 
above and some others that enable cancer cells to proliferate in an unregulated way and 
develop into a tumor are summarized in Figure 1.  
 
Figure 1. Hallmarks of cancer 
Properties acquired by cancer cells which render them resistant to mechanisms that regulate normal 
cell growth thereby allowing them to proliferate indefinitely (Adapted from Hanahan and Weinberg, 
2011). 
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3.2  Breast cancer 
3.2.1 Incidence and mortality 
Out of 14.1 million new cancer cases reported in 2012 worldwide, 1.7 million cases of breast 
cancer were reported which constituted 11.9% of all diagnosed cancers for both sexes 
combined and 25.2% of diagnosed cancers in females alone. In 2012, 8.2 million lives were 
claimed by cancer among which breast cancer alone resulted in 522,000 (6.4%) deaths and 
was the leading cause of cancer related death in women (3).  
Figure 2 demonstrates that the incidence of breast cancer did not vary too much between 
more developed regions and less developed regions (794,000 vs 883,000), but mortality was 
markedly higher in less developed regions (198,000 vs 324,000) (3). This was due to the fact 
that patients in less developed regions were diagnosed at advanced stages of breast cancer 
owing to lack of effective screening programs and did not have access to advanced 
therapeutic options (4). This was also reflected in the five year net survival rates of 80% or 
higher in regions with high development like Europe and North America compared to 60% in 
India and 53% in South Africa (5).  
 
Figure 2. Incidence and mortality estimates in 2012 
The numbers (in thousands) of estimated new cases and deaths due to various types of cancer in 
women in more developed and less developed regions of the world (Figure from GLOBOCAN 2012, 
Global Cancer Facts & Figures 3rd Edition). 
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Unlike cancers caused by viruses like cervical cancer and liver cancer which are caused by 
human papillomavirus (HPV) and hepatitis C virus (HCV) respectively, breast cancer cannot 
be prevented by vaccinations. However, there are some known risk factors which can be 
addressed. For example, women with mutations in BRCA1 (breast cancer 1) and BRCA2 
(breast cancer 2) genes are genetically predisposed to develop breast cancer. It has been 
reported that for women carrying BRCA1 and BRCA2 mutations,  prophylactic mastectomy 
can reduce the risk of developing cancer drastically (by 90% or more) (5). Prolonged 
exposure to estrogen due to early menarche and late menopause and external source of 
estrogen like oral contraceptives and hormone replacement therapy are also known to be 
associated with higher risk of developing breast cancer while tamoxifen and raloxifene was 
shown to lower breast cancer incidence in breast cancer prevention trials (6, 7). Other risk 
factors like obesity (8), lack of physical activity (9) and excessive alcohol consumption (10) 
can be managed by lifestyle changes. 
3.2.2 Development and characterization of breast cancer 
Staging of breast cancer helps clinicians to determine tumor burden and metastatic spread. 
Breast cancer is usually staged using the TNM system according to the American Joint 
Committee on Cancer (AJCC). T stands for tumor and its category (TX, T0, Tis, T1, T2, T3 
and T4) is decided based on the size of the primary breast tumor and whether it has grown 
into the chest wall or skin. TX signifies primary tumor that cannot be assessed, whereas T0 
indicates no evidence of primary tumor. Tis represents carcinoma in situ, whereas T1 to T4 
denotes invasive tumor of increasing size, T1 representing tumors smaller than 2 cm and T4 
is used to report tumors of any size that are growing into the chest wall or skin. Similarly 
different scores are assigned to the N category which is used to denote whether cancer cells 
have spread to lymph nodes and how many lymph nodes have been affected. NX stands for 
regional lymph nodes cannot be assessed whereas N0 means that no cancer cells were 
detected in regional lymph nodes. N1 indicates presence of metastases in axillary lymph 
nodes, N2 signifies that cancer cells have spread to internal mammary lymph nodes or have 
caused axillary lymph nodes to become matted and N3 indicates that cancer has been 
detected in the internal mammary lymph nodes or infraclavicular lymph nodes along with the 
axillary lymph nodes or in the supraclavicular lymph nodes. The presence of distant 
metastasis is indicated by the M category in which MX represents that distant metastasis 
cannot be assessed, M0 means lack of distant metastasis and M1 indicates that metastasis 
has been detected in distant organs like brain, bones or lungs. The information from T, N and 
M scores are then combined to obtain the stage of the cancer which varies between Stage 0 
to Stage IV, Stage 0 being the earliest form of breast cancer with the best prognosis, 
whereas Stage IV indicating advanced metastatic disease with the worst prognosis (11, 12). 
Histological classification of breast cancer is mainly based on the origin of the cancer cells 
and the extent of invasion into surrounding tissue. It can be classified as carcinoma in situ or 
as invasive carcinoma depending on whether or not it has invaded the surrounding tissue. If 
the cancer cells originated in the ducts of the mammary gland then it is called ductal 
carcinoma in situ (DCIS), whereas if the origin of the tumor cells was in the milk-producing 
glands (lobules) then it is known as lobular carcinoma in situ (LCIS). Additionally, breast 
cancer can be classified based on the expression of hormone receptors like estrogen 
receptor (ER) and progesterone receptor (PR) or growth receptors like Her2/neu/ERBB2. 
The receptor status of the breast cancer has a high prognostic value as it predicts 
susceptibility of the tumor to hormone therapy. Breast cancers which do not express any of 
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the receptors mentioned above are classified as triple negative breast cancer (TNBC) and 
are associated with poor prognosis as they are not eligible for hormone therapy. 
In the year 2000, there was an important breakthrough in the classification of breast cancer 
when microarray derived gene expression data was used to define intrinsic molecular 
subtypes of breast cancer (13). The analysis of gene expression patterns of 1,753 genes in 
84 cDNA microarrays from 42 individuals and 17 cultured cell lines showed that each tumor 
had a distinct molecular signature and samples could be clustered according to similarities in 
the expression of various genes. This study, besides others that followed (13-17) resulted in 
the definition of the following molecular or intrinsic subtypes of breast cancer. The Luminal A 
subtype is characterized by high expression of Estrogen receptor (ER), whereas Luminal B 
tumors have low expression of ER and high expression of proliferation markers like Ki-67 
(13, 16, 17). Basal like- or triple negative tumors are characterized by lack of ER, PR, Her2 
expression and were positive for keratins like keratin 5/6, 5/14 and 17 (16, 17). Her2 
enriched tumors over-express Her2 but are negative for ER whereas normal breast like 
tumors were defined by the genes typically expressed by basal epithelial cells and adipose 
cells (16, 17). Another subtype called Claudin low was identified later (14, 15). The different 
molecular subtypes are summarized in figure 3, originally published by Malhotra et al, 2010 
(18).  
 
Figure 3. Molecular classification of breast cancer 
Molecular subtypes of breast cancer are classified based on the clustering analysis of microarray gene 
expression data obtained from patient tumors. This led to identification of associated genes which 
effectively define the different subtypes. (Adapted from Malhotra et al, 2010). 
 
The most significant advantage of this classification is that each molecular subtype had 
distinct clinical outcomes in terms of survival of patients with Luminal A subtype having the 
most favorable prognosis and Luminal B and normal breast like- having intermediate 
prognosis followed by Her2 enriched and basal like- which have the worst outcome for 
patient survival (14, 16, 17, 19). Additionally, the molecular subtypes could explain previously 
observed differences in the varied clinical outcomes for ER+ subtypes which could not be 
explained based on ER+ status alone (18). However, using microarray analysis routinely in 
the clinics is not economic, thus Parker et al defined a group of 50 genes termed PAM 50 
(Prediction Analysis of Microarray) which could be tested by qPCR and could effectively 
classify tumors into the relevant intrinsic molecular subtype (19). Another method that can be 
used in clinics easily and reliably is to use immunohistochemistry of ER, PR and HER2 and 
combine it with Ki-67 index to distinguish Luminal A and Luminal B subtypes (20) and ER, 
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HER1, HER2 and cytokeratin 5/6 to identify basal-like tumors (21). The stage and the 
molecular subtype of the breast cancer are very important in determining the treatment 
options which are discussed in the following section. 
3.2.3 Current therapies 
The treatment options for breast cancer include surgery, radiation, hormone therapy, 
chemotherapy, targeted therapies and immunotherapy or a combination of two or more of the 
aforementioned therapies. The decision is based on how advanced the breast cancer is, the 
size of the tumor and on whether it has metastasized into neighboring lymph nodes or to 
distant organs. Additional information that helps in the decision making process is whether 
the breast cancer is positive for estrogen receptor and the status of Her2 expression. The 
indications for various treatments according to the stage of the breast cancer are discussed 
below.  
Surgery is included in the treatment options for most women and in DCIS patients, effective 
surgical intervention results in survival of nearly 100% of patients (22). For tumors that have 
a pathologically clear margin, breast conserving surgery is an option which is becoming 
increasingly popular among women with advancement in surgical techniques including the 
use of laser assisted surgery or robot assisted surgery. On the other hand, for locally 
advanced large or diffuse tumors without a clear margin, radical mastectomy is used which 
involves the removal of the entire breast, pectoralis fascia and axillary lymph nodes (22). 
Some women may opt for prophylactic mastectomy of the other breast (known as 
contralateral mastectomy) as well, especially if BRCA mutations are detected. Additionally, 
radiation therapy is prescribed to patients when patients opt for breast conserving surgery in 
order to minimize the chance of recurrence or when cancer was found to have spread to 
sentinel lymph nodes. The chest wall is targeted for radiation after a mastectomy when no 
lymph nodes were detected to be positive. In case lymph nodes were positive for cancer 
cells, then areas where axillary and supraclavicular lymph nodes are located can be targeted 
as well (23). Neoadjuvant chemotherapy can also be used to reduce tumor burden before 
surgery in order to increase the prospects of better surgical outcome or to enable breast 
conserving surgery instead of mastectomy. For metastatic breast cancer, the treatment 
options are decided according to the scheme in Figure 4. 
.  
Figure 4. Schematic for deciding treatment of metastatic breast cancer 
The therapeutic options for patients with metastatic breast cancer are based on expression of ER and 
Her2. For ER+ tumors, menopausal status of the patients is also taken under consideration. Her2
+
 
patients receive Her2 targeting agents and chemotherapy is prescribed to triple negative breast cancer 
patients (Adapted from Santa-Maria and Gradishar, 2015). 
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For hormone receptor positive tumors, endocrine therapy is the first option. Luminal A 
subtype is best treated with tamoxifen. However, Luminal B tumors have a better response to 
tamoxifen in combination with chemotherapeutic agents like doxorubicin and 
cyclophosphamide as Luminal B subtype is characterized by low ER expression and high 
expression of proliferation genes like Ki-67 (24, 25). For premenopausal women, ovarian 
suppression may be required in addition to tamoxifen administration as ovaries are an 
important source of estrogen. In case tamoxifen is not tolerated, then ovarian function 
suppression alone or with aromatase inhibitor can be used. Aromatase inhibitors work by 
inhibiting the enzyme aromatase which is required for the conversion of androgens into 
estrogen, however it does not work on premenopausal women as it cannot suppress 
estrogen production by ovaries (26). A new study in 2015 showed that aromatase inhibitors 
like exemestane in combination with ovarian suppression had slightly improved disease 
outcome for pre-menopausal women who were at sufficient risk for recurrence (27). On the 
other hand, post-menopausal women benefit from tamoxifen alone or combined with 
aromatase inhibitors if too many lymph node metastases have been detected (25). 
Aromatase inhibitors like anastrozole, letrozole and exemestane have been shown to be 
superior to tamoxifen (28) and letrozole and anastrozole are increasingly used as first-line 
treatment in postmenopausal women (26). Fulvestrant was better than anastrolzole as a 
single agent as first line treatment of advanced breast cancer (29). Combining fulvestrant 
and anastrozole prolonged progression free survival compared to anastrozole alone in a 
study conducted in 2012 (30).  
However, ER+ and PR+ tumors can become resistant to endocrine therapies as they can 
develop mutations that allow them to proliferate independently of ER signaling. For example, 
aberrations in PI3K-Akt-mTOR signaling pathway can result in resistance to endocrine 
therapy (31). A phase 3 clinical trial reported that mTOR inhibitor everolimus combined with 
aromatase inhibitor exemestane increased the progression free survival in postmenopausal 
patients with advanced breast cancer which was hormone receptor positive (32). However 
combining pictilisib which is a PI3K inhibitor with fulvestrant (ER antagonist) was not better 
that fulvestrant alone (33). Combination of Palbociclib which is a small molecule inhibitor of 
cyclin-dependent kinases (CDKs) 4 and 6 with letrozole was found to be effective in 
comparison to letrozole alone (34). 
HER2 overexpression is correlated to aggressive breast cancer (35-37) with one of the worst 
prognosis which is only better than triple negative breast cancer (TNBC). Trastuzumab, 
which is a recombinant humanized monoclonal antibody binding the extracellular domain of 
HER2 is now standard of care treatment for HER2+ tumors. The most notable mechanism of 
action of trastuzumab is the inhibition of the MAPK and PI3K-Akt-mTOR signaling pathways 
which are downstream of HER2 by blocking HER2 dimerization (38). Trastuzumab can also 
work by causing HER2 to be internalized followed by its degradation (38). It can also mediate 
antibody-dependent cellular cytotoxicity (ADCC) by attracting immune cells like natural killer 
(NK) cells to the tumor site (38). The combination of trastuzumab with standard 
chemotherapeutic agents like anthracyclines and cyclophosphamide or paclitaxel has been 
shown to work better than chemotherapy (39) or trastuzumab alone (40). Following the 
success of trastuzumab, other targeted therapies for HER2+ breast cancer that have been 
developed are lapatinib (which is a tyrosine kinase inhibitor), pertuzumab (Anti-HER2 
monoclonal antibody) and trastuzumab-emtansine (trastuzumab conjugated to emtansine). 
Addition of pertuzumab improved the median overall survival of Her2+ patients by 15 months 
compared to trastuzumab and decotaxel alone (41). However, not all HER2+ patients 
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respond to these therapies and the majority of responders relapse quickly due to a variety of 
resistance mechanisms like loss of the antibody binding extracellular domain, overexpression 
of Mucin-4 which masks the antibody binding site, aberrant expression of HER3 which 
cannot be inhibited by trastuzumab, loss of PTEN resulting in constitutively active PI3K/Akt 
signaling to name a few (38). To overcome this, various combination therapies are being 
tested in clinical trials. Combining everolimus, trastuzumab and paclitaxel showed improved 
clinical outcome in patients with HER2+ advanced breast cancer resistant to trastuzumab and 
taxane treatment in phase 2 studies (42). Also, novel tyrosine kinase inhibitors that target 
additional isoforms of HER2 like afatinib (which targets HER1 and HER2) and neratinib 
(which is a pan HER-TKI) are being tested in clinical trials (43). 
TNBC is the most aggressive form of breast cancer and has the worst prognosis. The 
therapy most widely applied to TNBC patients is based on anthracyclines and taxanes in 
combination with an alkylating agent like cyclophosphamide (25). However, a phase 2 study 
in 2014 showed that for TNBC patients with non-metastatic disease, addition of carboplatin 
to the combination of paclitaxel and doxorubicin improved the likelihood of achieving 
pathological complete response (44). A lot of women with TNBC also carry germline BRCA 
mutations (45) which results in defective homologous recombination DNA repair which in turn 
drives carcinogenesis due to high mutational load. However, this makes cells susceptible to 
PARP inhibition as double strand breaks in the DNA cannot be repaired effectively leading to 
a halt in DNA replication (46). PARP inhibitor olaparib has been shown to have benefits for 
BRCA positive patients with different tumor types including breast cancer (46, 47). Another 
PARP inhibitor iniparib was tested in combination with gemcitabine and cisplatin for 
treatment of TNBC patients and was found to improve overall survival when used as second-
/third-line therapy (48). Combination of angiogenesis inhibitor bevacizumab with paclitaxel 
was found to increase progression free survival compared to paclitaxel alone in advanced 
metastatic breast cancer and subgroup analysis showed that this was true for TNBC as well 
(49).  
In summary, hormone receptor positive early stage breast cancer has the best prognosis , 
however, once it has metastasized; it is treated with a combination of endocrine therapy and 
chemotherapy. Also HER2+ tumors and TNBC are more aggressive and although 
chemotherapy is used as standard of care, survival rates still need to be improved. Thus, 
other treatment approaches like immune therapy are promising and should be investigated. 
Immunotherapy for breast cancer is described in section 3.4, following a brief description of 
the immune system and the role of anti-tumor immune response.  
3.3 Immune system and cancer 
3.3.1 Role of immune system 
The immune system has evolved as a way to defend us against foreign particles including 
pathogenic microorganisms and allergens. Thus, it is capable of discriminating between self- 
and nonself-antigens (e.g. derived from invading pathogens) including altered self-antigens 
(e.g. tumor cells carrying mutated antigens). It is comprised of innate and adaptive immune 
response. The innate immune response acts as the first line of defense against invading 
pathogens and is composed of the complement system and cells like neutrophils, 
macrophages and NK cells. The complement system consists of a family of plasma proteins 
which upon activation can opsonize bacteria for phagocytosis or result in the formation of 
transmembrane pores causing them to lyse. Neutrophils and macrophages can phagocytose 
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pathogens, whereas NK cells can kill antibody coated cells. Components of the innate 
immune system can recognize pathogens based on glycoproteins selectively expressed by 
the pathogen. For example, the complement system is activated by carbohydrate containing 
mannose residues. Innate immune cells, on the other hand, are activated when their pattern 
recognition receptors (PRRs) recognize pathogen associated molecular patterns (PAMPs) 
like lipopolysaccharide (LPS) or double stranded RNA (50, 51).  
Conversely, the adaptive immune system is comprised of precursor cells with certain 
specificities which are activated upon encountering their cognate antigen. Upon activation 
they undergo clonal expansion to develop into effector cells, some of which persist as 
memory cells. The memory cells form the basis of immunological memory and provide long-
lasting immunity against pathogens. Since the specific effector cells require approximately a 
week to develop after the first exposure to a particular antigen, adaptive immune response 
takes longer than innate immune response to clear the pathogen. However, in the case of 
subsequent exposure to the same antigen, there is a rapid activation and proliferation of 
memory cells resulting in an accelerated pathogen clearance. The adaptive immune system 
is comprised of B and T cells both of which have antigen receptors which confer specificity 
for different pathogenic antigens. For example, T cell receptors (TCRs) are heterodimers 
composed of either combination of α/β chains or of γ/δ chains. There are multiple genes for 
each segment of the chain designated as follows: variable (V), diversity (D), joining (J) and 
constant (C). For instance, the α chain locus of the TCR has 70-80 Vα and 61 Jα genes 
followed by the constant gene, whereas the β chain locus is comprised of 52 Vβ, 2 Dβ, 13 Jβ 
and 2 constant genes (50). The genes undergo somatic rearrangement to give rise to 
numerous α and β chains which dimerize to yield a wide range of TCRs, each with a different 
specificity. For instance, in humans 25 α chains and 106 β chains have been identified which 
can pair to give rise to 25x106 clonotypes (52). Antigen receptors of B cells and γ/δ T cells 
are generated by a similar rearrangement process.  
B cells can secrete antibodies specific against foreign antigens which can opsonize 
pathogens and facilitate their phagocytosis or mediate antibody-dependent cell-mediated 
cytotoxicity (ADCC). T cells are classified into 2 major types: CD8+ cytotoxic T lymphocytes 
(CTLs) and CD4+ T helper (Th) cells. CTLs can kill target cells infected with intracellular 
pathogens by secreting perforins or granzyme B resulting in apoptosis of the recognized cell 
(53). Additionally, CD95L expressing CTLs can trigger apoptosis of CD95 positive target cells 
or kill target cells via secretion of cytokines like IFNγ and TNFα (53). There are different 
subtypes of CD4+ T helper (Th) cells. Th1 cells provide immunological help for activation of 
CD8+ cytotoxic T cells and macrophages, thus playing an important role in the elimination of 
intracellular pathogens (54). Th2 cells activate IgE production by B cells, thereby helping in 
the elimination of extracellular parasites including helminthes (54). Th17 cells secrete IL-17 
crucial for defense against extracellular pathogens (54). There is another class of CD4+ T 
cells, called regulatory T cells (Tregs) which can dampen CD8+ and CD4+ T cell proliferation 
and responses in order to prevent auto immunity (54). 
T cells can recognize their cognate antigen only when the relevant antigenic peptide is 
presented on the major histocompatibility complex (MHC) molecule. TCRs on CD8+ T cells 
can interact with MHC I-peptide complex, whereas TCRs on CD4+ T cells can recognize 
peptides presented on MHC II molecule. Both, CD8 and CD4 molecule act as a co-receptors 
as depicted in Figure 5. The peptides that are displayed on MHC I are derived from self-
proteins or from intracellular pathogens like viruses, but MHC II molecules can present 
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peptides originating from extracellular proteins that have been taken up by endocytosis or 
pinocytosis. This is due to the fact that antigen processing machinery is different for MHC I 
and MHC II restricted T cell epitopes. Endogenous cytosolic proteins synthesized within the 
host cell including viral proteins are enzymatically cleaved by the proteasome into smaller 
peptides which are transported in the endoplasmic reticulum (ER) by transporters associated 
with antigen processing (TAP) proteins 1 and 2 (55). Inside the ER, the peptides can bind the 
MHC I molecule and then the loaded MHC molecule is trafficked to the cell surface (55). 
Peptides originating from endocytosed extracellular pathogens are loaded onto the MHC II in 
endocytic vesicles called MHC class II compartment (MIIC) (55). However, certain subsets of 
DCs and macrophages can present exogenous antigens on MHC I context, the phenomenon 
is known as cross-presentation (56). Additionally autophagosomes can supply cytoplasmic 
antigens to the MHC II antigen loading pathway resulting in presentation of endogenous 
antigens on the MHC II molecule of both professional and non-professional APCs which can 
present cytosolic antigens on MHC II (57, 58). MHC I is expressed on all nucleated cells 
whereas MHC II is expressed mostly on professional antigen presenting cells (APCs) like 
dendritic cells (DCs) and macrophages. However, IFNγ can stimulate other cell types like 
endothelial cells, fibroblasts, epithelial cells and tumor cells to upregulate MHC II and they 
can act as non-professional APCs (58). 
 
Figure 5. Interaction of TCR with respective MHC-peptide complex 
The TCR on CD8
+
 T cells can recognize peptides presented on MHC class I molecules whereas the 
CD4
+
 T cells interact with antigen presenting cells via their TCRs which bind peptide-MHC class II 
complex (Figure from Immunobiology, 5
th
 Edition 2001).  
 
MHC molecules are encoded by the MHC complex and they are highly polymorphic. The 
MHC I molecule is composed of an α chain and a β2-microglobulin (β2m) whereas the MHC II 
molecule is a heterodimer of an α and a β chain (figure 5) (50). In humans, the MHC I α 
chain is encoded by the human leukocyte antigen (HLA) -A, -B and –C genes and the loci 
within the HLA complex encoding the α and the β chains of the MHC II molecules are 
designated as HLA-DR, -DP and DQ (50).  
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Due to its high degree of polymorphism, huge numbers of MHC I and MHC II allotypes are 
expressed within a population where each allotype displays an allele-specific peptide binding 
groove. Thus, only peptides with a given allele-specific binding pattern can bind to a given 
allotype and are therefore presented as an HLA-restricted epitope to T cells expressing a 
cognate TCR. Additionally, the size of the peptide that can bind the peptide binding grooves 
varies between MHC I and MHC II due to their structural differences. For example, the 
peptide cleft of MHC II is open and can hold peptides of 12-25 amino acids (59), however the 
peptide binding groove of MHC I is fixed and can accommodate shorter peptides of 8-11 
amino acids (59, 60). The information about the presence of anchor residues within the 
epitope sequence required for stable binding and the length of peptide that can fit into the 
peptide binding groove enables the in silico prediction of possible epitopes derived from a 
particular protein (60-62). Once the predicted epitopes are validated in vitro, synthetic 
peptides can be used for developing peptide vaccines.  
3.3.2 Immune surveillance of cancer 
The concept of immunosurveillance of cancer is well accepted. The idea was initially 
postulated by Paul Ehrlich and further propagated by Burnet and Thomas (63). Various 
studies have demonstrated that immunodeficient mice are more prone to tumor development 
(both spontaneous and carcinogen induced) (64). The role of various types of immune cells 
in controlling tumor growth has been shown using genetically engineered mouse models 
which lack particular cell types (64).  
Since the immune system can not only control tumor growth but also modify the tumor, the 
idea of cancer immunosurveillance has evolved into that of cancer immunoediting which has 
three stages denoted by ―3 Es‖: elimination, equilibrium and escape. The first stage is called 
elimination, where transformed cells which can potentially give rise to tumors are eliminated 
by the immune system. The next stage is called equilibrium where tumor cells are maintained 
in a steady state where they are present but cannot grow. It has been demonstrated that 
MCA transformed tumor cells are held in check by components of adaptive immunity and 
their ablation results in tumor outgrowth (65). The third stage is called escape and is 
characterized by the spontaneous escape of immune edited and less immunogenic tumor 
cells from the state of equilibrium leading to progressive tumor growth (65). Tumors evolve in 
order to escape immune mediated destruction by reducing antigen presentation or 
developing resistance to apoptosis (63). Besides, developed tumors are distinguished by an 
immunosuppressive microenvironment and are infiltrated by immune suppressive cells like 
myeloid derived suppressor cells (MDSCs), Tregs and tumor-associated macrophages 
(TAMs), which makes it difficult to sustain an effective anti-tumor immune response. In 
addition to being suppressed by the aforementioned cells, infiltrating T cells are rendered 
anergic due to persistent exposure to the tumor antigen (66, 67) or display an exhausted 
phenotype characterized by the expression of inhibitory receptors like programmed cell death 
protein 1 (PD-1), cytotoxic T lymphocyte antigen-4 (CTLA-4), lymphocyte activation gene 3 
protein (LAG-3) etc. (68). The presence of active anti-tumor immunity in humans has been 
substantiated by various studies which have shown strong correlation between immune cell 
infiltration and prognosis (69). This has led to the development of ‗Immunoscore‘ that takes 
into account number, type and location of immune cells infiltrating the tumor and it has 
proven to be a more robust prognostic factor than other clinical classifications like cancer 
staging or TNM staging (70, 71). The effect of the infiltrating immune cells is achieved by the 
net effect of opposing forces of anti-tumor T cells and immune suppressive cells. Anti-tumor 
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T cell responses and the types of antigens they recognize are described in more detail in the 
next section. 
3.3.3 Anti-tumor T cell responses 
The types of T cells infiltrating the tumor are crucial in determining whether they are 
beneficial to the patient or not. In general, infiltrating cytotoxic CD8
+
 T cells and Th1 cells are 
associated with improved survival and Tregs are associated with poor prognosis with some 
exceptions (69). Various studies have investigated the relation between high immune cell 
infiltration and patient outcome in breast cancer (72). High density of CD8+ tumor-infiltrating 
lymphocytes (TILs) positively correlates to better survival (73-75) and is indicative of an 
effective response to chemotherapy (76, 77) and Trastuzumab therapy (78). Different CD4+ T 
cell subsets have different roles in predicting patient outcome. CD4+ Th1 cells (79, 80) and 
follicular helper T (Tfh) cells (81) are good prognostic markers whereas, CD4+ Th2 (80) and 
Th17 (82) cells are associated with bad prognosis. The role of CD4+Foxp3+ Tregs is not clear 
in breast cancer as they are associated with high risk of relapse (83) but also with good 
prognosis (84) and response to therapy (77) especially in presence of CD8+ T cells. Cytotoxic 
CD8+ T cells can directly kill tumor cells through various mechanisms including secretion of 
granzyme B and perforin (85) whereas CD4+ Th1 cells are essential to prime and sustain an 
effective CTL response. CD4+ T cells are capable of killing tumor cells directly in response to 
antigen presented on MHC II of tumor cells (86) in addition to MHC II deficient tumor cells 
(87). 
The prognostic value of TILs confirms the fact that they play an active role in anti-tumor 
immunity, but the antigens recognized by these T cells had not been identified for a long 
time. Studies with TILs in melanoma have shown that they are reactive against various 
tumor-associated antigens (TAAs) (88, 89) and against neo-antigens generated by mutations 
(90). Tumor associated antigens include a wide range of antigens which arise from 
mutations, viral infection or due to deregulated expression in tumor cells. They are broadly 
classified as follows (91, 92) :  
a. Oncofetal: expressed during embryonic development and in cancer cells. E.g. 
carcinoembryonic antigen (CEA) 
b. Oncoviral: virus-derived proteins that drive oncogenesis. E.g. human papilomavirus 
(HPV) encoded E6 and E7  
c. Non-mutated overexpressed: expressed by normal tissues but overexpressed by 
malignant cells. E.g. Her2/neu and EpCAM1 
d. Cancer-testis: expressed in testis/placenta in healthy individuals but overexpressed in 
neoplastic tissue. E.g. MAGE and CAGE 
e. Neoantigens: antigens only expressed by cancer cells that arise from mutations. E.g. 
Ras and p53 
f. Differentiation antigens: expressed on differentiated cells and malignant tissue arising 
from them. E.g. Tyrosinase and MelanA 
g. Post-translationally altered: posttranslational modifications are altered in tumor tissue. 
E.g. MUC1 is hypoglycosylated in tumors 
Since T cells recognize epitopes presented on MHC molecules, various studies were carried 
out to identify epitopes derived from TAAs which are presented by tumor cells or by antigen 
presenting cells (APCs) themselves (93). Identifying TAAs can not only provide us with 
deeper insight into the process of tumorigenesis but also assist in the development of novel 
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diagnostic tools, prognostic markers or therapeutic targets. Another advantage of identifying 
tumor antigens/epitopes is that they can be used for strengthening anti-tumor immunity either 
by vaccination or by adoptive transfer of genetically engineered antigen specific T cells 
(details in section 3.4). The tumor associated antigen NY-BR-1 which is the focus of this 
project is described in the next section. 
3.3.4 NY-BR-1 
NY-BR-1 was first identified and cloned using SEREX (serological analysis of recombinant 
tumor cDNA expression libraries) technology (94). SEREX is based on screening of a cDNA 
expression library derived from tumor tissue with autologous patient sera which should 
contain high titer immunoglobulins against immunogenic tumor antigens. In healthy 
individuals, NY-BR-1 mRNA has been detected only in the mammary gland, testis and 
prostate, and at very low levels in the placenta (94, 95). However, 70-84% of breast tumor 
samples tested positive for NY-BR-1 mRNA (94, 95), whereas 60% expressed the NY-BR-1 
protein (96). The fact that NY-BR-1 is overexpressed in breast cancer was confirmed in 
another study using subtracted cDNA libraries and cDNA microarrays (97). Since NY-BR-1 is 
overexpressed by the majority of breast tumors, but not in healthy tissues with the exception 
of the ductal epithelium of breast, it appears as a suitable target for immune therapy of breast 
cancer. The function of NY-BR-1 is not yet known, however based on the presence of a 
nuclear localization signal and the bZIP motif, it was presumed to be a transcription factor 
(94). The detection of NY-BR-1 in the nucleus in breast tumor sections by confocal 
microscopy strengthens this hypothesis (96). However, subsequent studies showed that 
ectopically expressed NY-BR-1 localized to cytoplasm and the cell membrane in living cells 
and was only detected in the membrane fraction of metastatic lesions (98) which could be 
due to NY-BR-1 degradation products which have lost the hydrophobic membrane targeting 
domain. NY-BR-1 expression was found to positively correlate to ERα expression suggesting 
transcriptional control of NY-BR-1 by estrogen (99). The presence of 4 estrogen response 
elements (EREs) around the transcription start site (TSS) of NY-BR-1 suggests that estrogen 
might control NY-BR-1 expression. However, this is only partial as NY-BR-1 expression can 
occur independently of ERα expression, as some ERα- tumors express NY-BR-1 (99) and 
there was no significant difference in NY-BR-1 expression between pre-menopausal and 
post-menopausal women (100). Interestingly, it was found that in patients treated with 
Tamoxifen, NY-BR-1 expression was reduced in recurrent disease compared to primary 
tumor obtained from the same patient independent of ERα expression (99). Although some 
studies showed that NY-BR-1 expression was less frequent in higher grade tumors 
compared to lower grade tumors (96), comparison of a primary tumor with distant 
metastases and recurrent disease from the same patient showed that it does not seem to get 
lost while disease progresses (100). Importantly, NY-BR-1 expression was confirmed in 
metastatic samples (98), which is important if NY-BR-1 is to be targeted for immunotherapy. 
NY-BR-1 expressed on the membrane could be recognized by a monoclonal antibody, which 
makes it a potential target for antibody therapy (98). It is also an attractive target for T cell 
based therapies, as HLA-A2 restricted epitopes have been identified and CTL clones against 
these epitopes could be generated from PBMCs derived from healthy individuals and breast 
cancer patients (95, 101). Co-expression analysis of NY-BR-1 and HLA class I revealed that 
approximately 6% of the patients could be eligible for vaccination with recognized epitopes 
(100). Additionally, HLA-DRB1*0301and HLA-DRB1*0401-restricted CD4+ T cell epitopes 
have been identified (102). Since CD4+ Th1 cells are very important for sustained anti-tumor 
CTL response (103), this can augment immunotherapy directed against NY-BR-1. NY-BR-1 
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expression was found to be beneficial for patient outcome (100) which could be due to 
intrinsic anti-NY-BR-1 immunity. Thus, NY-BR-1 is an ideal target for cancer immunotherapy 
due to its selective expression pattern as well as the presence of detectable anti-NY-BR-1 
immune response in breast cancer patients.  
3.4 Immunotherapy of cancer 
3.4.1 Cancer immunotherapy 
Any therapeutic intervention in order to kill cancer cells or inhibit their proliferation, that 
includes the activation (or reactivation) of the host immune system or involves the 
administration of components derived from the immune system, can be classified as cancer 
immunotherapy. The various strategies developed for cancer immunotherapy have been 
described below according to the type of agent used: 
Cell based therapies 
DC vaccines 
Dendritic cell (DC) therapy is based on mostly autologous DCs that are matured or activated 
ex vivo, loaded or transfected with tumor antigen, and re-infused into patients in order to 
prime and activate T cells directed against tumor antigens. Mature DCs can be generated 
from peripheral blood mononuclear cell (PBMC) derived monocytes, which are loaded with 
synthetic peptides representing TAA derived epitopes (104), transfected (105) or 
electroporated (106) with mRNA encoding tumor antigen, or transduced with adenovirus 
expressing TAA (107). One of the first cellular vaccines to be approved by the Food and 
Drug administration (FDA) in 2010 was sipuleucel-T (APC 8015, trade name Provenge) 
based on its success in clinical trials (108). 
TILS 
Tumor infiltrating lymphocytes (TILs) can be isolated from pieces of resected tumor and can 
be expanded ex vivo with IL-2, monoclonal anti-CD3 antibody OKT3 and irradiated feeder 
cells (109), and can be adoptively transferred to the patients. In one of the pioneering 
studies, these T cells were shown to mediate effective anti-tumor responses in melanoma in 
60% of patients who had not received any IL-2 prior to treatment and 40% of patients who 
had received IL-2 previously (110). Successive studies that included lymphodepleting 
regimens (chemotherapy and/or irradiation) prior to adoptive cell therapy (ACT), achieved 
better outcomes in terms of prolonged cell persistence (111, 112). The most successful 
aspect of the therapy was that the majority of patients who had complete regressions, had 
durable responses which lasted during follow-up period of 5 years or longer (112).  
CAR T cells 
Alternatively, T cells can be engineered to express chimeric antigen receptors (CARs) that 
consist of an extracellular antigen binding domain derived from a single chain variable 
fragment (scFv) directed against a tumor antigen and an intracellular signaling domain 
derived from the CD3 δ chain of the TCR. This allows the T cells to target tumor cells 
independently of MHC expression on the tumor cells. Second and third generation CAR T 
cells express one or more co-stimulatory molecules respectively. Inclusion of domains from 
co-stimulatory molecules like CD27, CD28, OX40, 4-1BB etc. improves the quality of T cells 
in terms of prolonged persistence in vivo and better functional capacity (113). Different CAR 
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transduced T cells targeting CD19 which is expressed in B cell malignancies, have been 
successfully used in various clinical studies (114). 
TCR transduced T cells 
Another approach for adoptive transfer of T cells for cancer immunotherapy involves the use 
of T cells genetically engineered to express TCRs directed against tumor antigens. One 
advantage of this strategy over the use of TILs is that the generation of TILs depends on the 
presence of resectable metastatic lesions which are infiltrated by tumor-reactive T cells. The 
proportion of actual tumor reactive T cells can be highly variable in the TIL product, but the 
use of TCR transduced T cells allows the transfer of high number of specific T cells. A first 
study was performed with MART-1 TCR transduced T cells in metastatic melanoma patients 
(115), which was followed by others targeting carcinoembryonic antigen (CEA) for colorectal 
cancer (116).  
Peptide, recombinant protein, DNA and RNA vaccines  
Peptide, recombinant protein, DNA or RNA vaccines can act as a source of antigen in vivo 
resulting in their uptake by APCs which can prime or reactivate T cells specific for TAA. 
There has been some clinical success in the treatment of premalignant lesions caused by 
HPV 16 infection using synthetic long peptides (117) or a recombinant fusion protein (118) by 
targeting the HPV 16 derived E6 and E7 oncoproteins. The outcome of peptide vaccination 
can be enhanced by the use of synthetic long peptides or polyvalent vaccines or by 
combining them with anti-CD40 antibody or TLR ligands plus adjuvant (119). Vaccination 
using naked DNA has also been effective in generation of HPV 16 and HPV18 specific 
immune response (120, 121) and also in clearance of premalignant lesions and virus (121). 
Use of RNA encoding multiple TAAs as vaccine had limited clinical success (122, 123), 
probably due to limitations of the RNA delivery platform. However, recently the use of RNA 
encoding neo-epitopes (124) and RNA-lipoplexes (125) for efficient targeting of RNA to DCs 
has shown very promising results in pre-clinical models and could revive the use of RNA 
vaccines if ongoing clinical trials can recapitulate the success of the pre-clinical research. 
Viruses  
Viruses can be used for cancer immunotherapy either as a vector to deliver DNA for 
vaccination or as oncolytic agents (126, 127). Sometimes genes encoding 
immunomodulating agents like costimulatory molecules (e.g. CD80, ICAM-1), cytokines (IL-
2) or chemokines (GM-CSF) are added in order to generate a strong immune response 
(127). The efficacy can be further enhanced by a heterologous prime-boost regimen to 
prevent the premature clearance of the virus when the same virus is used for boosting 
vaccine induced immunity. For example, PROSTVAC which is directed against prostate-
specific antigen (PSA) utilizes a vaccinia virus vector followed by fowlpox virus vector for 
boosting. A phase II trial with PROSTVAC and GM-CSF was shown to have benefits for 
patients in terms of prolonged overall survival (128). Some oncolytic viruses have intrinsic 
tropism for cancer cells whereas others can be engineered in order to target them to 
malignant tissue which overexpresses their respective entry receptors. Of various oncolytic 
viruses tested in clinical trials, Herpes Simplex Virus-1 (T-VEC) (129) and Adenovirus (H101) 
(130) which had been genetically engineered to enhance tumor cell tropism and reduce 
pathogenicity to normal cells have advanced to Phase III and Phase II trials, respectively, 
where they have shown clinical benefit. The additional benefit of using oncolytic viruses is 
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that the lysed tumor cells release TAAs which can be taken up by APCs which can prime 
tumor-specific T cell response. Oncolytic viruses have danger signals (DAMPs) which further 
boost the anti-tumor immune response.  
Immunostimulatory cytokines, chemokines or PRR agonists 
Immunostimulatory cytokines, chemokines or PRR agonists augment the effect of 
immunotherapy. Interleukin-2 (IL-2) is one of the most widely used immunostimulatory 
cytokines which is essential for T cell proliferation and activation (131). It is used as a 
standalone therapy (132) or as an adjuvant in vaccination trials (133) or adoptive T cell 
transfer (111, 112, 134). Interferon-α2a and Interferon-α2b have also been demonstrated to 
have clinical benefit in some trials in melanoma patients (135). Granulocyte-macrophage 
colony-stimulating factor (GM-CSF) is a chemokine that is known to recruit antigen 
presenting cells like macrophages into the tumor and can support the generation of an 
effective anti-tumor immune response. GM-CSF is added to different vaccination modules 
including peptide vaccines (136), viral vaccines (129) where the virus encodes for GM-CSF 
to have a locally concentrated dose of GM-CSF or to engineer allogeneic tumor cells to 
express GM-CSF and use irradiated tumor cells (137) to prime anti-tumor T cell response. 
PRR agonists like poly-ICLC which is a toll-like receptor (TLR) agonist (138), CpG (139) and 
Imiquimod (118) can be used as adjuvants with vaccines to generate potent T cells 
responses.  
Monoclonal antibodies  
mAbs directed against tumor associated antigens 
Monoclonal antibodies can act against cancer in various ways. Tumor targeting monoclonal 
antibodies Trastuzumab (anti-Her2/neu) (39) and Cetuximab (anti-EGFR) (140) can either 
block or inhibit signaling pathways required by tumor cells for rapid proliferation. Additionally, 
such antibodies can be conjugated to a drug (e.g. Trastuzmab emtansine) (141) or to a 
radioisotope (yttrium-90 ibriturnomab tiuxetan) (142) for targeted killing of the tumor cells. 
Some antibodies like Rituximab (anti-CD20) can opsonize the tumor cells and can trigger 
complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity 
(ADCC) by recruiting effector cells (143). Bispecific T cell engagers like blinatumomab which 
is directed against CD19 can cross-link the tumor cell to T cells to facilitate T cell mediated 
tumor cell killing (144). 
Immunomodulatory antibodies 
Immunomodulatory antibodies can act either by activating the immune system or by 
abrogating immune suppressive mechanisms. The agonistic CD40 antibody has been 
demonstrated to mediate clinical responses by promoting tumoricidal function of 
macrophages (145). Anti-tumor immune responses can be dampened by the same 
mechanisms that help prevent tissue damage following pathogen clearance in the normal 
anti-pathogen immune response. Antibodies designed to block the function of these inhibitory 
ligands and receptors can reactivate the anti-tumor immune response. This is known as 
immune checkpoint blockade and anti-CTLA-4 antibody, Ipilimumab was the first antibody 
which showed clinical activity in advanced melanoma patients (146). Other antibodies 
targeting PD-1 that followed, like Nivolumab (147) and Pembrolizumab (148) have been 
successful and showed fewer toxicities compared to Ipilimumab. The unprecedented 
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success of this approach highlights the fact that successful immunotherapy relies on 
counteracting immunosuppressive mechanisms.  
Thus, the immune system can be harnessed in various ways to generate anti-cancer 
responses. Combination of different types of immunotherapy as an adjuvant therapy after the 
bulk of tumor has been resected might be more effective as the suppressive tumor 
microenvironment has been removed. It has been shown that low dose chemotherapy (149) 
and radiotherapy (150) have immunostimulatory properties and could be combined with other 
immunotherapies. Targeted therapies can also be combined with immunotherapy for better 
outcomes as they can modulate immune responses as well (151). The immunotherapeutic 
strategies employed to treat breast cancer are described in the next section.  
3.4.2 Immunotherapy of breast cancer 
Breast cancer suffered a lack of focus with respect to immunotherapy due to the initial belief 
that they are not immunogenic. However, it is now catching up and there are a lot of clinical 
trials ongoing that are testing various immunotherapies for breast cancer (sometimes in 
combination with other agents). Anti-Her2 antibody, trastuzumab is the most successful 
immunotherapy available for breast cancer as it improved the survival of Her2+ patients 
drastically, especially since it used to have one of the worst prognosis (39). Initially, it was 
believed that it only inhibits Her2 signaling but it turned out that it can also have immune 
mediated effects like ADCC (38). Trastuzumab-emtansine has shown promising results in 
clinical trials and is approved for Her2 positive metastatic breast cancer (141, 152). Bispecific 
antibody against Her2 (153) which links the tumor cells to T cells have been designed as well 
and has shown efficacy in preclinical models but clinical data is missing. On the other hand 
Ertumaxomab; a tri-functional Her2 directed antibody which can crosslink tumor cells to T 
cells and innate cells like macrophages and NK cells has been tested in Phase I trial which 
had acceptable toxicity profile (154). Antibodies targeting other breast cancer associated 
antigens have been used in clinical trials as well with limited success.  
Her2/neu has also been targeted for vaccination approaches of breast cancer. In a phase I/II 
trial breast cancer patients were vaccinated with HLA-A2/A3 restricted Her2 derived peptides 
in combination with GM-CSF to prevent disease recurrence. Even though the vaccine was 
found to be safe and successfully induced Her2/specific immunity (155), it improved 5 year 
disease free survival only in patients who were optimally dosed and not for the entire 
vaccinated group (156). A phase III trial is ongoing to determine efficacy of the vaccine. 
Other studies have tried to induce Her2/neu specific CD4+ T cell response using peptide 
pulsed DCs (157) or modified MHC II restricted Her2 epitope in order to generate long lasting 
immunity. PANVAC which is a virus based vaccine targeting MUC1 and CEA along with 
providing co-stimulatory signals also showed some promise in Phase II trials (158). However, 
most immunotherapeutic approaches for breast cancer have resulted in modest outcomes. 
This could be due to suboptimal vaccine formulation, lack of appropriate adjuvants or to a 
highly immune suppressive tumor microenvironment. Nevertheless, recent success of 
immune checkpoint blockade in a wide variety of tumor entities have led investigators to 
evaluate the possibility of this approach in breast cancer as well and several early phase 
trials with Tremelilumab (159), Pembrozilumab (160) and MPDL3280A (161) have shown 
feasibility and promising results. Until recently, most success stories of immunotherapy 
involve melanoma as it is highly immunogenic and has a high mutational load resulting in 
numerous neo-antigens which are targeted by TILs and make them susceptible to checkpoint 
blockade (90, 162). Even though breast cancer is considered less immunogenic, recent 
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studies have indicated that the presence of active anti-tumor immunity as T cell infiltration 
positively correlate with improved survival in Her2+ subtypes (163) and TNBC (78). However, 
the frequency of TILs is quite low in Her2+ breast tumors and TNBC (78) and thus checkpoint 
blockade might not function alone as there are not enough TILs that can be reactivated. 
Thus, a vaccine or TLR agonist can be used to elicit an anti-tumor immune response 
followed by checkpoint blockade to maintain it (164). Another approach is to use cryoablation 
(165), low dose chemotherapy or radiation to release tumor antigens to initiate an immune 
response followed by immune checkpoint blockade.  
3.4.3 Immunosuppressive tumor microenvironment (TME) 
As mentioned earlier, nascent tumors are constantly eradicated by the immune system, but 
the tumor adopts various mechanisms to escape immune surveillance. The recent success 
of immune checkpoint blockade therapy underscores the fact that the tumor 
microenvironment is very immunosuppressive and even if immune cells with potential to 
eradicate the tumor manage to infiltrate the tumor, they are quickly neutralized by the 
immunosuppressive micro-milieu. Evading immune destruction has been identified as one of 
the hallmarks of cancer (166) and is mediated either by avoiding recognition or by rendering 
the infiltrating immune cells non-functional. Tumors avoid T cell mediated killing by 
downregulation of surface expression of MHC molecules which can result from genetic 
alterations at the MHC locus or defective antigen processing machinery leading to empty 
MHC molecules which are rapidly internalized (167). Immunoediting by antigen specific T 
cells also selects for antigen loss variants (168, 169) which give rise to resistant tumors. 
Moreover, tumor cells express PD-L1 which is a ligand for PD-1, a receptor expressed on T 
cells that negatively regulates T cell function (170). Additionally, tumors are known to secrete 
cytokines like TGF-β, IL-4 and IL-10 and enzymes like IDO which have an immune 
suppressive effect. TGF-β (171) and IL-10 (172) induce Tregs whereas IL-4 (173) promote 
polarization of TAMs towards an M2-like phenotype both of which lead to suppression of T 
cell function. For example, Sousa et al showed that breast cancer cells secreted M-CSF 
which induces an M2-like phenotype in macrophages (174). Besides recruiting immune 
suppressive cells, IL-10 can directly impair cytokine release and cytotoxicity of T cells and 
priming by APCs (175). Tumor derived IDO contributes to the suppressive microenvironment 
by recruiting myeloid-derived suppressor cells (MDSCs) (176) while simultaneously impairing 
T cell activation by tryptophan depletion. Chemokines secreted by the tumor like CCL22 
facilitate the trafficking of CCR4 expressing Tregs into the tumor via CCL22-CCR4 
interaction (177). Thus, the immune suppressive tumor microenvironment is the result of 
tumor derived factors and recruitment of suppressor cells like Tregs, MDSCs and TAMs. The 
role of TAMs is described in more detail in the following section. 
3.4.4 Tumor associated macrophages 
Macrophages are part of the innate immune system and in case of an infection by 
pathogenic bacteria; macrophages are activated by TLR ligands like LPS and Th1 cytokines 
like IFNγ which results in the classical activation of macrophages (178). These classically 
activated macrophages are characterized by expression of pro-inflammatory cytokines like 
TNFα, IL-1, IL-12 etc. (178) and they initiate an adaptive immune response by 
attracting/activating effector cells. They can also produce reactive oxygen species or the 
enzyme nitric oxide synthase which generates nitrogen molecules both of which can directly 
kill infected cells. Thus, these cells mediate the clearance of pathogens following an 
infection. However in case of chronic infection or infection by a parasite, macrophages are 
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alternatively activated in response to Th2 cytokines like IL-4 or IL-13 (178, 179). They are 
characterized by secretion of immune-suppressive cytokines like IL-10 and TGF-β which are 
required to dampen the immune response. They express high levels of scavenging receptors 
like CD204 which allow them to take up dying tissue and secrete angiogenic factors like 
VEGF to promote neo-angiogenesis in order to facilitate tissue repair and wound healing 
(178, 179). Thus M1 and M2 polarized macrophages not only require different stimuli but 
also are characterized by different expression markers and functions (summarized in Figure 
6).  
 
Figure 6. Differential polarization of macrophages 
Differentiation and polarization of macrophages depend on the stimuli received. Differentiated 
macrophages can be distinguished based on expression of different surface markers and cytokines 
which also define their distinct functions (Figure from Quatromoni and Eruslanov, 2012). 
 
It has been demonstrated in mouse models that tumor-associated macrophages (TAMs) 
switch from classically activated M1-like phenotype to an alternatively activated M2-like 
phenotype as the tumor progresses (180, 181) and various studies have demonstrated that 
late stage tumors are dominated by immunosuppressive TAMs (182). This is mediated by the 
tumor which secretes various factors to skew the TME towards an immunosuppressive milieu 
as a mechanism to escape immune-mediated destruction (183). However, not all TAMs are 
tumor-promoting. It has been described that TAMs with different phenotypes can be found 
within the same tumor but distributed in different regions of the tumor (180). IFNγ activated 
macrophages have been shown to phagocytose chronic lymphocytic leukemia (CLL) cells by 
ADCC in presence of Rituximab (anti-CD20 antibody) (184). Additionally, macrophages 
activated by exposure to bacterial components have been shown to generate ROI (reactive 
oxygen intermediates) or RNI (reactive nitrogen intermediates) which have tumoricidal 
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properties (185). However, these intermediates can also promote tumor formation due to 
their mutagenic properties. On the other hand, M2-like TAMs have been shown to have pro 
tumorigenic function due to their ability to promote angiogenesis, extravasation and 
metastasis (183). This could explain why high macrophage infiltration can either be good or 
bad for patient survival depending on the functional phenotype and the location of TAMs 
present. 
For example, in case of colorectal cancer high infiltration of CD68+ macrophages along the 
tumor front correlated with good prognosis (186). Another tumor type where high density of 
infiltrating macrophages had beneficial effect on patient survival is non-small cell lung cancer 
(NSCLC) (187). However, for most tumors types like bladder, glioma and cervical cancer 
high density of infiltrating TAMs correlates with poor prognosis (188). Various studies have 
reported that high TAM infiltration is predictive of poor prognosis in breast cancer patients 
(189-196), even though there is some debate if CD68 which is the most commonly used 
marker for TAM infiltration has a prognostic value on its own and whether there are other 
markers like CD163 which could be more predictive. Also, the localization of the infiltrating 
TAMs could be a crucial factor as it was found that TAMs from the tumor stroma but not the 
tumor nest are an independent prognostic marker (193) which could be due to the fact that 
sessile and migratory TAMs which have different functional phenotype are differentially 
located (197). Additionally, high TAM infiltration was also found to correlate with other bad 
prognosticators like high tumor grade, ER and PR negativity and Her2 positivity (192, 193, 
195). The negative effects of TAM infiltration were partially mediated by their angiogenic 
properties as indicated by the high VEGF expression and microvessel density in these 
heavily infiltrated tumors (194) or by their ability to enhance migration and stem cell like 
properties of tumor cells (192).  
Since in breast cancer TAMs are associated with poor prognosis, they are an obvious target 
for therapeutic intervention. Various approaches have been applied for targeting TAMs for 
anti-cancer therapy (Figure 7). The first approach is to reduce the numbers of TAMs 
infiltrating the tumor either by depleting them or by inhibiting their recruitment into the tumor. 
The depletion of TAMs by the use of Clodronate loaded Liposomes (198) or Trabectedin 
(105) resulted in inhibition of tumor growth and reduction in tumor vascularization in mouse 
tumor models. Additionally, anti-CSF-1R antibody can also deplete TAMs resulting in 
delayed tumor growth which was accompanied by increase in the ratio of tumor infiltrating 
CD8+/CD4+ T cells (199). This antibody also showed effective TAM depletion and clinical 
benefit in patients (199). Blocking of recruitment of TAMs into the tumor can be achieved by 
blocking of one of the following: CCL2/CCR2 signaling, CSF-1 or VEGF signaling. Disruption 
of CCL2/CCR2 interaction by anti-CCL2 antibody resulted in reduced metastasis and 
prolonged survival in murine breast cancer model (200). In patients it was found to be safe, 
however did not have any clinical benefit as a monotherapy (201). Additionally, blocking of 
CSF-1 signaling by anti-CSF-1R antibody could control tumor growth (202) and this effect 
could have been mediated by the fact that anti-CSF-1R antibody can reduce the 
extravasation of monocyte precursors resulting in reduced MHC IIlo (M2-like) macrophages 
into the tumor (203). Inhibition of VEGF can also affect macrophage recruitment into tumors 
and blocking of VEGF resulted in delayed tumor growth in mouse tumor models (204). 
Another approach is to reprogram the TAMs from an immunosuppressive M2-like phenotype 
to an M1-like phenotype. Various studies in mouse models have demonstrated that TLR9 
ligands like CpG (205), bacterial products (206) or agonist CD40 antibody (145, 207) or 
histidine-rich glycoprotein (HRG) (208) which have shown anti-tumor activity do so by 
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repolarization of TAMs into a M1-like phenotype. Also low dose irradiation can shift the 
macrophages towards a more M1-like phenotype (150). Additionally, antigen specific CD4+ T 
cells can repolarize TAMs toward a MHC IIhi M1-like phenotype in an IFNγ dependent way 
which corresponds to successful immunosurveillance (209). This demonstrates that 
repolarization of TAMs is an attractive approach for anti-tumor therapy which needs to be 
investigated further in a clinical setting. 
 
 
Figure 7. Strategies for therapeutic targeting of TAMs 
Targeting of TAMs for anti-tumor therapy is based on either abrogation of the immunosuppressive 
macrophages in the tumor microenvironment or inducing an M1-like phenotype (Figure from Tang et 
al, 2013). 
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3.5 Aim of the study 
In the recent years immunotherapy of cancer has shown promising results in a variety of 
settings; however, there are major issues that need to be addressed for successful 
immunotherapy. Two major factors to consider include combining different treatments to 
activate different compartments of the immune system and overcoming the immune 
suppressive tumor microenvironment. The antigen specific CD4
+
 T cells can augment the 
therapeutic effect of tumoricidal CD8+ T cells by helping to break tolerance against self-
derived non-mutated tumor antigens (210, 211) or by activating memory CD8+ T cells (103, 
212). Additionally, antigen specific CD4+ T cells can re-polarize immunosuppressive M2-like 
TAMs pulsed with their cognate epitope to an M1-like phenotype (213). This is mediated by 
IFNγ secreted by the activated CD4+ T cells. It has been demonstrated in a myeloma model 
that TAMs can take up secreted tumor antigen and present it to the antigen specific CD4+ T 
cells thereby activating them (209, 214, 215) which results in successful immunosurveillance. 
We wanted to establish an NY-BR-1 expressing tumor model which would allow us to 
investigate if TAMs could take up and process the breast cancer associated differentiation 
antigen NY-BR-1 and present it to NY-BR-1 specific CD4+ T cells thereby activating them. 
This model could also be used to answer whether IFNγ secreted by the activated CD4+ T 
cells would re-polarize the TAMs to an M1-like phenotype allowing CD8+ T cells to eradicate 
the tumor. Since HLA-DR4 restricted NY-BR-1 specific CD4+ T cell epitopes and 
corresponding CD4+ T cell lines had been previously established our lab, the aim of the 
current thesis was to set up a transplantable NY-BR-1 expressing tumor model compatible 
with HLA-DR4tg mice. Another goal was to generate an NY-BR-1 specific CTL line which 
could be adoptively transferred into tumor bearing mice to study their anti-tumor activity 
following the re-polarization of TAMs by NY-BR-1 specific CD4+ T cells. 
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4 Materials and methods 
4.1 Materials 
4.1.1 General instrumentation 
Table 1. General instrumentation 
Machine Manufacturer 
ABI 7300 Real-time PCR System  Applied Biosystems, Foster City, USA 
Biofuge Fresco Centrifuge  Heraeus, Hanau, Germany 
Biological Safety Cabinet  Heraeus, Hanau, Germany 
BioPhotometer  Eppendorf, Hamburg, Germany 
BioRad Mini-gel apparatus  Bio-Rad, Richmond, USA 
CASY1 Cell counter  Schaerfe System, Reutlingen, Germany 
CO2 incubator  Binder, Tuttlingen, Germany 
ELISPOT Reader System AID Diagnostika, Straßberg, Germany 
ELISPOT Reader System 
Cellular Technology Limited, Shaker Heights, 
USA 
FACS Calibur1 Flow Cytometer  Becton Dickinson, Heidelberg, Germany 
FACSAria I Cell Sorter Becton Dickinson, Heidelberg, Germany 
FACSAria II Cell Sorter  Becton Dickinson, Heidelberg, Germany 
FACSCanto II Flow Cytometer Becton Dickinson, Heidelberg, Germany 
Fluoroskan Ascent Microplate Fluorometer  Thermo Scientific, Dreieich, Germany 
Gammacell 1000 Elite MDS Nordion, Ottawa, Canada 
Gel Documentation System 
INTAS Science Imaging Instruments, 
Göttingen, Germany 
Gene Mate Gel Electrophoresis System Star Lab, Hamburg, Germany 
Innova 4230 Incubator Shaker  New Brunswick Scientific, Edison, USA 
Innova 4230 Refrigerated Incubator 
Shaker 
New Brunswick Scientific, Edison, USA 
Leica DM1L Microscope  Leica, Wetzlar, Germany 
LSR II Flow Cytometer Becton Dickinson, Heidelberg, Germany 
Magnet Stirrer Heidolph Instruments, Schwabach, Germany 
Megafuge 2.0 R Heraeus Instruments, Hanau, Germany 
Microbiological Incubator  Heraeus, Hanau, Germany 
Microwave intellowave LG, Seoul, South Korea 
Mini-PROTEAN Tetra Handcast Systems Bio-Rad, Richmond, Germany 
MP220 pH Meter Mettler Toledo, Columbus, OH 
Multichannel Pipette  Eppendorf, Hamburg, Germany 
Multifuge X1R Thermo Scientific, Karlsruhe, Germany 
Multifuge x3 FR centrifuge  Heraeus, Hanau, Germany 
Neubauer counting chamber Brand, Wertheim, Germany 
peqstar 2x Gradient peqlab, Erlangen, Germany 
pH-meter 766 Calimatic Knick, Berlin, Germany 
Pipetboy  Brand, Wertheim, Germany 
Pipette (P2, P10, P100, P200, P1000)  Gilson, Bad Camberg, Germany 
Power PAC 300 power supplier  Bio-Rad, Richmond, Germany 
Refrigerator  Liebherr, Ochsenhausen, Germany 
Sorvall RT7 Centrifuge  Sorvall, Newton, CT 
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4.1.2 General consumables 
Table 2. General consumables 
Material Manufacturer 
Falcon tubes 15ml, 50ml  Greiner, Frickenhausen, Germany 
Pipette filter tips (10, 20, 100, 200, 1000µl)  Starlab, Milton Keynes, United Kingdom 
Pipette tips (10, 20, 100, 200, 1000µl)  Greiner, Frickenhausen, Germany 
Combitips (2.5, 5ml) Eppendorf, Hamburg, Germany 
Sterile serological pipettes (5, 10, 25ml)  Greiner, Frickenhausen, Germany 
Safe-Lock tubes (0.5, 1.5, 2ml)  Eppendorf, Hamburg, Germany 
Tissue culture flasks (25, 75, 150 cm
2
)  TPP, Trasadingen, Switzerland 
Cell culture test plates, flat bottom (6, 12, 
24, 96 wells) 
TPP, Trasadingen, Switzerland 
Round bottom 96-well plates TPP, 
Trasadingen, Switzerland 
TPP, Trasadingen, Switzerland 
Nunc™ MaxiSorp™ ELISA Plates, 
Uncoated 
BioLegend, San Diego, U.S. 
96 well black/clear flat bottom plates (for 
CellTiter-Glo® Assay) 
Corning, Big Flats, NY, USA 
UVette™ Cuvets Eppendorf, Hamburg, Germany 
PCR strip tube Greiner, Frickenhausen, Germany 
MicroAmp Optical 96-well pate  Applied Biosytems, Foster City, U.S. 
MicroAmp Optical adhesive film  Applied Biosytems, Foster City, U.S. 
Petri Dishes  Greiner, Frickenhausen, Germany 
Cryotubes  Greiner, Frickenhausen, Germany 
Nitrocellulose membrane  Whatmann, Dassel, Germany 
Needles (18G, 27G)  Becton Dickinson, Heidelberg, Germany 
Inject-F, Syringes  Braun, Melsungen, Germany 
Liquid reservoirs  Carl Roth GmbH, Karlsruhe, Germany 
FACS tubes  Becton Dickinson, Heidelberg, Germany 
Terumo Syringe (5, 10 ml) Terumo, Leuven, Belgium 
Cell strainers (40, 70 µm) Becton Dickinson, Heidelberg, Germany 
ELISpot plates  Merck Milipore, Darmstadt, Germany 
 
 
 
 
 
 
 
Spectrophotometer NanoDrop 2000 Thermo Scientific, Karlsruhe, Germany 
Tecan Infinite 200 PRO Tecan, Männedorf, Switzerland 
Thermomixer  Eppendorf, Hamburg, Germany 
UV light N90 LW, 366 nm Konrad Benda, Wiesloch, Germany 
Veriti 96 Well Plate Thermocycler Applied Biosystems, Foster City, USA 
Vortex Genie2 Scientific Industries, New York, USA 
Waterbath SW20 Julabo Labortechnik, Seelbach, Germany 
Wet Blotting System Mini Trans-Blot Cell Bio-Rad, Richmond, Germany 
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4.1.3 Chemicals and Reagents  
4.1.3.1 General chemicals 
Table 3. General chemicals 
Material Manufacturer 
Acetic Acid Avantor, Center Valley, USA 
Agarose Sigma-Aldrich, Saint Louis, USA 
Ammonium Persulfate (APS) Sigma-Aldrich, Saint Louis, USA 
Bovine Serum Albumin (BSA)  Sigma-Aldrich, Saint Louis, USA 
Bromphenol Blue Sigma-Aldrich, Saint Louis, USA 
Concanavalin A Sigma-Aldrich, Saint Louis, USA 
Dimethyl sulfoxide AppliChem, Darmstadt, Germany 
Ethanol Sigma-Aldrich, Saint Louis, USA 
Ethidium Bromide solution 0.025% Carl Roth, Karlsruhe, Germany 
Ethylenediaminetetraacetic acid (EDTA) Acros Organics, Geel, Belgium 
Glycerol Sigma-Aldrich, Saint Louis, USA 
Glycine Gerbu Biotechnik, Geiberg, Germany 
Methanol Sigma-Aldrich, Saint Louis, USA 
Non-fat milk powder  Carl Roth GmbH, Karlsruhe, Germany 
Paraformaldehyde Sigma-Aldrich, Saint Louis, USA 
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich, Saint Louis, USA 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich, Saint Louis, USA 
Tetramethylethylenediamine (TEMED) Bio-Rad, Munich, Germany 
Tris Base Sigma-Aldrich, Saint Louis, USA 
Trypan Blue Biochem, Berlin, Germany 
Tryptone Sigma-Aldrich, Saint Louis, USA 
Trypsin/EDTA 1x Life technologies, Carlsbad, U.S. 
Tween 20 Gerbu Biotechnik, Geiberg, Germany 
Water Sigma-Aldrich, Saint Louis, USA 
β-Mercaptoethanol Sigma-Aldrich, Saint Louis, USA 
Lipopolysaccharide (LPS) Sigma-Aldrich, Saint Louis, USA 
Methyl α-D-mannopyranoside (αMM) Sigma-Aldrich, Saint Louis, USA 
Thioglycolate Medim AppliChem, Darmsadt, Germany 
 
4.1.3.2 General reagents 
Table 4. General reagents 
Material Manufacturer 
BD Matrigel Basement Membrane Matrix  BD Biosciences, Bedford, MA, USA 
6x Orange Loading Dye Fermentas, St. Leon-Rot, Germany 
dNTP Mix 10 mM Thermo Scientific, Karlsruhe, Germany 
Gene Ruler 100bp DNA Ladder Fermantas, St. Leon-Rot, Germany 
O  Gene Ruler 1kb DNA Ladder Fermantas, St. Leon-Rot, Germany 
Power SYBR® Green PCR Master Mix Life technologies, Carlsbad, U.S. 
Effectene® Transfection Reagent Qiagen, Hilden, Germany 
PolyFect® Transfection Reagent Qiagen, Hilden, Germany 
X-tremeGENE HP DNA Transfection 
reagent 
Roche Diagnostics, Mannheim, Germany 
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Cell Lysis Buffer Cell Signaling Technology, Beverly, USA 
ECL Prime Western Blot Detection 
Reagent 
GE Healthcare, Munich, Germany 
Precision Plus Protein Dual Color Standard Bio-Rad, Munich, Germany 
Bio-Rad Protein Assay Reagent  Bio-Rad, Richmond, USA 
Qiazol Qiagen, Hilden, Germany 
BCIP/NBT Liquid Substrate System  Sigma, Saint Louis, MO 
TaqMan® Universal PCR Master Mix Applied Biosytems, Foster City, U.S. 
Pvu I restriction enzyme (#ER0621) Life technologies, Carlsbad, U.S. 
 
4.1.3.3 Cell culture 
Table 5. Cell culture 
Material Manufacturer 
Accutase (#SCR005) Merck Millipore, Schwalbach, Germany 
Dulbecco's phosphate-buffered saline 
(DPBS)  
Life technologies, Carlsbad, U.S. 
DMEM, high glucose, GlutaMAX™    Gibco-Invitrogen, Karlsruhe, Germany 
Fetal Bovine Serum Biochrom, Berlin, Germany 
HEPES buffer solution Sigma-Aldrich, Saint Louis, USA 
L-Glutamine Sigma-Aldrich, Saint Louis, USA 
Penicillin/Streptomycin (Pen/Strep) Life technologies, Carlsbad, U.S. 
RPMI Medium 1640 (1x) + GlutaMAX Life technologies, Carlsbad, U.S. 
X-VIVO 20 Lonza, Basel, Switzerland 
Zeocin Selection Reagent Life Technologies, Darmstadt, Germany 
αMinimum Essential Medium Eagle (MEM) Sigma-Aldrch, Saint Louis, USA 
ACK lysis Buffer Gibco-Invitrogen, Karlsruhe, Germany 
Hanks' Balanced Salt Solution (HBSS) Sigma-Aldrich, Saint Louis, USA 
Zeocin  Invitrogen, Carlsbad, CA 
G418(Neomycin)  Gibco-Invitrogen, Karlsruhe, Germany 
 
4.1.3.4 Cytokines 
Table 6. Cytokines 
Material Manufacturer 
Human IL-2 IS, premium grade                   
(#130-097-745) 
Miltenyi Biotec GmbH, Gladbach, Germany 
Mouse IFN gamma Recombinant Protein 
Carrier-Free (#34-8311-82) 
eBioscience, San Diego, U.S.  
Recombinant Mouse IL-4 (carrier-free) 
(#574302) 
BioLegend, San Diego, U.S. 
 
4.1.3.5 Bacteria 
Table 7. Bacteria 
Material Manufacturer 
One Shot® TOP10 Chemically Competent 
E. coli (#C4040-06) 
Life technologies, Carlsbad, U.S. 
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4.1.3.6 Reagents for flow cytometry 
Table 8. Reagents for flow cytometry 
Material Manufacturer 
LIVE/DEAD® Fixable Yellow Dead Cell 
Stain (#L-34959) 
Life technologies, Carlsbad, U.S. 
LIVE/DEAD® Fixable Blue Dead Cell Stain 
Kit (#L-23105) 
Life technologies, Carlsbad, U.S. 
7-AAD Viability Staining Solution 
(#420403) 
BioLegend, San Diego, U.S. 
Propidium Iodide (#P3566) Life technologies, Carlsbad, U.S. 
CountBright™ Absolute Counting Beads 
(#C36950) 
Life technologies, Carlsbad, U.S. 
CD16/CD32 (mouse BD Fc block) 
(#553142) 
BD Pharmingen, San Diego, U.S. 
OneComp eBeads (#01-1111-42) eBioscience, San Diego, U.S.  
Rat serum (#GTX73216) GeneTex, Irvine, USA 
Normal Syrian Hamster Serum                     
(#007-000-120) 
Jackson Immunoresearch, West Grove, USA 
Protein Transport Inhibitor (Containing 
Monensin) (#554724) 
BD Biosciences, San Jose, U.S. 
BD Cytofix/Cytoperm™ 
Fixation/Permeabilization Kit (#554714) 
BD Biosciences, San Jose, U.S. 
Lympholyte®-M cell separation medium 
(#CL5035) 
Cedarlane Labs, Burlington, Canada 
 
4.1.4 Primers for qRT-PCR using SYBR Green  
Table 9. Primers for qRT-PCR using SYBR Green 
Primer Sequence 5' to 3' Source 
Ym1_qPCR_FP1 CACCATGGCCAAGCTCATTCTTGT 
Tatano et al, 2014 
(216) 
Ym1_qPCR_RP2 TATTGGCCTGTCCTTAGCCCAACT 
Fizz1_qPCR_FP3 ACTGCCTGTGCTTACTCGTTGACT 
Fizz1_qPCR_RP4 AAAGCTGGGTTCTCCACCTCTTCA 
IL-6_qPCR_FP5 GTCTTCTGGAGTACCATAGC 
Movahedi et al, 2010 
(180) 
IL-6_qPCR_RP6 GTCAGATACCTGACAACAGG 
CXCL10_qPCR_FP7 TCTGAGTCCTCGCTCAAGTG 
CXCL10_qPCR_RP8 CCTTGGGAAGATGGTGGTTA 
CXCL9_qPCR_FP9 TCAACAAAAGAGCTGCCAAA 
CXCL9_qPCR_RP10 GCAGAGGCCAGAAGAGAGAA 
IL12b_qPCR_FP11 GAAAGACCCTGACCATCACT 
IL12b_qPCR_RP12 CCTTCTCTGCAGACAGAGAC 
NOS2_qPCR_FP15 GCTTCTGGTCGATGTCATGAG 
NOS2_qPCR_RP16 TCCACCAGGAGATGTTGAAC 
VEGFA_qPCR_FP17 CAGGCTGCTGTAACGATGAA 
VEGFA_qPCR_RP18 AATGCTTTCTCCGCTCTGAA 
ARG1_qPCR_FP19 TCACCTGAGCTTTGATGTCG 
ARG1_qPCR_RP20 TTATGGTTACCCTCCCGTTG 
Materials and methods Page 43 
 
Mrc1_qPCR_FP21 GCAAATGGAGCCGTCTGTGC 
Mrc1_qPCR_RP22 CTCGTGGATCTCCGTGACAC 
CD206_qPCR_FP23 TTGGACGGATAGATGGAGGG 
Zhu et al, 2014 (217) 
CD206_qPCR_RP24 CCAGGCAGTTGAGGAGGTTC 
HPRT_qPCR_FP25 AGTACAGCCCCAAAATGGTTAAG 
HPRT_qPCR_RP26 CTTAGGCTTTGTATTTGGCTTTTC 
bACTIN_qPCR_FP27 TGGAATCCTGTGGCATCCATGAAAC Davis et al, 2013 
(218) bACTIN_qPCR_RP28 TAAAACGCAGCTCAGTAACAGTCCG 
   
IL10_fw31 GCTCTTACTGACTGGCATGAG Shaul et al, 2010 
(219) IL10_rev32 CGCAGCTCTAGGAGCATGTG 
CD163_fw35  TCCACACGTCCAGAACAGTC Tatano et al, 2014 
(216) CD163_rev36 CCTTGGAAACAGAGACAGGC 
STAT6_fw37 CTGGGGTGGTTTCCTCTTG 
Shaul et al, 2010 
(219) 
STAT6_rev38  TGCCCGGTCTCACCTAACTA 
IL1β_fw39 CTGGTGTGTGACGTTCCCATTA 
IL1β_rev40 CCGACAGCACGAGGCTTT  
STAT1_fw41 CTGAATATTTCCCTCCTGGG 
STAT1_rev42 TCCCGTACAGATGTCCATGAT 
VEGF_fw43 CCTTCGTCCTCTCCTTACCC 
VEGF_rev44  AAGCCACTCACACACACAGC 
CD86_fw45 TCTCCACGGAAACAGCATCT 
CD86_rev46  CTTACGGAAGCACCCATGAT 
CD80_fw47  GGCAAGGCAGCAATACCTTA 
CD80_rev48 CTCTTTGTGCTGCTGATTCG 
TGFβ1_fw49 AAGTTGGCATGGTAGCCCTT 
TGFβ1_rev50   GCCCTGGATACCAACTATTGC 
PPARg_qPCR_FP51 CGAGTCTGTGGGGATAAAGC 
Ralph Schulz, DKFZ 
PPARg_qPCR_RP52 CAAACCTGATGGCATTGTGA 
 
4.1.5 Plasmids 
Table 10. Plasmids 
Material Source 
pcDNA3.1(-)zeo  Invitrogen, Carlsbad, CA 
pcDNA3.1(-)zeocin-NY-BR-1  Dr. Adriane Gardyan 
 
4.1.6 Peptides 
All peptides were synthesized and HPLC-purified at the peptide synthesis core facility of the 
German Cancer Research Center, Heidelberg.  
Table 11. List of peptides 
MHC RESTRICTION DESIGNATION IN THESIS SEQUENCE 
H2-D
b
 peptide # 3 VYTSNDSYI 
H2-D
b
 peptide # 6 STIYNNEVL 
H2-D
b
 peptide # 57 KASANDQRF 
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4.1.7 Antibodies and hybridoma supernatants 
4.1.7.1 Antibodies used for ELISPOT assay 
Table 12. ELISPOT antibodies 
Material Manufacturer 
Purified Rat Anti-Mouse IFN-γ (#551216) BD Pharmingen,  San Diego, U.S. 
Biotin Rat Anti-Mouse IFN-γ  (#554410) BD Pharmingen,  San Diego, U.S. 
Alkaline phosphatase streptavidin 
(#554065) 
BD Pharmingen,  San Diego, U.S. 
 
4.1.7.2 Antibodies and hybridoma supernatants used for Western blot analysis 
Table 13. Western blot antibodies 
Material Manufacturer 
mouse anti-NY-BR-1 monoclonal antibody 
clone#2 
group of Prof. Jäger, NCT, Heidelberg 
Mouse anti-Actin monoconal antibody 
(#691001) 
MP Biomedical, Solon, USA 
Goat-anti-mouse IgG-HRP (#sc2005) Santa Cruz Biotechnology, Santa Cruz, USA 
 
4.1.7.3 Antibodies used for flow cytometry 
Table 14. FACS antibodies 
Material Manufacturer 
Alexa Fluor® 488 anti-mouse CD107a 
(LAMP-1) Antibody (#121608) 
BioLegend, San Diego, U.S. 
PerCP/Cy5.5 anti-mouse/human CD11b 
Antibody (#101228) 
BioLegend, San Diego, U.S. 
V450 Hamster Anti-Mouse CD11c 
(#560521) 
BD Biosciences, San Jose, U.S. 
FITC anti-mouse CD14 Antibody 
(#123307) 
BioLegend, San Diego, U.S. 
Brilliant Violet 605™ anti-mouse CD206 
(MMR) Antibody (#141721) 
BioLegend, San Diego, U.S. 
PerCP/Cy5.5 anti-mouse CD3 Antibody 
(#100217) 
BioLegend, San Diego, U.S. 
Brilliant Violet 510™ anti-mouse CD3 
Antibody (#100233) 
BioLegend, San Diego, U.S. 
APC Anti-Mouse CD4 (#17-0041-81) eBioscience, San Diego, U.S.  
APC/Cy7 anti-mouse CD4 Antibody 
(#100414) 
BioLegend, San Diego, U.S. 
H2-D
b
 peptide # 136 HTHENENYL 
HLA-DRB1*0301 peptide #8797 VVTFLVDRKCQLDVL 
HLA-DRB1*0301 peptide #9017 DVSSTIYNNEVLHQP 
HLA-DRB1*0301 peptide #8756 KSKITIDIHFLERKM 
HLA-DRB1*0401 peptide #8862 AFELKNEQTLRADPM 
HLA-DRB1*0401 peptide #9251 TIYNNEVLHQPLSEA 
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PerCP/Cy5.5 anti-mouse CD4 Antibody 
(#100540) 
BioLegend, San Diego, U.S. 
V450 Rat anti-Mouse CD4 (#560470) BD Biosciences, San Jose, U.S. 
Alexa Fluor® 488 anti-mouse CD45.2 
Antibody (#109816) 
BioLegend, San Diego, U.S. 
APC Rat Anti-Mouse CD8a (#553035) BD Pharmingen,  San Diego, U.S. 
PE/Cy7 anti-mouse CD8a Antibody 
(#100722) 
BioLegend, San Diego, U.S. 
Anti-Mouse CD8a FITC (#11-0081-81) eBioscience, San Diego, U.S.  
Alexa Fluor® 647 anti-mouse F4/80 
Antibody (#123122) 
BioLegend, San Diego, U.S. 
Alexa Fluor® 700 anti-mouse Ly-6G/Ly-
6C (Gr-1) Antibody (#108422) 
BioLegend, San Diego, U.S. 
APC/Cy7 anti-human HLA-DR Antibody 
(#307618) 
BioLegend, San Diego, U.S. 
PE Mouse Anti-Mouse I-A[b] (#553552) BD Pharmingen,  San Diego, U.S. 
Purified Mouse Anti-Mouse I-A[b] 
(#553603) 
BD Pharmingen,  San Diego, U.S. 
Brilliant Violet 421™ anti-mouse IFN-γ 
Antibody (#505830) 
BioLegend, San Diego, U.S. 
Anti-Mouse NOS2 PE-Cyanine7 (#25-
5920-82) 
eBioscience, San Diego, U.S.  
APC mouse anti-mouse NK1.1 (#561117) BD Pharmingen,  San Diego, U.S. 
 
4.1.7.4 Isotype controls for flow cytometry antibodies 
Table 15. Isotypes for FACS antibodies 
Material Manufacturer 
Alexa Fluor® 488 Rat IgG2a, κ Isotype 
Ctrl Antibody (#400525) 
BioLegend, San Diego, U.S. 
PerCP/Cy5.5 Rat IgG2b, κ Isotype Ctrl 
(#400632) 
BioLegend, San Diego, U.S. 
 V450 Hamster IgG1, λ1 Isotype Control 
(#560552) 
BD Biosciences, San Jose, U.S. 
PerCP/Cy5.5 Rat IgG2b, κ Isotype Ctrl (# 
400631) 
BioLegend, San Diego, U.S. 
APC/Cy7 Rat IgG2b, κ Isotype Ctrl 
(#400624) 
BioLegend, San Diego, U.S. 
Alexa Fluor® 488 Mouse IgG2a, κ Isotype 
Ctrl(#400233) 
BioLegend, San Diego, U.S. 
Alexa Fluor® 647 Rat IgM, κ Isotype Ctrl 
(#400813) 
BioLegend, San Diego, U.S. 
APC Rat IgG2a κ Isotype Control 
(#553932) 
BD Pharmingen,  San Diego, U.S. 
PE/Cy7 Rat IgG2a, κ Isotype Ctrl 
(#400522) 
BioLegend, San Diego U.S. 
Brilliant Violet 605™ Rat IgG2a, κ Isotype 
Ctrl Antibody (#400539) 
BioLegend, San Diego, U.S. 
Alexa Fluor® 647 Rat IgG2a, κ Isotype 
Ctrl (#400526) 
BioLegend, San Diego, U.S. 
Alexa Fluor® 700 Rat IgG2b, κ Isotype 
Ctrl (#400628) 
BioLegend, San Dieg, U.S. 
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APC/Cy7 Mouse IgG2a, κ Isotype Ctrl 
(#400229) 
BioLegend, San Diego, U.S. 
PE Mouse IgG2a, κ Isotype Control 
(#553457) 
BD Pharmingen,  San Diego, U.S. 
PE/Cy7 Rat IgG2a, κ Isotype Ctrl 
(#400522) 
BioLegend, San Diego, U.S. 
Brilliant Violet 421™ Rat IgG1, κ Isotype 
Ctrl Antibody (#400429) 
BioLegend, San Diego, U.S. 
  
Brilliant Violet 510™ Rat IgG2b, κ Isotype 
Ctrl Antibody (#400645) 
BioLegend, San Diego, U.S. 
FITC Rat IgG2a, κ Isotype Ctrl Antibody 
(#400505) 
BioLegend, San Diego, U.S. 
 
4.1.7.5 Hybridoma supernatant for flow cytometry 
Table 16. Hybridoma supernatant for flow cytometry 
Name Specificity Species Isotype Reference 
E3-25 mouse H2-Kb mouse IgG2a Evan et al, 1983 
B22.249 mouse H2-Db mouse IgG2a Lemke et al, 1979 
 
4.1.7.6 Secondary antibodies for flow cytometry 
Table 17. Secondary FACS antibodies 
Material Manufacturer 
APC Goat Anti-Mouse Ig (#550826) BD Pharmingen,  San Diego, U.S. 
FITC conjugated AffiniPure F(ab')₂ Fragment Goat Anti-
Mouse IgG (H+L) 
Jackson Immunoresearch, West 
Grove, USA 
 
4.1.7.7 Antibodies for depletion of cells in vivo 
Table 18. In vivo antibodies 
Material Manufacturer 
InVivoMAb anti NK1.1 (#BE0036) BioXCell, West Lebanon, NH 
InVivoMAb Mouse IgG2a (#BE0085) BioXCell, West Lebanon, NH 
InVivoMAb anti-mouse CD4 (#BE003-1) BioXCell, West Lebanon, NH 
InVivoMAb Rat IgG2b Isotype control; anti 
KLH (#BE0090) 
BioXCell, West Lebanon, NH 
 
4.1.8 MHC multimers 
4.1.8.1 HLA-DR tetramers from NIH 
Table 19. HLA-DR tetramers 
MHC Allele Peptide sequence peptide designation 
HLA-DR*0301 VVTFLVDRKCQLDVL peptide #8797 
HLA-DR*0301 KSKITIDIHFLERKM peptide #8756 
HLA-DR*0301 PVSKMRMATPLLMQA CLIP 
HLA-DR*0401 AFELKNEQTLRADPM peptide #8862 
HLA-DR*0401 TIYNNEVLHQPLSEA peptide #9251 
HLA-DR*0401 PVSKMRMATPLLMQA CLIP 
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4.1.8.2 H2-Db dextramers from Immudex 
Table 20. H2-D
b
 dextramers 
MHC Allele Peptide sequence peptide designation product code 
H2-Db STIYNNEVL peptide #6 JA4335-APC 
H2-Db RAHYNIVTF HPV 16 E749-57 JA2195-APC 
 
4.1.9 Kits 
Table 21. Kits 
Material Manufacturer 
CD11b MicroBeads, mouse/human (#130-
049-601) Miltenyi Biotec GmbH, Gladbach, Germany 
CD4 Microbeads, mouse (#130-052-
301) Miltenyi Biotec GmbH, Gladbach, Germany 
CD8a (Ly-2) MicroBeads, mouse (#130-
049-401) Miltenyi Biotec GmbH, Gladbach, Germany 
CellTiter-Glo® Luminescent Cell Viability 
Assay (#G7572) Promega Corporation, Madison, U.S. 
Dynabeads® Mouse T-Activator 
CD3/CD28 (#11456D) Life technologies, Carlsbad, U.S. 
iScript cDNA Synthesis Kit (#170-8891) Bio-Rad, Richmond, USA 
Mouse IFN gamma ELISA Ready-SET-Go 
(#88-7314) eBioscience, San Diego, U.S.  
Mouse IFN-γ Secretion Assay (#130-090-
516) Miltenyi Biotec GmbH, Gladbach, Germany 
NK Cell Isolation Kit II, mouse (#130-096-
892) Miltenyi Biotec GmbH, Gladbach, Germany 
Pierce™ BCA Protein Assay Kit (#23225) Thermo Fisher Scientific, Waltham, U.S.  
QIAamp® DNA ini and Blood Mini 
Handbook (#51104) Qiagen, Hilden, Germany 
QIAGEN Plasmid Maxi Kit (#12162) Qiagen, Hilden, Germany 
QIAGEN Plasmid Midi Kit (#12143) Qiagen, Hilden, Germany 
QIAGEN Plasmid Mini Kit (#12123) Qiagen, Hilden, Germany 
QIAquick Gel Extraction Kit (#28704) Qiagen, Hilden, Germany 
QIAquick PCR Purification Kit (#28104) Qiagen, Hilden, Germany 
QIAshredder spin columns (#79654) Qiagen, Hilden, Germany 
QuikChange Lightning Site-Directed 
Mutagenesis Kit (#210518) Agilent Technologies, La Jolla, U.S. 
Rapid DNA Ligation Kit (#11 635 379 001) Roche Diagnostics, Mannheim, Germany 
RNeasy Plus Micro Kit (#74034) Qiagen, Hilden, Germany 
RNeasy Plus Mini Kit (#74134) Qiagen, Hilden, Germany 
Transcriptor First Strand 
cDNA Synthesis Kit (#04 379 012 001) Roche Diagnostics, Mannheim, Germany 
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4.1.10 Cells lines 
Table 22. Cell lines 
Cell line Species Source Cell line type  
EL4 Mus musculus 
German Cancer 
Research Center, 
Heidelberg (DKFZ), 
Germany 
T lymphoma (220) 
D8P3 Mus musculus 
German Cancer 
Research Center, 
Heidelberg (DKFZ), 
Germany 
EL4/NY-BR-1 clone 
(generated by Dr. 
Adriane Gardyan) 
A5P1 Mus musculus 
German Cancer 
Research Center, 
Heidelberg (DKFZ), 
Germany 
EL4/NY-BR-1 clone 
(generated by Dr. 
Adriane Gardyan) 
EO771 Mus musculus 
TEBU-Bio 
(Offenbach, 
Germany) 
mammary 
adenocarcinoma (221) 
EONY #9 Mus musculus 
generated in this 
thesis 
EO771/NY-BR-1 clone  
EONY #17 Mus musculus 
generated in this 
thesis 
EO771/NY-BR-1 clone 
EONY #19 Mus musculus 
generated in this 
thesis 
EO771/NY-BR-1 clone 
EONY/PX458 Mus musculus 
German Cancer 
Research Center, 
Heidelberg (DKFZ), 
Germany 
control EONY #19 
transfectant (222) 
EONY/M1KO Mus musculus 
German Cancer 
Research Center, 
Heidelberg (DKFZ), 
Germany 
EONY #19 derived MHC 
I knockout (222) 
B16F10 Mus musculus 
German Cancer 
Research Center, 
Heidelberg (DKFZ), 
Germany 
melanoma 
B16F10/PX458 Mus musculus 
German Cancer 
Research 
Center,Heidelberg 
(DKFZ), Germany 
control B16F10 
transfectant (222) 
B16F10/M1KO Mus musculus 
German Cancer 
Research Center, 
Heidelberg (DKFZ), 
Germany 
B16F10 derived MHC I 
knockout (222) 
HEK293T Homo sapiens 
ATCC, Rockville, 
MD 
human embryonic 
kideny 
T2 Homo sapiens 
T2 (ATCC®CRL-
1992TM) 
174xCEM.Z2; fusion of 
B-LCL 721 and T 
lymphoma (223) 
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T2/DR3 Homo sapiens 
German Cancer 
Research Center, 
Heidelberg 
T2 transfectant 
expressing HLA-
DRB1*0301 
T2/DR4 Homo sapiens 
German Cancer 
Research Center, 
Heidelberg 
T2 transfectant 
expressing HLA-
DRB1*0401 
 
4.1.11 Software 
Table 23. Software 
Software Source 
Microsoft Office 2010 Microsoft, Redmont, USA 
GraphPad Prism 5 GraphPad Software, Inc., San Diego, USA 
Cell Quest BD Biosciences, San Jose, U.S. 
Ascent Software Thermo Scientic, Dreieich, Germany 
FlowJo BD Biosciences, San Jose, U.S. 
 
4.2 Methods 
4.2.1 Preparation of buffers and medium 
4.2.1.1 Molecular Biology 
Table 24. Buffers for molecular biology 
Name Composition 
50x Tris-acetate-EDTA (TAE) Buffer 242 g Tris base 
 
57.1 ml Acetic acid 
 
100 ml 500 mM EDTA solution 
 
Adjust to a final volume of 1 L with ddH2O 
  pH 8.0 
 
4.2.1.2 Microbiology 
Table 25. Buffers for microbiology 
Name Composition 
LB Medium 10 g Tryptone 
 
5 g Yeast extract 
 
10 g NaCl 
 
Adjust to a final volume of 1 L with ddH2O 
  pH 7.5 
LB-amp Medium LB medium pu 150 μg/ml Ampicilin 
LB-amp Plates 7.5 g Agar in 500 ml LB-amp edium 
 
4.2.1.3 Cell Biology and Cell Culture 
Table 26. Composition of various cell culture media 
Name Composition 
Complete CTL Medium 500 ml αMinimum Essential Medium Ea 
 
10% FCS 
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100 U/ml penicillin 
 
100 μg/ml streptomycin 
 
2 mM L-glutamine 
 
50 μM β-mercaptoethanol 
 
5% (v/v) culture supernatant frm concavalin A 
stimulated rat spleen cells 
  5% (v/v) Methyl α-D-mannopyranoside (αMM) 
Freezing Medium 90% (v/v) FC 
  10% (v/v) Dimethyl sulfoxide (DMSO) 
RPMI Complete Medium RPMI Medium 1640 (1x) + GlutaMAX 
 
10% FCS 
 
100 U/ml penicillin 
  100 μg/ml strepomycin 
RPMI Complete Medium with HEPES RPMI Medium 1640 (1x) + GlutaMAX 
 
10% FCS 
 
100 U/ml peniclln 
 
100 μ/ml streptomycin 
  5mM HEPES 
DMEM Complete medium for PECs DMEM, high glucose, GlutaMAX™ 
 
10% FCS 
  100 U/ml penicillin 
DMEM Complete medium for NK cells DMEM, high glucose, GlutaMAX™ 
 
10% FCS 
 
100 U/ml penicillin 
 
50 µM β-ME 
 
2 mM L-gltamine 
 
1x MEM non-essential amino acids 
 
1 mM sodium pyruvate 
  1700 U/ml human IL-2 
 
4.2.1.4 Immunobiology 
Table 27. Buffers for immunobiology 
Name Composition 
FACS Buffer 3% FCS v/v) 
 
5ml 2% Sodium Azide (NaN3) 
  Adjust to a final volume of 500 ml with PBS 
MACS Buffer 4 ml 0.5M EDTA 
 
5g BSA 
  Adjust to a final volume of 1 L with 1x PBS 
 
4.2.1.5 Protein Biochemistry 
Table 28. Buffers for protein biochemistry 
Name Composition 
10% Separation Gel 4 ml H2O 
 
2.6 ml Lower Buffer, pH 8.8 
 
3.3 ml 30% Acrylamide 
 
100 μl 10% APS 
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  4 μl TEMED 
10x Running Buffer 7.5 g Trisma Base 
 
25 ml 10% SDS 
  fill up to 250 ml with ddH2O 
10x Transfer Buffer 15 g Trisma Base 
 
72.5 g Glycine 
 
20 ml 10% SDS 
  fill up to 250 ml with d2O 
1x TBS 2.24g Tris Base 
 
57.1 ml acetic acid 
 
100 ml 0.5 M EDTA solution 
 
fill up to 1 L with ddH2O 
1x TBS-T 1x TBS 
  0.1% Tween20 
1x Transfer Buffer 100 ml 10x transfer buffer 
 
200 ml methanol 
  fill up to 1 L with ddH2O 
5% Stacking Gel 2.7 ml H2O 
 
540 μl Upper Buffer, pH 6.8 
 
680 μl 30% Acrylamid 
 
40 μl 10% APS 
  4 μl TEMED 
5x Protein Loading Dye 0.02% Bromophenol Blue 
 
30% Glycerol 
 
10% SDS 
 
250 mM Tris-Cl pH 6.8 
  add 10% β-Mercaptoethanol before use 
Lower Buffer 90.85 g 1.5M Trisma Base 
 
20 ml 10% SDS 
 
fill up to 250 L with ddH2O 
  pH 8.8 
Upper Buffer 15.15 g 0.5M Trisma Base 
 
10 ml 10% SDS 
 
fill up to 250 ml with ddH2O 
  pH 6.8 
 
4.2.1.6 ELISPOT washing buffer 
Table 29. washing buffer for ELISPOT 
Name Composition 
1x PBS-T PBS 
  0.5% Tween20 
 
 
4.2.2 Cell culture  
EL4, B16F10, B16F10/PX458 and B16F10/M1KO cells were cultured in complete RPMI 
1640 medium. D8P3 and A5P1 cells were cultured in complete RPMI 1640 medium 
supplemented with 40 µg/ml Zeocin. EO771, EONY #9, EONY #17, EONY #19, 
EONY/PX458 and EONY/M1KO cells were cultured in complete RPMI 1640 medium 
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containing 1mM HEPES buffer and 40 µg/ml Zeocin was used for all EONY cells. All cell 
lines were maintained at 37°C in a humidified 5% CO2 incubator. 
4.2.3 IFNγ treatment of tumor cells 
EO771 or EONY#17 cells were seeded at a density of 1x105 cells per well in a 6 well plate 
with 2 ml of culture medium. Mouse IFNγ (eBioscience, #34-8311-82) was added to the 
culture medium to a final concentration of 20U/ml and the cells were incubated overnight. 
4.2.4 Titration of Zeocin concentration on EO771 cells 
EO771 cells were seeded at a density of 1x105 cells per well in a 12 well plate and 24 hours 
later Zeocin was added at various concentrations ranging from 0 µg/ml to 1600 µg/ml with 
increments of 200 µg/ml. The proportion of viable cells was monitored with an optical 
microscope to determine the minimal concentration of Zeocin that was lethal to 100% cells 
within duration of 3 days. 
4.2.5 Generation of stable NY-BR-1 expressing transfectant clones 
EO771 cells were seeded at a density of 2.5x105 cells per well in a 6 well plate and allowed 
to attach overnight and transfected with 1.2 µg of linearized pcDNA3.1(-)zeo-NY-BR-1 DNA 
on the next day using the Effectene
®
 Transfection Reagent from Qiagen. The DNA was 
diluted in EC buffer to a final volume of 100 µl and 9.6 µl of enhancer was added. The 
mixture was vortexed briefly and incubated for 5 minutes at room temperature, following 
which it was centrifuged for 5 seconds. Ten microliter Effectene
®
 reagent was added and 
mixed by vortexing for 10 seconds. The mixture was incubated for 10 minutes at room 
temperature. During the incubation period, medium from the cell culture plates containing the 
cells was aspirated and the cells were washed once with PBS following which 1.6 ml culture 
medium was added to each well. Six hundred microliter of culture medium was added to the 
DNA- Effectene
® 
complexes. It was mixed by pipetting up and down twice and was added 
immediately to wells in drop-wise manner. The medium was replaced with fresh culture 
medium 48 hours after transfection and 400 µg/ml Zeocin was added to select for 
successfully transfected cells. Culture medium containing 400 µg/ml Zeocin was replaced 
every 2-3 days and the cells were expanded for 6 weeks when the bulk culture was tested for 
NY-BR-1 expression. Once NY-BR-1 expression confirmed, single cell clones were obtained 
by limiting dilution. Briefly, cells were adjusted to a concentration of 3 cells/ml in a total 
volume of 60 ml and 100 µl was distributed in each well of 96 well plate; with the assumption 
that every 3rd well will have a single cell which will give rise to clone. Single cell clones 
obtained as such were further characterized for NY-BR-1 expression by qRT-PCR and 
Western blot. 
4.2.6 RNA isolation  
RNA isolation was performed using the RNeasy Plus Mini Kit for cell lines and whole tumor 
lysates or using the RNeasy Plus Micro Kit for tumor infiltrating macrophages sorted by flow 
cytometry. Cells and sorted macrophages were lysed using the RLT Plus buffer included in 
the kit. Tumors were snap frozen in liquid nitrogen and homogenized using the Retsch Mixer 
Mill following which they were lysed with RLT Plus buffer. The lysates were further 
homogenized by passing through QIAshredder spin columns and RNA isolation was carried 
out according to manufacturer‘s instructions. 
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4.2.7 Reverse transcription and qPCR 
RNA isolated from cell lines and whole tumor lysates was quantified with a Nanodrop 
Spectrophotometer and reverse transcribed using the Transcriptor First Strand cDNA  
Synthesis Kit  (Roche) according to the protocol below. 
Step 1 Components Volume per reaction 
 
RNA template (500 ng) x µl 
 
nuclease free water (12-x) µl  
 
Anchored-oligo(dT)18 primer (50 pmol/µl) 1 µl 
 
Total volume  13 µl 
 
 
The reaction mix was incubated at 65 °C for 10 minutes and rested on ice for 5 minutes 
before adding the remaining components. 
Step 2 Components Volume per reaction 
 
Reaction mix from Step 1 13 µl 
 
Transcriptor Reverse Transcriptase Reaction 
Buffer (5x) 4 ml 
 
Protector RNase Inhibitor (40 U/ µl) 0.5 µl 
 
Deoxynucleotide Mix (10 mM each) 2 µl 
 
Transcriptor Reverse Transcriptase (20 U/µl) 0.5 µl 
 
Total volume  20 µl 
 
 
Complete reaction mix was incubated in a thermal cycler at 50 °C for 60 minutes, at 85 °C for 
5 minutes and cooled down to 4 °C and strored at -20 °C until further use. 
RNA isolated from sorted macrophages was eluted in a volume of 17 µl in nuclease free 
water but was not quantified due to low RNA yield. 15 µl was used for reverse transcription 
using the iScript cDNA Synthesis Kit (Roche) according to the protocol below. 
 
Components Volume per reaction 
 
RNA template  15 µl 
 
5x iScript reaction mix 4 µl 
 
iScript reverse transcriptase 1 µl 
 
Total volume  13 µl 
 
 
Complete reaction mix was incubated in a thermal cycler at 25 °C for 5 minutes, at 42 °C for 
30 minutes, at 85 °C for 5 minutes and cooled down to 4 °C and strored at -20 °C until further 
use. 
Quantitification of gene expression was performed using quantitative real-time PCR with 
TaqMan® Universal PCR Master Mix (Applied Biosystems) for NY-BR-1 expression or Power 
SYBR® Green PCR Master Mix (Life Technologies) for macrophage markers in the ABI 7300 
Real-time PCR System (Applied Biosystems) according to the protocol below. 
qRT-PCR using TaqMan® Universal PCR Master Mix 
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Components Volume per reaction 
 
cDNA (diluted 1:5 in nuclase free water) 2 µl 
 
TaqMan® Universal PCR Master Mix  (2X) 10 µl 
 
TaqMan® primer + probe (20X) 1 µl 
 
water 7 µl 
 
total 20 µl 
 
 
 
Pre-incubation                       
(1 cycle) 
50 °C  2 minutes 
 
95 °C  10 minutes 
 
Amplification                        
(45 cycles) 
95 °C  15 seconds 
 
60 °C  1 minute 
 
 
qRT-PCR using Power SYBR® Green PCR Master Mix 
 
Components Volume per reaction 
 
cDNA (diluted 1: 4.3 in nuclease free water) 2 µl 
 
Power SYBR® Green PCR Master Mix (2X) 10 µl 
 
Forward primer (10 µM) 0.4 µl 
 
Reverse primer (10 µM) 0.4 µl 
 
water 7.2 µl 
 
total 20 µl 
 
 
 
Pre-incubation                                
(1 cycle) 
50 °C  2 minutes 
 
95 °C  10 minutes 
 Amplification                                  
(45 cycles) 
95 °C  15 seconds 
 
60 °C  1 minute 
 
72 °C  30 second 
 Melting curve                                   
(1 cycle) 
98 °C  15 seconds 
 
60 °C 1 minute 
 
95 °C  15 seonds 
 
60 °C  15 seonds 
 
 
4.2.8 Isolation and quantification of protein 
Cell lysates were generated addition of appropriated amounts of the Cell Lysis Buffer (Cell 
Signaling) and incubated for 15 min on ice followed by 30 min centrifugation at 13,000 rpm, 
4°C. Protein concentration was determined either by Bio-Rad Protein Assay or by  
PierceTM BCA Protein Assay kit. For the Bio-Rad Protein Assay, the reagent was diluted 1:5 
with ddH2O and 500 µl was added to 5µl protein lysate and incubated for 5 minutes at room 
temperature. The Cell Lysis Buffer was used to set the Blank and protein concentration was 
measured using the ―Bradford‖ program on the BioPhotometer. Protein lysates were stored 
at -80°C until further use. 
4.2.9 Protein detection by Western blot 
Heat denatured whole cell protein samples (15µg- 50µg) were mixed with 5x loading dye and 
separated on a 10% polyacrylamide gel, and electro-transferred onto nitrocellulose 
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membranes. Successful protein transfer was confirmed by Ponceau S staining of the 
nitrocellulose membrane. Before blocking of the membrane with 5% of non-fat milk in TBS-T, 
Ponceau S was washed away with TBS-T buffer. After blocking, the membranes were 
incubated overnight at 4°C on a shaking platform with the respective primary antibody or NY-
BR-1 hybridoma supernatant diluted in 0.5% non-fat milk in TBS-T buffer. Next membranes 
were washed with TBS-T three times, first time after 10 minutes followed by two 5 minute 
intervals. Then the membrane was incubated with the respective horseradish peroxidase 
conjugated secondary antibody diluted in 0.5% non-fat milk in TBS-T for 1h at RT. Following 
another interval of washing with TBS-T buffer, protein signals were detected using the 
enhanced chemiluminescence (ECL) system either by exposing blots to an X-ray film or by a 
charge-coupled device (CCD)-camera .  
4.2.10 Estimation of cell viability (CellTiter-Glo® Assay) 
Cell viability was assessed by CellTiter-Glo® (CTG) assay and it relies on measuring the ATP 
content which is directly proportional to the amount of cells present. Briefly, a known number 
of viable cells were seeded in a flat bottomed 96 well plate in 100µl culture medium (RPMI 
medium with 10% FCS and 1% Pen/Strep). 100 µl of CellTiter-Glo® reagent was added to 
each well of 96 well plate. The contents were mixed for 2 minutes by gentle shaking on an 
orbital shaker and incubated for 10 minutes at room temperature. A luminescent signal is 
generated which is directly proportional to the amount of ATP released from the lysed. The 
luminescence signal was with the Fluoroskan Ascent-Microplate Fluorometer according to 
the manufacturer´s recommendation.  
4.2.11 Immunization of mice with peptide  
For immunization of mice with peptides, peptide #6 (H2-Db-restricted NY-BR-1 specific CTL 
epitope) was adjusted to a concentration of 4 mg/ml and the H2-IAb-restrcited epitope HBV 
core 128-140 was adjusted to a concentration of 5.6 mg/ml. 250µl of each peptide prepared 
above was mixed with 500µl IFA and taken up in an 1 ml syringe and passed through a 
special adapter to another 1 ml syringe. This process was repeated 10-20 times to obtain a 
homogenized emulsion and this was stored once ice until injection. Each mouse was 
immunized with 50 µl peptide emulsion injected s.c. on the left and right breast. The 
immunized mice were sacrificed and spleens were harvested 14 days post immunization 
unless mentioned otherwise. 
4.2.12 Immunization of mice with recombinant adenovirus (Ad.NY-BR-1 or  
Ad.Control) 
Recombinant adenovirus encoding NY-BR-1 (Ad.NY-BR-1) and the empty virus (Ad.Control) 
were purchased from GeneCust (Dudelange, Luxembourg). The gene encoding the E1 viral 
protein was deleted by the supplier thus rendering the virus replication deficient. The virus 
was provided at a concentration of 1012 VP/ml which corresponds to 1x1010 pfu/ml and it was 
diluted 1:1 to obtain a working solution of 5x109 pfu/ml. For immunization, each mouse was 
injected with 5x108 pfu (100µl of the working solution) intraperitoneally. Splenocytes were 
harvested 14 days post immunization unless indicated otherwise. 
4.2.13 Establishment and in vitro propagation of antigen specific CD8+ T cells  
Immunized mice were sacrificed 14 days post immunization and spleens were harvested. 
Single cell suspension of splenocytes was prepared by passing the spleens through a 70 µm 
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cell strainer using a plunger. The cells were centrifuged at 1400 rpm for 10 minutes and the 
cell pellet was resuspended in 1 ml of ACK lysis buffer and incubated for 1 minute at room 
temperature. The ACK lysis buffer was neutralized by adding 49 ml PBS and the cells were 
again centrifuged at 1400 rpm for 10 minutes. The cells were then resuspended in 
incomplete CTL medium (complete CTL without ConA supernatant) and 2x107 spleen cells 
were restimulated in a total volume of 10 ml in upright standing T25 flasks by co-cultivating 
them with different stimulator cells as described below. On day 5, cells were harvested from 
T25 flasks and centrifuged at 1400 rpm for 10 minutes. The cells were then resuspended in 1 
ml of complete CTL medium and distributed in one row of a 24 well plate in roughly titrated 
aliquots with the highest number of cells being seeded in the first well receiving and the 
lowest number of cells in the last well. For in vitro propagation of the T cells, the cells were 
restimulated with the same stimulator cells as the first round every 7 days. The cells were 
used for assays on day 5 after the last restimulation and half of the culture medium was 
replaced with fresh complete CTL medium on the same day. 
4.2.13.1 Restimulation with irradiated NY-BR-1 transfectant cells  
Restimulation with NY-BR-1 transfectant cells as stimulator cells were carried out with 
EL/NYBR-1 transfectant clone D8P3 or with EO771/NY-BR-1 transfectant clone #19 
(EONY#19). The first restimulation ex vivo was carried out by adding 2x106 stimulator cells 
which had been irradiated at 200 Gy to the splenocytes. For subsequent in vitro propagation 
of NY-BR-1 specific CD8+ T cells, 2x105 stimulator cells irradiated at 200 Gy and 5x106 
syngeneic feeder cells irradiated at 33 Gy were added to each well of the 24 well plate. In 
case of CD8+ T cells sorted for dextramer-labeled cells, the first restimulation step was 
skipped. 
4.2.13.2 Restimulation with peptide loaded feeder cells 
Ex vivo restimulation was performed by adding the antigenic peptide (peptide #6 or peptide 
#136) to the splenocytes at the final concentration of 100 ng/ml. For subsequent 
restimulation rounds, syngeneic splenocytes were harvested and adjusted 5x10
6
 cells/ml in 
XVIVO-20 medium and incubated with 1µg/ml peptide #6 or peptide #136 at 37°C for 1 hour. 
The cells were then washed 3 times with PBS to wash away the unbound peptide and 
resuspended in complete CTL medium at a concentration of 5x107 cells/ml. The cells were 
then irradiated at 33 Gy and 100 µl containing 5x10
6
 cells/ were added to each well of the 24 
well plate.  
4.2.13.3 Restimulation with Dynabeads® Mouse T-Activator CD3/CD28 
Dynabeads® Mouse T-Activator CD3/CD28 were used to stimulate single CD8+ T cells 
sorted for dextramer-labeled cells in 96 well plate. One milliliter MACS buffer was added to 
5µl beads and vortexed for 5 seconds and placed on the magnet for 3 minutes and the 
supernatant was discarded. The beads were resuspended in 40 ml complete CTL medium 
and 100 µl was added to each well of 96 well plate. 
4.2.14 In vitro propagation of antigen specific CD4+ T cells 
HLA-DRB1*0401-restricted NY-BR-1 specific CD4+ T cell lines #8862 and #9251 were 
thawed and the cells were seeded in 24 well plates in 2 ml complete CTL medium (with 
ConA supernatant), and restimulated with 2µg/ml respective peptide. Additionally, 5x106 
syngeneic splenocytes were irradiated at 33 Gy and added as feeder cells to each well. 
Every 5-7 days, half of the supernatant was exchanged with fresh complete CTL medium. 
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Restimulation was repeated every 4 weeks by addition of 5x106 irradiated syngeneic feeder 
cells and 2 µg/ml antigenic peptide. 
4.2.15 Peptide binding assay 
For the peptide binding assay, 2x105 cells were incubated overnight with varying 
concentrations of the peptide and the stabilization of the H2-D
b
 and H2-K
b
 molecule on the 
cell surface was quantified by flow cytometry as an indirect measure of peptide binding. 
RMA-S cells were harvested and adjusted to a concentration of 2x106 cells/ml in X-VIVO 20 
medium. Peptide working solution with concentration of 200 µg/ml was prepared. In round 
bottom-96 well plate, the wells highlighted in pink were filled with 100 µl X-VIVO 20 medium 
and the 110 µl of the peptide working solution was added to the wells A1-A3. Ten microliter 
of peptide working solution was transferred from the wells A1-A3 to wells in the second row 
and mixed by pipetting. The process was repeated by transferring 10 µl from the wells in the 
second row to those in the third row and so on. The final 10 ml from the 7th row (row G) was 
discarded and the 8th row did not contain any peptide (see scheme below). Finally, 100 µl of 
RMA-S cell suspension containing 2x105 cells were added to each well and incubated at 37 
°C overnight. This was followed by measurement of MHC I molecule on the cell surface 
using the H2-Db-specific monoclonal antibody B22.249 or H2-Kb-specific monoclonal 
antibody E3-25. 
4.2.16 IFNγ ELISPOT  
Splenocytes from immunized mice or established T cell lines were isolated and IFNγ 
secretion was analyzed in an IFNγ ELSIPOT assay. Briefly the PVDF membrane of 
MultiScreenHTS-IP (Merck Milipore, Darmstadt, Germany) was activated by addition of 15 µl 
of 80% Ethanol and then washed twice with 200 µl PBS. The membrane was then coated 
with 5 µg/ml anti-mouse IFNγ capture antibody (BD Pharmingen,  San Diego, U.S.) for 1 hour 
at 37 °C or overnight at 4°C. The unbound antibody was washed twice with 200 µl PBS and 
the membrane was blocked with 200 ml of culture medium (RPMI with 10% FCS and 
1%Pen/Strep) for 1 hour at 37°C. Unless otherwise indicated, 1x10
5
 effector cells were 
incubated overnight at 37°C and 5% CO2 with 5x10
4 target cells or 100 ng/ml peptide. The 
cells were discarded and plates were washed 4 times with 1x PBS-T followed by one wash 
with PBS. 100 µl of 1µg/ml biotinylated anti-mouse IFNγ was added to each well and 
incubated at 4°C for 1 hour. The antibody was washed 4 times with PBS and 100 µl of avidin-
conjugated alkaline phosphatase antibody (diluted 1:500) was added to each well and 
incubated for 30 minutes at room temperature. The wells were washed 4 times with PBS IFN 
γ secretion was detected by adding  100 µl BCIP/NBT (Sigma, Saint Louis, U.S.) per well 
and incubation at room temperature for 5 minutes. The reaction was stopped by washing the 
wells with distilled water. ELISPOT results were analyzed using the AID ELISPOT reader or 
CTL ELISPOT reader.  Statistical anaylsis performed using Mann Whitney test. 
4.2.17 IFNγ catch assay  
To analyze NY-BR-1 specific CD8+ or CD4+ T cell responses, splenocytes obtained from 
immunized mice were stained for CD8+IFNγ+ or CD4+IFNγ+ T cells by Mouse IFN-γ Secretion 
Assay – Detection Kit (Miltenyi Biotec GmbH, Gladbach, Germany) according to the 
optimized manufacturer´s protocol. Briefly, 2x106-2.5x106 murine spleen cells were seeded in 
12 well plates in 2 ml culture medium (RPMI plus 10% FCS and 1% Pen/Strep) and 
stimulated overnight with 5 μg/ml of the respective peptide. On the following day, cells were 
harvested and transferred to a round bottomed 96 well plate and washed twice with MACS 
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buffer before addition of the IFNγ catch reagent. The cells were then incubated at 37 °C for 
2-3 hours for the secretion period. Subsequently, cells were washed twice with PBS and 
dead cells were stained using the LIVE/DEAD® Fixable Yellow Dead Cell Stain or 
LIVE/DEAD® Fixable Blue Dead Cell Stain Kit. The cells were then washed twice with FACS 
buffer and following which they were stained with fluorochrome labelled anti-mouse CD4 
antibody, anti-mouse CD8 antibody and anti-IFN-γ PE (Miltenyi Biotec GmbH, Gladbach, 
Germany). Data was acquired on a FACS Calibur1, FACS Canto II or LSR II and analyzed 
with FlowJo software. Statistical anaylsis performed using Mann Whitney test. 
4.2.18 IFNγ ELISA 
Secreted mouse IFNγ was quantified using the Mouse IFN gamma ELISA Ready-SET-Go 
(BioLegend, San Diego, U.S.) according to manufacturer‘s instructions. Briefly, Nunc™ 
MaxiSorp™ ELISA Plates, Uncoated (BioLegend, San Diego, U.S.) were coated with the 
capture antibody by incubating overnight at 4°C. The unbound antibody was washed twice by 
adding 250 µl wash buffer per well and the wells were blocked with 100 µl of 1x 
ELISA/ELISPOT Diluent for 1 hour at room temperature. Two fold serial dilution of the 
provided IFNγ was performed to obtain standards with concentrations ranging from 2000 
pg/ml to 15.625 pg/ml. The wells were washed once with 250 µl wash buffer per well before 
addition of the IFNγ standards and the samples which were incubated overnight at 4°C. On 
the following day, the wells were washed 5 times with 250µl wash buffer per well and the 
diluted 1x detection antibody was added (100ml/well) and incubated for 1 hour at room 
temperature. The wells were washed again 7 times with 250 µl wash buffer per well and the 
diluted 1x avidin-HRP antibody was added (100µl/well) and incubated for 30 minutes at room 
temperature. 100µl substrate was added per well and incubated for 5-10 minutes at room 
temperature followed by addition of 50 µl stop solution per well. The absorbance was 
measured on Tecan reader at 450 nm. The IFNγ concentration of the samples was 
determined by using the standard curve generated using GraphPad Prism.  
4.2.19 CD107a degranulation assay 
Fifty thousand NK cells were incubated with RMA, RMA-S, EONY#19, EONY/PX458, 
EONY/M1KO, B16F10, B16F10/PX458 or B16F10/M1KO cells at an effector to target ratio of 
1:10 or with 50 ng/ml PMA and 250 ng/ml Ionomycin for unspecific stimulation. The 
incubation was carried out at 37°C for 4 hours in the presence of anti-CD107a antibody 
(diluted 1:100) or the corresponding isotype control (diluted 1:100) in a total volume of 200 µl. 
The protein transport inhibitor containing Monensin was added at a final dilution of 1:1500 
during the last 3 hours of the incubation period. The cells were washed and the Fc receptors 
were blocked by incubating the cells with FCR block (diluted 1:10) and rat serum and 
hamster serum (diluted 1:100) for 30 minutes at 4°C. The cells were washed and stained 
with antibody cocktail containing LIVE/DEAD® Fixable Blue stain (diluted 1:1000) and anti-
CD3 and anti-NK1.1 antibody (both diluted 1.100) in FACS buffer for 1 hour at 4 °C. The cells 
were washed and analyzed by flow cytometry.  
4.2.20 Isolation of peritoneal exudate cells (PECs) and in vitro polarization 
Mice were injected with 1 ml of 3% Thioglycollate broth (AppliChem, Darmstadt, Germany) 
intraperitoneally and 4 days later mice were sacrificed. The abdomen was sterilized with 70% 
ethanol and a small part of the skin was removed without breaking the peritoneum. 1 ml cold 
PBS was injected into the peritoneum and the abdomen was massaged gently. The 
peritoneal exudate was collected using an 18G needle and a Pasteur pipette. The cells were 
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counted and 1.8x106 cells were seeded in each well of 6 well plate in PECs culture medium 
(DMEM with 10% FCS and 1% Pen/Strep). The macrophages were allowed to attach for 2 
hours at 37°C and the remaining unattached cells were washed away with warm PBS. M1-
like macrophages were obtained by culturing them with PECs culture medium with 100 ng/ml 
LPS and 50 ng/ml IFNγ whereas M2-like macrophages were obtained by polarizing them by 
addition of 10 ng/ml IL-4 to PECs culture medium. 
4.2.21 In vivo tumor growth 
Tumor cells were harvested by trypsinization and the trypsin was neutralized by addition of 
culture medium containing FCS. The harvested cells were washed three time with PBS and 
resuspended  in PBS. Viable cells were counted and cell count was adjusted as required and 
100 µl was injected onto the right flank of mice. In case of tumor cell injections with Matrigel 
(BD Pharmingen, San Diego, U.S.), cells were prepared in Matrigel diluted 1:1 with PBS. For 
injection into mammary fat pad, cells were prepared similarly but 50µl cell suspension was 
injected onto 4th right mammary fat pad. 
4.2.22 Isolation of tumor infiltrating leukocytes 
Tumors were harvested and cut into small pieces using a scalpel. This was digested using a 
mix of Collagenase D (0.5 mg/ml), DNAse I (10 µg/ml), TLCK inhibitor (0.1 µg/ml) and 
HEPES buffer (10mM) in HBSS by shaking at 200 rpm for 1 hour at 37 °C. The tumor pieces 
were then passed through a 70 µm cell strainer using a plunger and the cell strainer was 
flushed with PBS. The cell suspension was centrifuged at 1400 rpm for 10 minutes. The cell 
pellet was resuspended in 5 ml RPMI medium and layered on the top of 5 ml Lympholyte M 
in a 15 ml Falcon tube. The cells were centrifuged at 1500g without brake at room 
temperature. The leukocytes from the interphase were collected and washed with PBS and 
used for further experiments like flow cytometry or MACS. The tumor cell pellet at the bottom 
of the tube was washed with PBS and used for RNA and protein isolation as required. 
4.2.23 Isolation and activation of murine NK cells for in vitro assays 
Spleens were isolated from C57/BL6 mice and single cell suspensions prepared by passing 
them through 70 µM cell strainer using a plunger and the cell strainer was flushed with PBS. 
The cell suspension was centrifuged at 1400 rpm for 10 minutes. Erythrocyte lysis was 
performed by resuspending the cells in 2ml ACK lysis buffer followed by 1 minute incubation 
at room temperature. The cells were washed with 49 ml PBS and resuspended in MACS 
buffer to obtain a single cell suspension. NK cells were isolated using the mouse NK Cell 
Isolation Kit II (Miltenyi) according to the manufacturer‘s instructions . In order to activate the 
NK cells, 1x106 NK cells were seeded in a 6 well plate with 5ml NK cell medium containing 
1700 U/ml IL-2 and cultured for 7 days for use in ELISPOT assay or 6 days for CD107a 
degranulation  assay. 
4.2.24 Magnetic activated cell sorting (MACS) for positive selection  
Cytotoxic T cells among in vitro cultured T cells were enriched by using the CD8a 
microbeads. The cells were harvested and counted using Neubauer chamber. The cells were 
resuspended in MACS buffer and 10 µl CD8a microbeads were added for every 1x10
7
 cells 
at a final dilution of 1:10 and incubated for 30 minutes at 4 °C. The cells were then washed 
twice with MACs buffer and resuspended in 500 µl MACS buffer. An MS column was placed 
on the OctoMACS magnet and washed with 500 µl MACS buffer. The cells were then applied 
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to the column and allowed to pass through the column and the column was washed thrice 
with 500 µl MACS buffer during which the unlabeled cell fraction was collected. The column 
was then removed from the magnet and 1 ml MACS buffer was added to the column. The 
cells were immediately flushed out by firmly applying the plunger. Tumor-infiltrating myeloid 
cells were enriched using CD11b microbeads. Tumor-infiltrating leukocytes were isolated as 
described above and counted using a Neubauer chamber. For every 1x107 cells, 80 µL 
MACS buffer and 20 µl CD11b microbeads were added to the cells and mixed. The cells 
were incubated for 30 minutes at 4 °C. The cells were washed twice with MACS buffer and 
resuspended in 3 ml MACS buffer.  An LS column was placed on the QuadroMACS magnet 
and washed with 3 ml MACS buffer. The cells were then applied to the column and allowed 
to pass through the column and the column was washed thrice with 3 ml MACS buffer during 
which the unlabeled cell fraction was collected. The column was then removed from the 
magnet and 1 ml MACS buffer was added to the column. The cells were immediately flushed 
out by firmly applying the plunger. 
4.2.25 Dextramer staining 
Spleens were harvested from mice immunized with Ad.NY-BR-1 or Ad.Control and single cell 
suspensions were prepared followed by erythrocyte lysis and cells were counted using a 
Neubauer Chamber. The cells were washed with PBS and 1x106 cells were incubated with 
LIVE/DEAD® Fixable Yellow Dead Cell Stain diluted 1:1000 in PBS for 30 minutes at 4 °C. 
The cells were washed again with PBS and incubated with dextramers diluted as indicated in 
60 µl FACS buffer for 30 minutes at room temeperature in dark. Fluorescently labeled FACS 
antibodies for CD3, CD8, CD4 and CD14 or the respective isotype control were diluted 1:50 
in 60 µl FACS buffer and added to the cells without washing of the dextramers so that the 
final diltuon of the antibodies was 100 fold. They cells were incubated with the antibody mix 
at 4°C for 30 minutes. The cells were then washed and analyzed by flow cytometry or sorted 
for live CD3+CD14-CD8+dextramer+ cells. 
4.2.26 Tetramer staining 
CD4+ T cells were harvested and counted in a Neubauer chamber. The HLA-DRB1*0401 and 
HLA-DRB1*0301 tetramers were diluted in FACS as indicated and 1x106 CD4+ T cells were 
incubated with the tetramer at 37°C or at 4 °C, as indicated for the duration indicated. The 
cells were then washed with FACS buffer and counterstained with anti-CD4 and anti-CD8 
antibody diluted 1:100 in FACS buffer by incubating them at 4 °C for 1 hour or 45 minutes. In 
some cases, the tetramer staining was carried out in FACS buffer containg 5 nM dasatinib. 
4.2.27 Flow cytometry for analysis and cell sorting 
For flow cytometry analysis, 1x106 cells were used for each sample unless otherwise 
mentioned. Cells were harvested and washed with twice with 200 µl FACS buffer. A mix of 
0.05mg/ml Purified Rat Anti-Mouse CD16/CD32 (BD Pharmingen, San Diego, U.S.), rat 
serum (GeneTex, Irvine, USA) and hamster serum (Jackson Immunoresearch, West Grove, 
USA) was used for blocking the FC receptors on tumor infiltrating leukocytes and PECs by 
incubating them at 4° for 20 minutes. For tumor cell lines and splenocytes this step was not 
done. The cells were then washed twice with 200 µl PBS. LIVE/DEAD® Fixable Yellow Dead 
Cell Stain or LIVE/DEAD® Fixable Blue Dead Cell Stain Kit, for UV excitation (Life 
technologies, Carlsbad, U.S.) was diluted 1:1000 in PBS and 100 µl was added to each 
sample. The cells were incubated for 30 minutes at 4°C and washed twice with 200 µl FACS 
buffer. The cells were stained for surface markers with respective antibodies (or isotype 
Materials and methods Page 61 
 
controls) diluted 1:100 in 100µl FACS buffer per sample and incubation was carried out for 1 
hour at 4°C. The cells were then washed twice with 200 µl FACS buffer and resuspended in 
200-400 µl FACS buffer and analyzed or sorted on a flow cytometer. In case intracellular 
proteins needed to be stained, the cells were fixed and permeabilized using the BD 
Cytofix/Cytoperm Fixation/Permeabilization Kit (BD Biosciences, San Jose, U.S.). Briefly, the 
cells were resuspended in 100µl fixation permeabilization solution and incubated at 4°C for 
20 minutes and then washed twice with 200 µl 1x BD Perm/Wash buffer. The antibodies for 
intracellular staining (or isotype controls) were diluted 1:100 in 100 µl 1x BD Perm/Wash 
buffer per sample and the cells were incubated for 1 hour at 4°C. The cells were washed 
twice with 200 µl 1x BD Perm/Wash buffer and resuspended in 200-400 µl FACS buffer for 
analysis. 
4.2.28 In vivo depletion of NK cells and CD4+ T cells  
For NK cell depletion, 100 μg NK1.1 specific monoclonal antibody clone PK136, or isotype 
control clone C1.18.4 (both BioXcell, West Lebanon, NH) were administered intraperitoneally 
2 days prior to the day of tumor injection. To maintain NK cell depletion, antibody injection 
was repeated on the day of tumor injection and on days 7 and 13 after tumor inoculation. For 
CD4+ T cell depletion, 100 µg CD4 specific monoclonal antibody clone GK1.5, or isotype 
control clone LTF-2 (both BioXcell, West Lebanon, NH) were administered intraperitoneally 
daily for 3 days prior to tumor inoculation and repeated on days 1, 4, 7, 10, 13 and 16 after 
tumor inoculation. 
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5 Results 
5.1 Establishment of a heterologous transplantable NY-BR-1 expressing tumor 
model 
The lymphoma cell line EL4 is derived from C57BL/6 mice (220) and expresses the MHC I 
molecules namely the H2-Db and H2-Kb. EL4 cells are negative for MHC II expression on the 
surface and fail to upregulate it even after IFNγ treatment. This makes them suitable for 
being used as a stimulator cell for the in vitro expansion of NY-BR-1-specific H2b-restricted 
CTLs and for transplantation in HLA-DR4tg mice since HLA-DR4tg mice have H2-Db and H2-
Kb for MHC I and chimeric HLA-DR4 molecule for MHC II. This cell line had been transfected 
previously in our lab with linearized plasmid pcDNA3.1(-)zeo-NY-BR-1, giving rise to single 
cell clones expressing NY-BR-1 (Gardyan et al). EL4/NY-BR-1 clone D8P3 and clone A5P1, 
referred to as D8P3 and A5P1 from now on were found to express high levels of NY-BR-1 
RNA and protein and thus were selected for in vivo experiments.  
5.1.1 Characterization of EL4/NY-BR-1 transplantable model 
5.1.1.1 Determination of optimal number of transplanted tumor cells in vivo 
In order to characterize the growth kinetics of EL4/NY-BR-1 transfectants in vivo, single cell 
clones D8P3 and A5P1 were injected subcutaneously into HLA-DR4tg mice in varying 
numbers and growth rate was monitored. Tumors developed in all mice latest by day 13 after 
tumor cell injection, even with the lowest cell number of 5x104 cells per mouse. Palpable 
tumors could be detected in the mice receiving 5x105 cells or 1x105 cells already 7 days after 
tumor inoculation (Figure 8). On day 13 after tumor injection, tumors derived from 5x105 
A5P1 cells showed signs of necrosis and hence were excluded from further group analysis. 
Thus, the dose dependent effect of the tumor cell number on the tumor growth curve is not 
apparent in this group (Figure 8B). The tumor growth rate in the remaining mice was 
monitored (Figure 8B, right panel). The growth rate of D8P3 clearly showed a dose 
dependent effect with the highest cell number of 5x105 cells giving rise to tumors of average 
size of 285 mm2 by day 18 (Figure 8A) when they were sacrificed owing to large tumors. The 
other tumors were monitored until they attained the maximum allowed size or until day 24 
when the experiment was terminated. Due to the fact that different numbers of D8P3 cells 
gave rise to tumors with corresponding growth kinetics without developing necrosis, they 
were selected for further experiments. 
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Figure 8. Comparison of tumor growth curves of EL4 derived, NY-BR-1-expressing clones 
D8P3 and clone A5P1 
(A) 5x10
4
, 1x10
5
 or 5x10
5
 D8P3 or (B) A5P1 cells were injected s.c. into the right flank of HLA-
DRB1*0401tg mice (n=4) and tumor growth was monitored for 24 days after injection. Tumor 
dimensions were measured by calipers and tumor size was calculated by the following formula (area= 
length x breadth). Error bars represent SEM. Mice were sacrificed when tumor size reached 225 mm
2
 
and mean tumor size is depicted until the first mouse dropped out. The tumor growth curve of 
individual mice is depicted on the right. 
 
5.1.1.2 NY-BR-1 expression is retained in tumors in vivo 
In order to test whether NY-BR-1 expression alters the growth rate of the parental EL4 cell 
line in vivo, the growth rate of EL4 and D8P3 derived tumors was initially compared applying 
Results Page 64 
 
1x106 tumor cells. Both tumor cell lines injected subcutaneously into the flank of HLA-DR4tg 
mice grew at a comparable rate (Mann Whitney test, p=0.6857) (Figure 9A). The NY-BR-1 
transfectants were always cultured under Zeocin selection pressure in vitro, however once 
inoculated into mice the tumor cells can lose NY-BR-1 expression. To address this issue, the 
tumors were harvested on day 14 after tumor inoculation and the expression of NY-BR-1 
protein and RNA was analyzed in the excised tumors. The highest level of NY-BR-1 RNA 
was detected in mouse 1 followed by mouse 3 (Figure 9B) which corresponds to the level of 
NY-BR-1 protein detected by Western blot (Figure 9C, lane 1 and 3). NY-BR-1 was not 
detected in the tumors derived from the parental cell line EL4 either at the RNA level (Figure 
9B, grey bars) or at the protein level (Figure 9C). It is important to note that NY-BR-1 protein 
is known to have a molecular weight of 159kDa which is the uppermost band detected (as 
indicated by the arrow) but additional unspecific bands of lower sizes were detected in all 
tumor lysates. 
 
Figure 9. NY-BR-1 expression in EL4 cells did not alter its growth in vivo 
(A) HLA-DRB1*0401tg mice were injected s.c. on the right flank with 1x10
6 
EL4 cells or D8P3 cells 
and tumor growth was monitored for 14 days after injection. Tumor dimensions were measured as 
described earlier. Error bars represent SEM (n=4). The tumor growth curve of individual mice is 
depicted on the right. (B) Tumors were resected 14 days post injection and expression of NY-BR-1 
mRNA was analyzed by qRT-PCR. Bars represent individual mice and error bars depict SEM of 
triplicates in qRT-PCR. (C) NY-BR-1 expression at protein level could also be detected in at least 2 
mice that were injected with D8P3 cells (Exposure time: NY-BR-1, 20 minutes and β-Actin, 5 
seconds). (D) EL4 cells and D8P3 cells were treated with lactacystin as described earlier and NY-BR-
1 expression was analyzed by Western blot (Exposure time: NY-BR-1, 15 minutes and β-Actin, 10 
seconds). More NY-BR-1 protein was detected in D8P3 cells after lactacystin treatment as a result of 
impaired protein degradation. 
 
Results Page 65 
 
5.1.1.3 NY-BR-1 protein has a high turnover rate in EL4/NY-BR-1 transfectant clone 
D8P3 
The continuous expression of NY-BR-1 protein by the tumor cells in vivo is indispensable for 
their recognition by T cells. However, T cells recognize the antigenic peptides derived from 
degradation products when displayed on MHC molecules. Thus, absence of high levels of 
intracellular NY-BR-1 protein could be due to the fact that it is degraded very rapidly by the 
proteasome. Therefore, inhibiting the proteasome activity should allow the detection of native 
NY-BR-1 protein. In order to test whether the low level of NY-BR-1 expression by D8P3 cells 
was due to high turnover of NY-BR-1 in these cells, they were treated with 5 µM lactacystin 
for 18 hours and NY-BR-1 expression was analyzed by Western blot. The inhibition of 
proteasome increased the detectable amount of NY-BR-1 protein in D8P3 cells (Figure 9D) 
compared to untreated D8P3 cells. EL4 cells on the other hand, remained negative for NY-
BR-1 even after lactacystin treatment.  
5.1.2 Establishment of EO771/NY-BR-1 tumor model 
Since EL4 tumors are lymphoma derived and NY-BR-1 is a breast cancer associated 
differentiation antigen, a mammary carcinoma cell line would allow the establishment of an 
orthotopic model. Thus, a murine mammary adenocarcinoma cell line derived from C57BL/6 
mice called EO771 was selected to generate NY-BR-1 expressing mammary carcinoma cell 
line. 
5.1.2.1 Generation and characterization of EO771/NY-BR-1 transfectant clones 
EO771 cells were seeded at a density of 1x105 cells per well in a 6 well plate and one day 
later Zeocin was added at varying concentrations to determine the minimal lethal 
concentration. The number of viable cells was monitored optically under a microscope and 
the concentration 400 µg/ml was found to be lethal to 100% cells within 3 days. Thus, this 
concentration was used for selection of EO771 cells successfully transfected with the 
linearized plasmid pcDNA3.1(-)zeo-NY-BR-1.  
Transfected EO771 cells were cultured with 400 µg/ml Zeocin in order to select for 
successfully transfected cells. Seven days after selection with Zeocin, colonies of 
successfully transfected cells were observed under the microscope as the untransfected 
cells failed to grow. The cells were then expanded and harvested for analyzing NY-BR-1 
RNA and protein expression. The NY-BR-1 was protein corresponding to a molecular weight 
of 160 kDa was detected by Western blot in the EO771/NY-BR-1 transfectants (Figure 10A, 
lane 4) but not in the parental EO771 cells (Figure 10A, lane 3). Protein lysates from 
MaMel21 cells infected with control adenovirus Ad5.Control were used as a negative control 
whereas MaMel21 cells infected with NY-BR-1 expressing Ad.NY-BR-1 were used as a 
positive control. NY-BR-1 RNA was quantified using qRT-PCR and was absent in the EO771 
cells as expected whereas EO77/NY-BR-1 transfectant cells tested positive for NY-BR-1 
RNA (Figure 10B). 
Single cell clones of EO771/NY-BR-1 transfectant cells were obtained by limiting dilution and 
in total 19 clones tested for NY-BR-1 expression levels by Western blot and qRT-PCR. All 
EO771/NY-BR-1 clones are henceforth designated as EONY followed by the clone number. 
All the 19 clones tested positive for NY-BR-1 protein and clones #9, #20 and #22 were found 
to possess the highest levels of NY-BR-1 protein (Figure 10D). This correlated well with NY-
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BR-1 RNA expression results obtained by qRT-PCR (Figure 10C). Additionally, the clone 
EONY #19 was also found to express high levels of NY-BR-1 RNA.  
 
Figure 10. Generation of EO771/NY-BR-1 transfectant clones 
EO771 cells were transfected with a linearized plasmid pcDNA3.1-NY-BR-1 and stably transfected 
cells were selected by culturing them under Zeocin selection pressure. (A) The bulk culture was 
tested for NY-BR-1 expression by Western blot to confirm successful transfection. The molecular 
mass (in kDa) of NY-BR-1 and β-actin is indicated on the right hand side.  (B) The expression of NY-
BR-1 in the bulk culture of EO771/NY-BR-1 was confirmed at the mRNA level by qRT-PCR. Several 
single cell clones of EO771/NY-BR-1 cells were obtained by limiting dilution and they were tested for 
the level of NY-BR-1 expression by (C) qRT-PCR and (D) Western blot. NY-BR-1 expression relative 
HMBS is shown and error bars depict SEM of triplicates in qRT-PCR. 
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Figure 10 (contd). Generation of EO771/NY-BR-1 transfectant clones 
(D) Expression of NY-BR-1 protein in the various single cell clones was tested by Western blot. 
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Using linearized plasmid instead of circular plasmids for transfection allows the plasmid to be 
integrated into the genomic DNA resulting in stable transfectants. However, the genomic 
DNA locus where it integrates is random and could potentially affect cell viability if for 
example it disrupts an important gene or promoter. Thus, 8 clones with different levels of NY-
BR-1 expression were selected for assessing cell viability. Equal numbers of cells were 
 
Figure 11. Characterization of EO771/NY-BR-1 transfectant clones 
(A) 2x10
4
 cells of different EONY clones were seeded and the amount of viable cells was measured 
after 48, 72 and 96 hours later using the CellTiter-Glo
®
 Assay. The relative luminescence units (RLU) 
obtained is proportional to the number of viable cells. The viability of each clone normal ized to parental 
EO771 cells is depicted for the different time points. (B) NY-BR-1 protein expression in the selected 
clones after 6 weeks in vitro culture was analyzed by Western blot. 
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seeded and the amount of viable cells was measured after 48, 72 and 96 hours later using 
the CellTiter-Glo® Assay. There was no substantial effect on the viability of the EO771/NY-
BR-1 clones compared to the EO771 cells (Figure 11A). In order to confirm that NY-BR-1 
expression was retained in vitro after prolonged culture of the clones, cell lysates were 
prepared from EONY clones cultured for 6 weeks and NY-BR-1 protein expression was 
tested by Western blot. It was observed that EONY#9 consistently expressed the highest 
amount of NY-BR-1 protein, whereas EONY#19 lost its high expression of NY-BR-1 over 
time (Figure 11B). Still, EONY #19 was chosen for the initial in vivo experiments since the 
NY-BR-1 protein was clearly detected in clone #19 without a lot of unspecific products as in 
the case of clones #9, #20 and #22 (Figure 10D). Besides, it expressed NY-BR-1 RNA at 
high levels and displayed no reduction in cell viability. However, after it was discovered that 
NY-BR-1 expression is not stable in EONY#19, EONY#9 and EONY#17 were selected for 
later experiments. 
5.1.2.2 EO771 cells lack surface expression of I-Ab molecules 
 
Figure 12. EO771 and EONY#17 cells lack surface expression of I-A
b
 molecules  
Untreated EO771 or EONY#17 cells or those stimulated overnight with 20 U/ml IFNγ were stained for 
MHC I molecule using hybridoma supernatant which specifically binds  H2-D
b
 and for MHC II molecule 
using a monoclonal antibody directed against I-A
b
. The staining results are displayed as histograms for 
unstained sample (grey curve), without IFNγ treatment (light blue curve) and with overnight IFNγ 
treatment (dark blue curve). The level of MHC I expression on EO771 cells (left panel), MHC II on 
EO771 cells (middle panel) and MHC II on EONY#17 cells (right panel) is depicted.  
 
EO771 cells are derived from C57BL/6 mice and therefore are syngeneic to HLA-DR4tg mice 
with respect to MHC I molecule and express H2-Kb and H2-Db but differ in terms of their 
MHC II expression. Since C57BL/6 mice express I-Ab molecules, tumor cells derived from 
C57BL/6 mice might generate an immune response when transplanted into HLA-DR4tg mice 
which are knocked out for I-Ab molecule and therefore would recognize it as a xeno-antigen. 
Thus, EO771 cells were tested for the expression of I-Ab molecules on their surface by flow 
cytometry. No I-Ab molecules were detected on EO771 cells (Figure 12, middle panel) and on 
EONY#17 cells (Figure 12, right panel). In vivo, IFNγ might be present in high amounts in the 
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tumor microenvironment resulting in the upregulation of both MHC I and MHC II molecules 
(224). The level of MHC I expression on EO771 cells was increased when exposed to 20 
U/ml IFNγ overnight (Figure 12, left panel), however EO771 cells (Figure 12, middle panel) 
and EONY #17 (Figure 12, right panel) failed to upregulate I-Ab on their cell surface following 
stimulation with IFNγ. Thus, EO771 and EONY#17 appear suitable for transplantation into 
HLA-DR4tg mice without the risk of inducing xenoreactive immune responses. 
5.1.2.3 Characterization of EO771/NY-BR-1 clones in vivo 
 
Figure 13. Optimization of transplantation of EO771 and EO771/NY-BR-1 clone #19 in the flank 
and in the mammary fat pad 
EO771 or EONY #19 cells (5x10
5
 or 2x10
5
) were injected s.c. into the right flank or the fourth 
mammary fat pad on the right side of HLA-DRB1*0401tg mice (n=4) and tumor growth was monitored 
for 22 days post injection. (A) Average size of tumors derived from 5x10
5
 EO771 cells (black), 5x10
5
 
EONY#19 cells (red) and 2x10
5
 EONY#19 cells injected s.c. into the flank is depicted (left panel) and 
the corresponding tumor growth curves of individual mice are shown (right panel). (B) Comparison of 
tumor growth kinetics of 5x10
5
 or 2x10
5
 EONY#19 cells injected s.c. into the right flank or the fourth 
mammary fat pad is shown (left panel) along with the individual growth curves  of each mouse.  
 
NY-BR-1 is a breast cancer associated antigen and EO771 is a murine mammary 
adenocarcinoma cell line, thereby making EONY#19 cells an ideal candidate for establishing 
an orthotopic model. Thus, 5x105 or 2x105 EONY#19 cells were injected into the right flank or 
the fourth mammary fat pad of HLA-DR4tg mice and the growth rate was monitored. When 
EONY#19 cells were injected into the flank, the first tumors were apparent by day 6 for 5x105 
cells and by day 11 for 2x105 cells (Figure 13A). Thus, the growth rate of the tumors 
Results Page 71 
 
corresponded to the number of tumor cells injected. On the other hand, injection of cells in 
the mammary fat pad was not as successful in giving rise to tumors. There was no difference 
in the growth rate between the groups receiving different numbers of tumor cells. Even 
though the tumors began to develop after day 6, they failed to develop in size over time 
(Figure 13B). Notably, the tumors transplanted into the mammary fat pad turned necrotic and 
this could also be the reason why they did not grow in size.  
 
Figure  13 (contd). Optimization of transplantation of EO771 and EO771/NY-BR-1 clone #19 in 
the flank and in the mammary fat pad 
(C) The growth rate 5x105 or 2x105 EONY#19 tumor cells transplanted orthotopically into the 
mammary fat pad with Matrigel (diluted 1:1) or without it is presented (left panel) in addition to the 
growth rate of individual tumors. 
 
Matrigel is solubilized basement membrane matrix that is derived from Engelbreth-Holm-
Swarm cells (mouse sarcoma) and is known to be a liquid at 4°C but solidifies at room 
temperature. It is used in tumor models especially for hematologic tumors to facilitate 
formation of a solid tumor. Additionally, it can act as a short term reservoir for growth factors 
enhancing the growth rate of tumor cells in vivo. Thus EONY#19 cells were injected in the 
mammary fat pad in Matrigel diluted 1:1 and the effect on tumor growth was measured. 
Addition of Matrigel did not improve the formation of mammary tumors by orthotopically 
transplanted EONY#19 cells as there was no difference in the tumor growth curves when 
5x105 or 2x105 EONY#19 cells were injected in Matrigel (Figure 13C).  
Thus, it was decided to use the heterotopic transplantation model where the breast cancer 
derived tumor cells are injected s.c. into the flank of the recipient mice. As described in the 
previous section, EONY#19 lost its NY-BR-1 expression over time and thus EONY#9 and 
EONY#17 cells were selected for subsequent studies. Tumor growth rates of EONY#9, 
EONY#17 and EO771 cells subcutaneously transplanted into HLA-DR4tg mice were 
measured. The different tumor cell lines grew at significantly different rates. Among mice 
injected with 2x105 EO771 cells the first palpable tumors could be detected by day 7 and all 
mice developed tumor by day 10 (Figure 14A, black curve). In spite of slight variations in the 
growth rate among the individual mice all the tumors progressively grew in size and reached 
an average size of 102.57 mm2 by day 18 (Figure 14A, black curve). Even though tumor 
growth was monitored until day 20 and individual growth curves are depicted (Figure 14A, 
right panel, black curves), comparison of tumor sizes was terminated on day 18 as some of 
the EO771 derived tumors developed necrosis and shrank in size. The same number of 
Results Page 72 
 
EONY #9 cells failed to grow in vivo in all mice and only 7 out of 10 mice developed 
detectable tumors 20 days after tumor inoculation (Figure 14A, right panel, red curves). 
EONY#17 cells grew at intermediate rate giving rise to tumors in all mice 18 days after 
injection (Figure 14A, blue curve). Twenty days after tumor injection, the tumors were 
harvested and snap frozen in liquid nitrogen and NY-BR-1 expression in the tumors was 
analyzed by qRT-PCR and Western blot. NY-BR-1 RNA could be detected in EONY#9 and 
EONY#17 derived tumors but not in EO771 tumors (Figure 14B). RNA from EONY#9, 
EONY#17 and EO771 cells isolated on the day of injection of the tumors were included as 
positive and negative controls, respectively for reference. Unfortunately, NY-BR-1 protein 
could not be detected in the resected tumors originating from EONY#9 cells (Figure 14C, red 
line) or EONY#17 cells (Figure 14C, blue line). NY-BR-1 expression in EONY#9 and 
EONY#17 cell lysates prepared on the day of tumor injection could be confirmed (Figure 
14C, green line). However, an indirect evidence of persistent NY-BR-1 protein expression in 
vivo was observed as NY-BR-1 specific T cells were detected in mice bearing NY-BR-1 
expressing tumors. This is described in detail in section 5.4.1.  
 
Figure 14. Comparison of tumor growth curves of parental EO771 cells and EONY #9 and 
EONY #17 
HLA-DRB1*0401tg mice were injected s.c. on the right flank with 2x105 EO771, EONY #9 or EONY 
#17 cells and tumor growth was monitored for 20 days post injection. On day 20, tumors were 
resected and single cell suspensions were prepared by enzymatic digestion. Immune cells were 
isolated by performing gradient centrifugation using Lympholyte-M and collecting the interphase. The 
remaining cell pellet containing tumor cells was used for RNA isolation and NY-BR-1 expression was 
analyzed by qRT-PCR and Western blot. (A) Tumor area was calculated from tumor dimensions 
measured as described earlier. Error bars represent SEM (n=10) and statistical analysis was 
performed for tumor size of EONY#9 and EONY#17 tumors compared to EO771 tumors . ***, 
p<0.001; ****, p<0.0001 (Mann Whitney test). The tumor growth curve of individual mice is depicted 
on the right.  
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Figure  14 (contd) Comparison of tumor growth curves of parental EO771 cells and EONY #9 
and EONY #17 
(B) NY-BR-1 expression relative to HMBS is depicted here and each bar represents tumor derived 
from an individual mouse and error bars represent SEM of triplicates in qRT-PCR. Tumors derived 
from some mice have not been included here due to poor RNA yield or quality. (C) Western blot 
analyzing the NY-BR-1 expression in tumor lysates and β-actin used as a loading control. The origin of 
the sample is indicated with different colors (red line, EONY#9 tumors; blue line, EONY#17 tumors; 
black line, EO771 tumors and green line, cell lysates from the day of injection.  
 
5.1.2.4  Characterization of MHC I knockout cells 
Cytotoxic T cells and NK cells are known as major effector populations of the cellular 
immune system, able to directly kill tumor cells. Whereas CTL mediated target cell 
recognition depends on cell surface expression of MHC I molecules, NK cells on the contrary 
attack tumor cells lacking expression of MHC I molecules on the cell surface. Thus, in order 
to have a tool available enabling investigation of NK cell and CTL responses in our NY-BR-1-
expressing tumor model, MHC I knockout tumor cell line was created to delineate the 
functional contributions of CD8+ T cells and NK cells in the scenario of immunological tumor 
eradication.  
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Figure 15. MHC I knockout tumor cell lines fail to grow out in vivo 
C57BL/6 mice (n=10) were injected s.c. on the right flank with 2x10
5
 tumor cells and tumor growth 
was monitored. Tumor dimensions were measured and tumor area was calculated as described 
earlier. Mean tumor area of transplanted (A) EONY #19, EONY/PX458 or EONY/M1KO tumors or (B) 
B16F10, B16F10/PX458 or B16F10/M1KO tumors is depicted. Error bars represent SEM (n=10) and 
statistical analysis was performed for tumor size of EONY/M1KO tumors compared to EONY/PX458 
tumors. ***, p<0.001; (Mann Whitney test). The tumor growth curve of individual mice is depicted on 
the right.  
 
MHC I complex is comprised of an α chain and a β2-microglobulin (β2m) molecule (Figure 5). 
The β2m molecule is critical for the stability of the MHC I complex on the cell surface and 
defective β2m expression results in lack of surface expression of MHC I (225). Hence we 
deleted the β2m molecule using the CRISPR/Cas9 technology for gene editing, resulting in 
β2m deficient clone EONY/M1KO and MHCI expressing control clone EONY/PX458 (222).  
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In order to characterize the tumor growth kinetics in vivo, the growth rate of subcutaneously 
transplanted EONY-M1KO and B16F10-M1KO tumors (the latter described in Das et al. 
2017) was compared to those obtained from their respective parental cell lines and 
EONY/PX458 and B16F10/PX458 tumors. The growth of EONY-M1KO tumors was delayed 
and the first palpable tumors developed 12 days after inoculation compared to 7 days in the 
case of EONY/PX458 and EONY #19 derived tumors (Figure 15A, left panel). Notably, only 
50% mice injected with EONY-M1KO cells developed tumors which were significantly smaller 
and the mean tumor area on day 20 was 4 times smaller compared to EONY/PX458 and 
EONY#19 tumors which had comparable growth kinetics (Figure 15A). Remarkably, 
B16F10/M1KO cells on the other hand completely failed to give rise to tumors compared to 
B16F0/PSX458 and B16F10 cells (Figure 15B).Since NK cells can sense the lack of MHC I 
expression on the cell surface and can reject tumor cells lacking MHC I (226), we tested if 
the EONY/M1KO and B16F10/M1KO cells were susceptible to NK cell mediated killing. NK 
cells isolated from splenocytes of C57BL/6 mice were activated with IL-2 and co-cultured 
with the MHC I knockout cell lines and their corresponding parental cells. NK cell activation 
was measured in the form of secreted IFNγ in an ELISPOT assay and by ELISA. RMA-S cell 
which are known NK cell targets (226) were included as a positive control along with the 
parental RMA cells. The activated NK cells secreted high amount of IFNγ which resulted in 
partially saturated wells in the ELISPOT assay especially when RMA-S, B16F10/PX458 and 
B16F10/M1KO were used as targets, which made the quantification of spot number difficult 
(Figure 16A). Therefore, we attempted to quantify the secreted IFNγ by ELISA. NK cells 
secreted 140% more IFNγ when stimulated with the MHC I knockout cells compared to the 
parental cell lines or those transfected with PX458 (Figure 16B). As expected, the MHC I 
deficient mutant cell line RMA-S was  recognized by NK cells resulting in a strong IFNγ 
response which was 4 fold higher compared to IFNγ secreted in response to wildtype RMA 
cells (Figure 16B). This confirmed that MHC I knockout cells generated by CRISPR/Cas9 
system become NK cell targets and stimulated them to secrete IFNγ. In order to prove that 
lack of MHC I surface expression also renders these cells more susceptible to NK cell 
mediate killing we performed CD107a degranulation assay (227). Activated NK cells were 
incubated with target cells and the extent of degranulation was measured by surface staining 
for CD107a. Fifty percent more NK cells upregulated CD107a on their cell surface in 
response to EONY/M1KO cells compared to EONY/PX458 cells (Figure 16C). 
B16F10/M1KO cells induced degranulation in 1.9 times more NK cells compared to 
B16F10/PX458 (Figure 16C). Parental B16F10 cells which have been demonstrated to 
express activating NK cell receptors NKp46 and DNAM-1 (228) were also targets for NK cell 
mediated cytoxicity as indicated by degranulation of NK cells (Figure 16C). RMA-S cells 
which were used as positive controls were two times more susceptible to NK cell cytolysis 
compared to RMA cells (Figure 16C). Since MHC I knockout clones were susceptible to NK 
cell mediated cytotoxicity; we wanted to investigate if NK cells were the effector population 
that mediate the rejection of MHC I knockout cell lines in vivo after transplantation into 
C57BL/6 mice. In order to do so we depleted the NK cells in the recipient mice prior to tumor 
inoculation by using a NK cell depleting antibody (PK136). Figure 17A depicts the scheme of 
administration of depleting antibody or the corresponding isotype control and of tumor 
inoculation. Indeed B16F10/M1KO cells could give to tumors in mice which received the NK 
cell depleting antibody (Figure 17B, closed red circles) as compared to the isotype control 
(Figure 17B, open red circles). B16F10/PX458 derived tumors also grew at a faster rate in 
the absence of NK cells (Figure 17B, closed blue triangles) but the difference was not 
statistically significant when compared to those in mice treated with the isotype control 
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(Figure 17B, open blue triangles). Thus, we could show that CRISPR/Cas9 system could be 
successfully utilized to generate MHC I knockout cells which are susceptible to NK cell 
recognition and killing both in vitro and in vivo. 
 
Figure 16. Knockout of MHC I surface expression on tumor cell lines by CRISPR/Cas9 makes 
them NK cell targets 
NK cells were isolated from splenocytes of C57BL/6 mice by negative selection and activated for 7 
days with 1700 U/ml IL-2. The activated NK cells were co-cultured with RMA, RMA-S, B16F10, 
B16F10/PX458, B16F10/M1KO, EONY #19, EONY/PX458 and EONY/M1KO cells and their 
susceptibility to NK cell recognition and NK cell mediated killing was analyzed. (A) 5x10
4
 activated NK 
cells were co-cultured for 8 hours with 2.5x10
5
 target cells and the IFNγ response was measured by 
an ELISPOT assay. The representative wells of the ELISPOT plate are depicted but spot number 
could not be quantified to due to partially or fully saturated wells. (B) The secreted IFNγ present in the 
supernatant of the co-culture was quantified using an IFNγ ELISA and is depicted in pg/ml. Error bars 
show SEM of duplicates measured by ELISA. (C) 5x10
4
 activated NK cells were incubated with target 
cells at an effector to target ratio of 1:10 for 4 hours in the presence of anti-CD107a antibody and 
protein transport inhibitor monensin followed by surface staining for CD3 and NK1.1. The percentage 
of CD107a
+
 cells among CD3
-
NK1.1
+
 cells normalized to the respective controls is depicted (RMA-S 
was normalized RMA, B16F10 and B16F10/M1KO were normalized to B16F10/PX458 and EONY #19 
and EONY/M1KO were normalized to EONY/PX458).   
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5.2 Generation of NY-BR-1 specific CD8+ T cells 
Among the two HLA-DR3-restricted, NY-BR-1 specific CD4+ T cell epitopes previously 
identified in our lab (102), immunization of HLA-DR3tg mice with one of the epitopes namely 
#9017 (Table 11) resulted in the NY-BR-1 specific CD8+ T cell response which suggested 
that a H2-Kb- or H2-Db-restricted NY-BR-1 specific CD8+ T cell epitope is contained within 
this CD4+ T cell epitope. A combination of in silico prediction by SYFPEITHI and in vivo 
experiments previously performed in our lab had resulted in the identification of an H2-Db-
restricted NY-BR-1 specific CD8+ T cell epitope (M. Vormehr, unpublished). This epitope is 
referred to as peptide #6 from now on. The amino acid sequence of the all the epitopes used 
in this study including the published epitopes are depicted in Table 11. 
In order to generate a NY-BR-1 specific CD8+ T cell line specific for this epitope, HLA-
DRB1*0301tg or C57BL/6 mice both of which express the murine MHC class I molecules, 
H2-Db and H2-Kb were immunized by various methods as described in section 4.2. Spleen 
 
Figure 17. NK cells inhibit the outgrowth of MHC I knockout cells in vivo 
C57BL/6 mice (n=10) received 100 µg of PK136 antibody (α-NK) or the C1.18.4 isotype control (iso) 
intraperitoneally and 2x10
5
 B16F10/PX458 or B16F10/M1KO cells were injected s.c. on the right flank 
and tumor growth was monitored. On day 15 after tumor inoculation spleens were harvested and the 
single cell suspensions were prepared. The depletion of NK cells in the splenocytes was analyzed by 
flow cytometry after surface staining for NK cell marker NK1.1. (A) The time points of administration of 
depleting antibody (PK136) or the isotype control (C1.18.4) and of tumor transplantation is depicted. 
(B) Tumor area was calculated as described earlier and mean tumor area of the different groups is 
depicted. Error bars represent SEM (n=10) and statistical analysis was performed using the Mann 
Whitney test (ns, not significant; ***, p<0.001). (C) The frequency of NK1.1
+
 NK cells among 
splenocytes of mice which received the isotype control (iso) or the NK cell depleting antibody (α-NK) is 
depicted. 
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cells were isolated from immunized mice and restimulated by different protocols as reported 
in the methods section to allow the expansion of NY-BR-1 specific CD8+ T cells.  
5.2.1 Peptide immunization results in NY-BR-1 specific T cell response 
 
Figure 18. NY-BR-1 specific T cell response generated in HLA-DRB1*0301tg mice by peptide 
immunization 
HLA-DRB1*0301tg mice (n=4) were immunized with 100 µg synthetic peptide #6 and 140 µg helper 
epitope HBV core #128-140 in IFA, and splenocytes were harvested 14 days post immunization. 
Harvested splenocytes were restimulated with (A) irradiated EL4/NY-BR-1-transfectant clone D8P3 
together with syngeneic feeder cells (9M1B, 9M2B, 9M3B and 9M4B) or (B) with irradiated syngeneic 
feeder cells loaded with 100 ng/ml peptide #6 (9M1A, 9M2A, 9M3A and 9M4A). After six rounds of 
restimulation, the different T cell lines were tested in an ELISPOT assay with 1x10
5
 responder cells, 
5x10
4
 target cells per well and peptide concentration of 500 ng/ml. Each bar represents T cell line 
derived from an individual mouse. Error bars represent SEM of triplicates in IFNγ ELISPOT assay.  
 
Four T cell lines obtained by immunization of 4 HLA-DR3tg mice with synthetic peptide #6 
followed by 6 rounds of in vitro restimulation with irradiated D8P3 cells and irradiated feeder 
cells from syngeneic mice were tested for specificity in an ELISPOT assay. Each line was 
generated from an individual mouse. Lines 9M2B and 9M3B specifically recognized NY-BR-1 
expressing D8P3 cells but not the parental EL4 cells (Figure 18A, red and blue bars) as 
measured by IFNγ spots. The soluble peptide #6 elicited the IFNγ response in the two T cell 
lines indicating that they were specific for this epitope. The T cell lines 9M1B and 9M4B on 
the other hand did not show any reactivity against NY-BR-1 expressing transfectants D8P3 
or the soluble peptide (Figure 18A, black and green bars). The baseline IFNγ secretion by T 
cells in the assay medium was negligible in all cell lines except 9M2B. However, the number 
of IFNγ spots obtained with 9M2B cells co-cultured with the NY-BR-1 positive targets viz. 
D8P3 cells and the soluble peptide was 8.6 times and 14.35 times, respectively compared to 
medium alone (Figure 18A). T cells restimulated with peptide #6 pulsed syngeneic feeder 
cells could not be stimulated by D8P3 cells or soluble peptide#6 to stimulate IFNγ (Figure 
18B). The T cell line 9M2B and 9M3B which had a NY-BR-1 specific IFNγ response were 
further characterized by flow cytometry to quantify the frequency of CD4+ and CD8+ T cells. 
Unexpectedly, the T cell line 9M2B consisted of 88.8% CD4+ T cells and 2.64% CD8+ T cells 
whereas in the line 9M3B the proportion of CD4
+
 and CD8
+ 
T cells was 83.7% and 0.16%, 
respectively (Figure 18C, left column). Thus, enrichment of the CD8+ T cell was attempted by 
MACS using magnetic microbeads coupled to anti-CD8 antibody. However, the percentage 
of CD8+ T cells changed to 2.78% from 2.64% after MACS for line 9M2B (Figure 18C, middle 
column). The frequency of CD8+ T cells in line 9M3B increased 38 fold from 0.16% to 6.10% 
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(Figure 18C, middle column) even though it is clear that the enrichment was not effective as 
the high proportion of CD4+ T cells was still present. The unlabeled fraction (flow through) on 
the other hand did not have many CD8+ T cells remaining (Fig7C, right column). 
 
Figure 18 (contd). NY-BR-1 specific T cell response generated by peptide immunization 
(C) The proportion of CD4
+
 and CD8
+
 T cells in the T cell lines 9M2B and 9M3B before MACs 
purification, in the column fraction and in the flow through as determined by flow cytometry is depicted 
as dot plots. The cells were pre-gated on single cells based on forward and side scatter 
characteristics. (D) The CD8
+
 enriched and CD8
+
 depleted fractions of the T cell lines 9M2B and 
9M3B were separately expanded by restimulation with irradiated D8P3 cells and syngeneic feeder 
cells. They were tested for their reactivity against NY-BR-1 by using either soluble peptide #6 or 
D8P3 cells or T2/DR3 cells with soluble peptide #9017 as targets in an ELISPOT assay. Soluble 
peptide #8, parental EL4 cells or T2/DR3 cells alone were used as controls. 1x10
5
 responder cells 
and 5x10
4
 target cells per well were used for the ELISPOT assay and the peptide concentration used 
was 500 ng/ml. Error bars represent SEM of triplicates in IFNγ ELISPOT assay.   
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The different fractions were separately maintained in culture and restimulated for another two 
rounds and the cells were tested again in an IFNγ ELISPOT assay. Since the 9 mer peptide 
#6 sequence is contained within a HLA-DR3 restricted CD4+ T cell epitope designated 
peptide #9017, it was speculated that the CD4+ T cells present in the T cell lines 9M2B and 
9M3B could be specific for this epitope. Thus, T2/DR3 cells pulsed with the synthetic peptide 
#9017 were used as targets in addition to previously used targets. The CD8+ T cell enriched 
fraction derived from both cell lines could be activated by soluble peptide #6 and peptide 
#9017 presented on the HLA-DR3 molecule on the surface of T2/DR3 cells to secreted IFNγ 
which was measured by ELISPOT assay (Figure 18D). The 9M3B line after enrichment for 
CD8
+
 T cells seemed more specific as there was not much baseline IFNγ secretion in the 
medium control, T2/DR3 cells alone or when an irrelevant H2-Db restricted epitope namely 
peptide#8 was added as a soluble peptide (Figure 18D). On the other hand, the CD8+ 
enriched fraction of line 9M2B had a high IFNγ secretion on its own (medium control), with 
T2/DR3 cells alone and with peptide #8 which meant the signal to noise ratio was low (Figure 
18D). Importantly, D8P3 cells were not recognized by either of the cell lines specifically when 
compared to the parental EL4 cell line (Figure 18D). The CD8
+
 depleted fractions had weak 
positive response to peptide pulsed T2/DR3 cells and soluble peptide #6 and the few number 
of IFNγ spots meant that they were not functionally active even though they might possess 
specificity. Further restimulation of these cells was not successful as the cells  did not expand 
and died. Thus it was decided to adopt another immunization approach which is described in 
the next section. 
5.2.2 Adenovirus immunization results in strong NY-BR-1 specific T cell 
response in C57BL/6 mice 
Since C57BL/6 mice express H2-D
b
 molecule, they should be capable of developing H2-D
b
 
restricted CD8+ T cell response following a successful immunization. Since the peptide 
immunization resulted in a T cell line predominantly composed of CD4+ T cells, we decided to 
test the Ad5.NY-BR-1 vector encoding the whole NY-BR-1 protein for immunization and 
generation of NY-BR-1 specific CD8
+
 T cell line. Ad5.NY-BR-1 vector is a recombinant 
adenovirus vector derived from adenovirus serotype 5. The deletion of its E1 genes resulted 
in a replication deficient vector which can be used for immunization by inserting the antigen 
of interest into the viral genome (229). It is known to be highly immunogenic and induces 
strong antigen specific immune responses (229).  
Four C57BL/6 mice were immunized with 5x10
8
 pfu Ad.NY-BR-1 and 14 days later the 
immunized mice were sacrificed and spleens were harvested. Splenocytes isolated from 
individual mice were cultured separately and restimulated with irradiated D8P3 cells and 
syngeneic feeder cells as described earlier. After one round of restimulation, the T cell lines 
obtained were tested for specific recognition of NY-BR-1 expressing D8P3 cells and peptide 
#6 as targets. T cell line AdNyM1B was strongly reactive to peptide #6 and resulted in 
saturated ELISPOT wells making it impossible to obtain a spot count and thus this is 
represented by open bars (Figure 19A). It is noteworthy that this line displayed reactivity to 
D8P3 cells and resulted in two times more spots compared to medium alone or NY-BR-1 
deficient EL4 cells. The absolute spot number was quite low (40 spots for 1x105 cells) even 
though it appears that recognition of D8P3 was NY-BR-1 specific. Unlike the response to 
transfectant clone D8P3, the response to soluble peptide #6 resulted in saturated wells 
(Figure 16A). On the other hand, T cell lines AdNyM2B and AdNyM3B showed a weak IFNγ 
response against peptide #6 and resulted in an average spot number of 40-50 for 1x105 
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effector cells (Figure 16A). The line AdNyM4B had barely detectible IFNγ response against 
peptide #6 (mean spot number = 10). Concavalin A (Con A) which is known to be a mitogen 
and acts as a strong T cell stimulus resulting in their activation and IFNγ production was 
used a positive control to assess the potential of the T cell lines to produce IFNγ following 
activation. The mean spot number obtained after activation with ConA for the cell lines 
AdNyM2B, AdNyM3B and AdNyM4B was quite low and ranged between 30 and 66. Since 
the T cell lines were generated from whole splenocytes without any enrichment, it is probable 
that the frequency of activated antigen specific T cells is too low to result in a strong NY-BR-
1-specific IFNγ response. 
 
Figure 19. NY-BR-1 specific T cell response generated by immunization with recombinant 
adenovirus 
C57BL/6 mice (n=4) were immunized with 5x10
8
 pfu Ad.NY-BR-1 i.p. and splenocytes were harvested 
14 days post immunization. Harvested splenocytes from individual mice were restimulated with 
irradiated EL4/NY-BR-1-transfectant clone D8P3 together with syngeneic feeder cells  to obtain four T 
cell lines. These T cell lines were tested for their NY-BR-1 specific response in an IFNγ ELISPOT 
assay using either peptide #6 in a soluble form or EL4 cells or D8P3 cells as target cells. Concavalin A 
was used as positive control. The ELISPOT assay was performed after (A) 3 or (B) 5 rounds of 
restimulation. 1x10
5
 responder cells and 5x10
4
 target cells per well were used for the ELISPOT assay 
and the peptide concentration used was 500 ng/ml in the first ELISPOT (A) and either 100 ng/ml or 
500 ng/ml in the second ELISPOT (B). Error bars represent SEM of triplicates in IFNγ ELISPOT 
assay. Oversaturated wells are depicted by out of range bars. (C) The dot plots depict the distribution 
of CD4
+
 and CD8
+
 T cells in the different T cell lines. All T cell lines except AdNyM2B have a majority 
of CD8
+
 T cells. 
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Figure 19 (contd). NY-BR-1 specific T cell response generated by immunization with 
recombinant adenovirus 
C57BL/6 mice (n=3) were immunized with 5x10
8 
pfu Ad.NY-BR-1 i.p. and splenocytes were harvested 
14 days post immunization. Harvested splenocytes from individual mice were restimulated in various 
ways to obtain different T cell lines. They were restimulated with either irradiated EL4/NY-BR-1-
transfectant clone D8P3 together with syngeneic feeder cells  (R1B, R2B and R3B) or with irradiated 
syngeneic feeder cells loaded with either peptide #6 (R1C6, R2C6 and R3C6) or with peptide #136 
(R1C136, R2C136 and R3C136). The splenocytes from one of the mice were also restimulated with 
irradiated EO771/NY-BR-1-transfectant clone EONY #19 together with syngeneic feeder cells (R3D). 
(D) The various T cell lines thus obtained were tested for their NY-BR-1 specific response in an IFNγ 
ELISPOT assay using either peptide #6 or peptide #136 in a soluble form. Additionally EL4 cells, 
D8P3 cells, EO771 cells or EONY #19 cells were used as target cells. Concavalin A was used as 
positive control. The ELISPOT assay was performed after 3 rounds of restimulation. 1x10
5
 responder 
cells and 5x10
4
 target cells per well were used for the ELISPOT assay and the peptide concentration 
used was 100 ng/ml. Error bars represent SEM of triplicates in IFNγ ELISPOT assay.  (E) Only the T 
cell lines R3B, R3C6, R3C136 and R3D could be expanded effectively and they were tested again 
after 9 rounds of restimulation in an ELISPOT assay with similar conditions as described above. (F) 
The best expanding T cell line R3B was analyzed by flow cytometry to check the distribution of CD4
+
 
and CD8
+ 
T cells. The dot plots depict the distribution of CD4
+
 and CD8
+
 T cells among single cells. 
Anti-Trp2 CTL line was used as positive control. 
 
Thus, the assay was repeated after another round of restimulation with D8P3 transfectants, 
expecting that an additional round of restimulation will allow the expansion of antigen specific 
T cells and increase their proportion in all the T cell lines. All the T cell lines demonstrated 
strong reactivity against peptide #6 which resulted in saturation of IFNγ signal but no 
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recognition of the D8P3 cells was observed (Figure 19B). In order to determine the 
distribution of CD8+ and CD4+ T cells in the T cell lines they were analyzed by flow 
cytometry. It was observed that lines AdNyM1B, AdNyM3B and AdNyM4B comprised of over 
80% CD8+ T cells among live single cells whereas AdNyM2B consisted of 47% CD8+ T cells 
(Figure 19C). Thus, immunization with the global NY-BR-1 antigen using the Ad.NY-BR-1 
followed by restimulation with irradiated D8P3 cells and feeder cells turned out to be more 
successful in the generation of NY-BR-1 specific CD8+ T cells. Since the majority of cells 
were CD8+ T cells, the cells were restimulated further to expand them for subsequent 
experiments. Unfortunately, the cells did not proliferate further and started to die. Attempts to 
expand these T cell lines from vials frozen earlier as a backup also failed as the frozen cells 
did not grow after thawing. This led us to hypothesize that the restimulation protocol might 
not have been optimal for long term in vitro culture of these cells. 
Thus, immunization was repeated in three C57BL/6 mice (designated R1, R2 and R3) with 
Ad.NY-BR-1 in order to evaluate other protocols for restimulation. Splenocytes isolated 14 
days after immunization were divided into three fraction for mice R1 and R2 and four 
fractions for mouse R3 and each fraction was restimulated differently. The first fraction was 
restimulated with irradiated D8P3 cells in combination with irradiated syngeneic feeder cells 
as previously described and this is designated by the suffix B (e.g. R1B, R2B and R3B). The 
other two parts were restimulated with syngeneic splenocytes that were pulsed with the 
synthetic peptide #6 or peptide #136 followed by irradiation. Peptide #136 is another 
predicted H2-Db-restricted epitope derived from NY-BR-1 which is described in more detail in 
section 5.3.3. These spleen cell lines are indicated with the suffix C6 and C136 respectively 
(e.g. R1C6 and R1C136). Additionally, some of the splenocytes from mouse R3 were 
restimulated with the irradiated EONY#19 cells along with irradiated feeder cells and they are 
called R3D. It was observed that the restimulation with peptide pulsed feeder cells and 
irradiated EONY#19 cells was not optimal for inducing proliferation of the T cell lines. 
Nonetheless, an ELISPOT assay was performed with these cells after one round of 
restimulation to estimate if one of the restimulation methods would result in generation of an 
NY-BR-1 specific CTL line. R2B cells could specifically recognize the EONY#19 cells 
compared to parental EO771 cells but not D8P3 cells or the soluble peptide #6 and #136 
(Figure 19D). Even though the baseline IFNγ secretion by R2B T cells was quite high, a two 
fold increase was observed when they were stimulated by EONY#19 cells (Figure 19D). The 
line R3B also showed a tendency to specifically recognize the EONY#19 cells and the 
soluble peptide #6 when compared to the EO771 cells or medium only. R3C6 had a weak 
reactivity towards EONY#19 cells with respect to EO771 cells. Only the cells derived from 
mouse R3 could be successfully maintained for the next 8 rounds of restimulation to obtain 
enough cells to repeat an ELISPOT assay with these cell lines. However, none of the T cell 
lines secreted IFNγ in response to NY-BR-1 transfectant clones or H2-Db restricted NY-BR-1 
epitope added in the form of a soluble peptide (Figure 19E). The line R3B which proliferated 
slightly better than the others was also tested in FACS to test whether they constituted of 
CD8+ T cells. Surprisingly, this line was entirely composed of CD4+ T cells (Figure 19F). Anti-
Trp-2 CTL line was included as a positive control (Figure 19F). The fact that adenovirus 
immunization does induce a strong NY-BR-1 specific immune response is demonstrated in 
the next section. However, it seemed that during restimulation CD4
+
 T cells expand 
preferentially overgrowing the antigen specific CD8+ T cells. Thus, we thought that 
enrichment of antigen specific CTLs before in vitro expansion would allow us to circumvent 
this issue. The strategy used is described in the following section. 
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5.2.3 Identification of new H2-Db restricted NY-BR-1 epitopes 
Peptide-MHC multimers are routinely used to identify antigen specific T cells. They were 
introduced as tetramers comprised of biotinylated HLA-A2 monomers loaded with the peptide 
and held together by a PE conjugated deglycosylated avidin molecule (230). The antigen 
specific T cells which express the specific TCR can bind the MHC-peptide complex. Since 
the MHC multimer is fluorescently labeled, they can be used to sort the specific T cells by 
flow cytometry. MHC I dextramers are based on a similar principle but are comprised of 
multiple peptide-MHC I monomers and fluorophores assembled on a dextran backbone 
thereby being more sensitive and stable. Thus, they could be used to enrich for NY-BR-1 
specific CTLs before expansion. However, it is important to choose a strong epitope to 
synthesize the MHC dextramer to increase the likelihood of isolating high quality T cells. 
Thus it was decided to test additional H2-Db-restricted NY-BR-1 epitopes that have been 
predicted by SYFPEITHI to identify a suitable candidate for generating the dextramer. The 
details are listed in Table 30. 
Table 30. Nomenclature and sequence of predicted H2-D
b
-restricted epitopes 
 
 
The binding affinity of the peptide to the corresponding MHC molecule is important for the 
generation of a high quality dextramer. Thus, the binding affinity of the candidate epitopes for 
H2-Db molecule was assessed. As described in the methods section, RMA-S cells which 
have low MHC I expression due to defective antigen processing machinery, can be loaded 
externally with peptides which stabilize the MHC molecule on the cell surface. The level of 
MHC I expression can then serve as an indirect measure of the peptide binding affinity of the 
corresponding peptide. Thus, RMA-S cells were incubated with different concentrations of 
the candidate epitopes and the surface MHC I expression was measured by flow cytometry 
using hybridoma supernatant B22.249 or E3-25 specifically binding to H2-Db or H2-Kb 
molecules, respectively. Peptide #6 had the highest binding affinity and could stabilize 
surface expression of H2-Db molecules at concentrations as low as 10 ng/ml (Figure 20A). 
There is a dose dependent effect observed in the peptide binding with increasing peptide 
concentration (Figure 20A). Peptide #136 displayed weak binding capacity to the H2-Db 
molecule whereas peptide #3 and #57 did not manage to stabilize the H2-Db molecule at the 
cell surface, even at the highest concentration of 100 µg/ml (Figure 20A). A known H2-Db-
restricted epitope derived from the HPV16 oncoprotein E7 (E749-57) (231); was used as a 
positive control and interestingly, peptide #6 had a stronger binding affinity compared to it 
(Figure 20A). To demonstrate that the epitopes are indeed H2-Db restricted, the surface 
expression of H2-Kb molecule was also measured following peptide incubation. None of the 
predicted epitopes bound to the H2-Kb molecule in contrast to the H2-Kb-restricted ovalbumin 
derived SIINFEKL peptide which served as the positive control (Figure 20B). 
MHC RESTRICTION
DESIGNATION IN 
THESIS SEQUENCE POSTION SYFPEITHI score
H2-D
b
peptide # 3 VYTSNDSYI 25-33 24
H2-D
b
peptide # 6 STIYNNEVL 1241-1249 26
H2-D
b
peptide # 57 KASANDQRF 460-468 24
H2-D
b
peptide # 136 HTHENENYL 1092-1100 24
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Figure 20. Identification of new H2-D
b
 restricted NY-BR-1 specific CTL epitopes 
Peptide binding assay was performed for the predicted H2-D
b
-restricted NY-BR-1 specific CTL 
epitopes to test their binding affinity to the H2-D
b
 molecule. Briefly, empty MHC I (H2-D
b
/H2-K
b
) 
molecules on the surface of TAP deficient RMA-S cells are stabilized on binding externally added 
predicted NY-BR-1 epitopes. Surface expression of stabilized MHC I molecules was measured by 
flow cytometry using (A) H2-D
b
-specific monoclonal antibody B22.249 or (B) H2-K
b
-specific 
monoclonal antibody E3-25 to provide an estimate of peptide binding. The H2-D
b
 restricted E7 
epitope E749-57 and the H2-K
b
-restricted OVA epitope SIINFEKL served as positive controls.  
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Figure 20 (contd). Identification of new H2-D
b
 restricted NY-BR-1-specific CTL epitopes 
HLA-DRB1*0401tg mice were immunized i.p. either with 5x10
8
 pfu Ad.NY-BR-1 (n=3) or with 5x10
8
 
pfu Ad.Control (n=3) and splenocytes were harvested 14 days post immunization. Harvested 
splenocytes from individual mice were incubated overnight with various predicted H2-D
b
 restricted NY-
BR-1 epitopes (peptide #3, peptide #57 and peptide #136) in the form of synthetic peptides. Secreted 
IFNγ by activated T cells was measured by IFNγ catch assay  and IFNγ ELISPOT assay. (C) Gating 
scheme employed for the IFNγ catch assay is depicted. (D) The IFNγ response by CD8
+
 T cells 
reactive to peptide #6 in mice immunized with Ad.Control (upper panel) or with Ad.NY-BR-1 (lower 
panel) is shown in a representative dot plot. 
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Figure 20 (contd). Identification of new H2-D
b
 restricted NY-BR-1-specific CTL epitopes 
The percentage of IFNγ
+
 cells among live (E) CD3
+
CD8
+
 T cells and (F) CD3
+
CD4
+
 T cells for all the 
peptides tested is depicted. 
 
 
Since the tumor model is based on HLA-DR4tg mice it was decided to immunize HLA-DR4tg 
mice in order to assess if Ad.NY-BR-1 can induce an effective anti-NY-BR-1 immune 
response in these mice and to ensure that the epitopes that are identified are naturally 
processed and presented in these mice. Therefore, three HLA-DR4tg mice were immunized 
with Ad.NY-BR-1 or with Ad.Control and induction of NY-BR-1 specific T cells in the spleens 
was analyzed by IFNγ catch assay. Briefly, splenocytes from immunized mice were isolated 
14 days post immunization and stimulated overnight with the synthetic peptides representing 
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the predicted epitopes. The activation of the specific T cells was estimated by the secreted 
IFNγ. In order to analyze the IFNγ secreting T cells, the cells were first gated based on their 
forward and side scatter characteristics, followed by singlet discrimination. Viable cells were 
selected by excluding the cells which stained positive for a dye that selectively binds dead 
cells. The CD3+ T cells were then analyzed for the expression of CD8+ or the CD4+ co-
receptor in combination with IFNγ expression. The gating scheme employed is depicted in 
Figure 20 C. The NY-BR-1 response is quantified by the frequency of CD3+CD8+ T cells 
which secrete IFNγ following stimulation by peptide #6 (Figure 20D). The percentage of 
CD8+IFNγ+ among live CD3+ is clearly enhanced in mice immunized with Ad.NY-BR-1 
(Figure 20D, lower row) compared to those in mice which received the control adenovirus 
(Figure 20D, upper row). Each dot plot represents an individual mouse. Adenovirus 
immunization successfully induced a strong CD8+ T cell response against the peptide #6 but 
not against the other predicted H2-Db epitopes viz. peptide #3, #57 and #136 (Figure 20E). 
HLA-DR4-restricted CD4
+
 T cell epitopes #8862 and #9251 were included as positive 
controls and CD4+ T cells specific for peptide #9251 could be detected at a higher frequency 
following Ad.NY-BR-1 immunization (Figure 20F). Since, ELISPOT is more sensitive in 
detecting IFNγ response compared to IFNγ catch assay (232, 233); splenocytes from 
adenovirus immunized HLA-DR4tg mice were also tested in an IFNγ ELISPOT assay to 
screen for responses against the predicted epitopes. Administration of the control adenovirus 
did not result in NY-BR-1 specific T cells as expected (Figure 20G) but immunization with 
NY-BR-1 encoding adenovirus gave rise to T cells which showed strong peptide #6 reactivity 
in all the mice including the ones which were immunized with a lower dose of adenovirus 
(Figure 20G, blue bars). Additionally, peptide #57 specific T cells were detected in one 
mouse immunized with 5x108 pfu virus and in one mouse immunized with 5 times low dose 
of 1x108 pfu virus (Figure 20G, purple bars). Very weak responses to peptide #3 could be 
detected as well (Figure 20G, pink bars). The efficacy of the immunization was monitored by 
using previously validated HLA-DR4 restricted epitopes #9251 and #8862 which resulted in a 
positive IFNγ signal in the ELISPOT assay (Figure 20H). Since the strength of the responses 
were generally weaker and not consistent among individual mice when 1x108 pfu virus was 
used (Figure 20G,H); it was decided to use the manufacturer recommended dose of 5x108 
pfu for the subsequent experiments. So far, peptide #6 reactive cells seemed to be the 
strongest candidate epitope.  
Thus peptide #6 qualified as the best candidate for the synthesis of dextramers since 
adenovirus immunization resulted in T cells specific for this epitope and it had the highest 
binding affinity to the H2-Db molecule. The optimization of dextramer staining and its use for 
sorting NY-BR-1 specific T cells is described in the following section. 
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Figure 20 (contd). Identification of new H2-D
b
 restricted NY-BR-1 epitopes 
Induction of NY-BR-1 specific T cell response in HLA-DR4tg following immunization with 5x10
8
 or 
1x10
8
 pfu Ad.NY-BR-1 and 5x10
8
 Ad.Control was measured by ELISPOT assay. 1x10
6
 splenocytes 
from the immunized mice were incubated overnight with 2µg/ml peptide in the ELISPOT plate. (G) The 
IFNγ response to the predicted H2-D
b
-restricted NY-BR-1 epitopes is depicted as number of spots. (H) 
HLA-DRB1*0401-restricted NY-BR-1 epitopes #8862 and #9251 were also included as a positive 
control and specific IFNγ responses could be detected against these peptides indicating that the 
immunization with the Ad.NY-BR-1 was successful. Each bar represents an individual mouse and 
error bar show SEM. 
 
5.2.4 Optimization of dextramer staining for NY-BR-1 specific CTLs 
Adenovirus immunization has resulted in a very strong NY-BR-1 specific T cell response 
against peptide #6. Thus, splenocytes from adenovirus immunized HLA-DR4tg mice were 
used to test the binding of the dextramer to peptide #6-specific CTLs. The dextramer was 
purchased from Immudex and as recommended by them, the cells were incubated with the 
dextramer diluted 1:6 times followed by surface staining with anti-CD8 and anti-CD4 
antibodies. The gating strategy used is depicted (Figure 21A). Briefly, the cells were gated 
based on their forward and side scatter characteristics followed by exclusion of doublets and 
dead cells. They were then analyzed for CD8 and dextramer double positive population. In 
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order to ascertain the specificity of the NY-BR-1 dextramer, a control dextramer loaded with 
an irrelevant peptide was used at the same dilution. Splenocytes from mice immunized with 
the control virus (Ad5.Control) which should not contain T cells reactive against peptide #6 
served as an additional negative control. As expected, CD8+dextramer+ cells could be 
detected only in mice immunized with Ad5.NY-BR-1 when the specific dextramer was used 
and not with the control dextramer (Figure 21B). Surprisingly, both the control and NY-BR-1 
specific dextramer did bind a population which was CD8- irrespective of what virus the mouse 
was immunized with; indicating that this was unspecific binding (Figure 21B). The cumulative 
data depicting the frequency of dextramer+ CD8+ cells among live cells from mice immunized 
with control virus (n=2) and with NY-BR-1 encoding virus (n=3) shows that dextramer 
positive cells can be induced in all mice by immunization with the Ad5.NY-BR-1 (Figure 21C). 
CD14+ monocytes are known to unspecifically bind MHC I multimers (234), thus it was 
decided to use an anti-CD14 antibody to exclude monocytes from analysis of dextramer 
labeled cells. In order to optimize the amount of dextramer used, dextramer diluted 1:10, 
1:25 and 1:100 times was also included. Splenocytes were obtained from mice immunized 
with Ad.Control or Ad.NY-BR-1 and dextramer staining was performed as described in 
section 4.2. Following the dextramer staining, anti-CD3 and anti-CD14 antibodies were used 
in addition to anti-CD8 and anti-CD4 antibodies for surface staining. For quantification of 
dextramer+ cells, cells were first gated on based on forward and side scatter followed by 
selection of single and live cells and then CD3+CD14- cells were analyzed for the frequency 
of CD8+dextramer+ cells (Figure 21D). Among CD3+CD14- lymphocytes, dextramer+ cells 
were primarily detected among CD8+ population but not among CD4+ cells (Figure 21D). An 
exemplary dot plot shows that the percentage of dextramer labeled CD8+ cells among 
CD3+CD14- cells is 0.19% among splenocytes derived from control virus immunized mouse 
compared to average of 3.5% among splenocytes of mice receiving NY-BR-1 adenovirus 
when the dextramer was diluted 1:6 for the staining (Figure 21E). The specificity of the 
dextramer for NY-BR-1 specific T cells was demonstrated by the fact that dextramer positive 
cells were detected only in Ad.NY-BR-1 immunized mice but not in the Ad.Control immunized 
mice. Detection of peptide #6 specific T cells by the dextramer was not impaired when 
dilution of 1:10 was used compared to 1:6 as recommended by the manufacturer (Figure 
21F). However, diluting the dextramer 50 or 100 times did reduce the number of NY-BR-1 
specific CD8+ T cells which could be successfully detected (Figure 21F). Thus, it was 
decided to use the dextramer with dilution 1:10 for further experiments.  
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Figure 21. Dextramer staining 
Splenocytes harvested from HLA-DR4tg mice received either with 5x10
8
 pfu Ad.NY-BR-1 (n=3) or with 
5x10
8
 pfu Ad.Control (n=2) i.p. 14 days later splenocytes were isolated and stained with NY-BR-1 
specific dextramer or control dextramer followed by surface staining for CD4 and CD8. (A) The gating 
scheme employed for analysis of dextramer
+
 cells is shown for a representative sample. (B) 
Representative dot plot depicts the proportion of dextramer
+
CD8
+
 T cells among live splenocytes from 
Ad.Control immunized mice (left panel) or from Ad.NY-BR-1 immunized mice (right panel). Each 
column represents splenocytes from an individual mouse stained with control dextramer (top row) or 
NY-BR-1 specific dextramer (bottom row) both used at the dilution of 1:6. (C) The frequency of 
CD8
+
dextramer
+ 
cells of live spleen cells for all mice is plotted. 
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Figure  21 (contd). Dextramer staining 
Splenocytes harvested from HLA-DR4tg mice immunized i.p. either with 5x10
8
 pfu Ad.NY-BR-1 (n=3) 
or with 5x10
8
 pfu Ad.Control (n=3) after 14 days were used for testing dextramer staining. Harvested 
splenocytes from individual mice were incubated with the NY-BR-1 specific dextramer or control 
dextramer and counterstained for CD3, CD4, CD8 and CD14. (D) The gating scheme of a 
representative sample is shown. (E) Representative dot plot depicts the proprtion of dextramer
+
CD8
+
 
T cells among live CD14
-
CD3
+
 lymphocytes for splenocytes from Ad.Control immunized mice (left 
panel) or from Ad.NY-BR-1 immunized mice (right panel). Each column represents splenocytes from 
an individual mouse stained with control dextramer (top row) or NY-BR-1 specific dextramer (bottom 
row) both used at the dilution of 1:6. (F) The frequency of dextramer
+ 
cells of live CD14
-
CD3
+
CD8
+
 
cells for all mice and different dilutions of dextramer used is summarized.  
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5.2.5 Expansion of sorted dextramer+ T cells from immunized mice 
The NY-BR-1 specific CD8+ T cells induced by adenovirus immunization could be 
successfully recognized by H2-Db dextramer loaded with peptide #6. Previously we observed 
that CD4
+
 T cells expanded preferentially over CD8
+
 T cells when splenocytes obtained from 
immunized mice were restimulated with irradiated NY-BR-1 expressing target cells (Section 
5.2.1). To overcome this issue, we decided to sort the NY-BR-1 specific CD8+ T cells so that 
if CD4+ T cells expand faster than CD8+ T cells, they cannot overgrow the T cell culture. 
 
Figure 22. Establishment of NY-BR-1 specific CD8
+
 T cell lines  
(A) The schematic representation of the workflow for establishment of NY-BR-1 specific CD8+ T cell 
lines by sorting dextramer labeled CD8
+
 T cells.  
 
Thus, splenocytes from three HLA-DR4tg mice immunized with Ad.NY-BR-1 were isolated 
and divided into two parts; one part was cultivated in vitro with irradiated NY-BR-1 
expressing target cells (D8P3) along with feeder cells and the other part was stained with 
NY-BR-1 specific H2-Db dextramer. Single dextramer+ cells were sorted into 96 well plate 
and the remaining dextramer+ cells were sorted as a bulk culture and restimulated with anti-
CD3/CD28 T activator beads or irradiated cells as mentioned above. The average frequency 
of dextramer+ cells detected ex vivo was quite low (Figure 22B) compared to previous 
experiment (Figure 21F). The frequency of dextramer+ cells among CD3+CD14- splenocytes 
derived from mouse 1 was 0.15% when labeled with NY-BR-1 specific dextramer compared 
to 0.20% when labeled with the control dextramer (Figure 22B) indicating that the 
immunization was not effective in this mouse. Thus the cells from mouse 1 were not sorted 
for further culture. Adenovirus immunization resulted in the strongest induction of NY-BR-1 
specific CD8+ T cells in mouse 3 which had a 5 fold increase in the frequency of NY-BR-1 
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specific CD8+ T cells (1.02%) compared to background dextramer staining (0.19%). Mouse 2 
had an intermediate response resulting in the specific signal of (0.41-0.16 = 0.25%) cells. 
Single dextramer+CD8+ T cells from mouse 2 and mouse 3 were sorted into individual wells 
of 96 well plate to obtain single cell clones and the remaining cells were sorted as bulk 
culture to generate a T cell line. The sorted cells were then restimulated with Dynabeads
®
 
Mouse T-Activator CD3/CD28 or with irradiated target and feeder cells (as described in 
section 4.2). Since the frequency of dextramer positive cells was quite low, we decided to 
test the whole splenocytes which were restimulated for 5 rounds to check if there were 
dextramer positive cells that could be sorted again. Mouse 1 was still negative for dextramer 
positive cells and the ratio of dextramer positive cells detected by NY-BR-1 specific 
dextramer to those detected by control dextramer was 4.8 for mouse 2 and 11.5 for mouse 3, 
respectively (Figure 22C). Thus, these cells were then bulk sorted and cultured in vitro by 
restimulating with irradiated D8P3 and feeder cells. Anti CD3/CD28 beads were not used for 
restimulation as the T cells from the first round did not proliferate with the beads. The 
workflow used is detailed in Figure 22A. Only three cell lines could be finally expanded after 
12 weeks and were tested for the proportion of dextramer+ T cells and their reactivity to 
peptide #6 in an ELISPOT assay. The proliferating T cell clone and the cell line bulk sorted 
ex vivo surprisingly comprised of CD4+ CD8- cells (Figure 22D, top row) whereas T cells 
obtained from the second bulk sort comprised of 90% CD8+CD4- T cells. Interestingly, among 
T cells bulk sorted ex vivo, all CD8+ T cells were strongly dextramer positive but among the 
cells sorted later, only 68.45 % of CD8+ T cells were labeled by the dextramer and the 
intensity was in general lower (Figure 22D, bottom row). Since the single cell clone was  
CD8-, they also did not bind the H2-Db restricted dextramer (Figure 22D, bottom row). The T 
cells could be activated by the soluble peptide #6 to secrete IFNγ which was detected by 
ELISPOT assay. The single cell clone comprising of CD4
+
 T cells had some unspecific 
response; however, cells bulk sorted later were strongly reactive with high levels of secreted 
IFNγ which resulted in saturated wells (Figure 22E). The cells bulk sorted ex vivo were also 
strongly reactive but corresponding to fewer CD8+dextramer+ T cells, the wells were only 
partially saturated (Figure 22E). The cells were further expanded and only the ex vivo bulk 
sorted cells could be maintained in culture for 23 weeks. To characterize the T cells, they 
were tested by FACS for presence of CD8+dextramer+ cells but unfortunately they could not 
be detected (Figure 22F). In a functional assay it was shown that the cells were not capable 
of recognizing specifically the soluble peptide #6 or the NY-BR-1 transfectant clones as no 
selective IFNγ production was observed (Figure 22G).  Thus, immunization with Ad.NY-BR-1 
results in NY-BR-1 specific CTLs which can be successfully labeled by H2-Db dextramers 
loaded with peptide #6 and can be expanded in vitro using irradiated D8P3 cells but not with 
Dynabeads
®
 Mouse T-Activator CD3/CD28. Functionally active antigen specific CD8+ T cells 
could be maintained in vitro for as long as 12 weeks but prolonged restimulation for 23 
weeks was not suitable.  
Thus, in the first part of this thesis, a transplantable NY-BR-1 expressing tumor model in 
HLA-DR4tg mice was established. Additionally, natural processing of a H2-Db-restricted T 
cell epitope was confirmed as peptide #6 specific CD8+ T cells were induced following 
immunization with the global NY-BR-1 antigen. These cells could be successfully labeled by 
H2-Db dextramers loaded with the cognate peptide. Unexpectedly, CD4+ T cells preferentially 
expanded when splenocytes from peptide immunized mice were restimulated in vitro with 
inactivated NY-BR-1 expressing tumor cells in the presence of irradiated feeder cells. 
Immunization with the Ad.NY-BR-1 on the other hand performed better and NY-BR-1 specific 
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CD8+ T cells could be expanded especially when they were pre-selected using the 
dextramers. However, these T cells were not suitable for long term culture. 
 
 
Figure  22 (contd). Establishment of NY-BR-1 specific CD8
+
 T cell lines  
(B) Splenocytes from HLA-DR4tg mice immunized with Ad.Control (n=1) or with Ad.NY-BR-1 (n=3) 
were stained with dextramer (diluted 1:10) and co-stained for CD14, CD3, CD4 and CD8. The 
frequency of sorted CD8
+
dextramer
+
 T cells within CD14
-
CD3
+ 
cells is depicted for cells stained with 
the control dextramer (upper row) and with the NY-BR-1 dextramer (lower row). (C) Dot plots show 
the proportion of CD8
+
 T cells among splenocytes restimulated with irradiated D8P3 and feeder cells 
for 5 weeks, which were labeled by the control dextramer (upper row) or the NY-BR-1 specific 
dextramer (lower row). 
 
 
Results Page 96 
 
 
Figure 22 (contd). Establishment of NY-BR-1 specific CD8
+
 T cell lines 
Characterization of the three T cell lines obtained after 12 weeks of in vitro expansion of cells sorted 
for dextramer
+
CD8
+
 T cells was done by FACS staining and ELISPOT assay. (D) The percentage of 
CD4
+
 and CD8
+
 cells within the CD3
+
 lymphocyte population is shown (top row). The frequency of 
dextramer labeled CD8
+
 T cells among the CD3
+
 T cells is depicted for the control dextramer (middle 
row) and the NY-BR-1 dextramer (bottom row). (E) The presence of NY-BR-1 specific T cells in the 
different T cell lines was tested in an IFNγ ELISPOT assay. 1x10
5
 effector cells were incubated 
overnight with 100 ng/ml peptide #6 and the representative wells of the ELISPOT plate are depicted. 
Spot number not shown as it could not be quantified to due to partially or fully saturated wells.  
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Figure 22 (contd). Establishment of NY-BR-1 specific CD8
+
 T cell lines 
Characterization of the T cell line obtained by bulk sorting of dextramer+ cells ex vivo after 23 rounds 
of restimulatuion by dextramer staining and functional assay. (F) The percentage of dextramer
+
CD8
+
 
cells among all T cells is represented as dot plots. (G) The reactivity of the T cells against NY-BR-1 
expressing D8P3 and EONY#17 cells was tested in an IFNγ ELISPOT assay. 1x10
5
 effector cells 
were incubated overnight with 5x10
4 
target cells or with 100 ng/ml of peptide #6. Parental cell lines, 
EL4 and EO771 which are devoid of NY-BR-1 expression were included as negative controls. 
Representative wells of the ELISPOT plate are depicted as spot number could not be determined. 
 
5.3 Characterization of NY-BR-1 specific CD4+ T cell lines 
 
Successful tumor eradication mediated by cytotoxic CD8+ T cells is dependent on CD4+ T 
cell help. Tumor antigen specific CD4+ T cells have been shown to be important for activation 
of memory CD8+ T cells to effector cells (212) however there are numerous other 
mechanisms by which antigen specific CD4+ T cells support successful immunesurveillance. 
One of them includes the activation of TAMs and inducing tumoricidal phenotype (214) or 
repolarizing them towards an M1-like phenotype (209). Thus, in the second part of this thesis 
we investigated whether TAMs would take up NY-BR-1 protein from dying tumor cells and 
present MHC II restricted T cell epitopes derived thereof to established NY-BR-1 specific 
CD4+ T cell lines (102). Therefore, HLA-DR4 tetramers loaded with NY-BR-1 specific CD4+ T 
cell epitopes would serve as an important tool for detection and quantification of NY-BR-1 
specific CD4+ T cells infiltrating the tumor. As the name suggests, they are composed of four 
peptide-MHC monomers and are fluorescently labeled. The class II-associated invariant 
peptide derived (CLIP) is known to occupy the peptide binding groove of the MHC II 
molecule before it gets replaced by exogenous peptides within the late endosomes. To test 
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the specificity of the available HLA-DR3 and HLA-DR4 restricted NY-BR-1 specific CD4+ T 
cells, peptide-HLA-DR3 and -DR4 tetramers including CLIP loaded tetramers as negative 
controls were used. Additionally, specificity of CD4+ T cell lines for the epitopes they were 
raised against was tested in an IFNγ ELISPOT assay. The sequences HLA-DRB1*0301- and 
HLA-DRB1*0401-restricted NY-BR-1–specific T cell epitopes identified previously (102) and 
their amino acid positions and the respective SYFPEITHI prediction scores are listed in Table 
31. The peptide designations used in the thesis and corresponding published designations 
are depicted as well. The CD4+ T cell lines are named accordingly. For example, the T cell 
line specific for peptide #8862 is designated as CD4+ T cell line #8862. 
 
5.3.1 Testing of specificity and affinity of established CD4+ T cell lines 
The HLA-DRB1*0301- restricted CD4+ T cell lines #8756 and #8797 and HLA-DRB1*001 
restricted CD4+ T cell lines were tested in a functional IFNγ ELISPOT assay. HLA-DR3- 
restricted T cell lines #8756 and #8797 had lost their specific activity (Figure 20A). HLA-DR4-
restricted T cell lines #8862 and #9251 on the other hand could be specifically stimulated by 
the cognate peptide presented on the DR4 molecule of T2/DR4 cells and not the irrelevant 
CLIP peptide (Figure 23A). 1x105 T cells stimulated with 5x104 target cells pulsed with  
1 µg/ml of the relevant peptide resulted in an average of 921 and 116 IFNγ spots for Th line 
#8862 and Th line #9251, respectively (Figure 23A). Importantly, the HLA-DR4 restriction 
was further confirmed by the fact that T2/DR3 cells pulsed with the relevant peptide did not 
result in IFNγ secretion (Figure 23A). Thus, HLA-DR4- restricted lines were still functional 
and specific for their respective epitope that they were raised against. The functional avidity 
of the T cell lines #9251 and 8862 was tested in an ELISPOT assay by titrating the 
concentration of the cognate peptide loaded on T2/DR4 cells. The highest concentration of 
peptide used was 1 µg/ml and this resulted in the saturated IFNγ response for both cell lines 
(Figure 23B). The line #8862 had a higher avidity and 1x10
5
 T cells incubated with 5x10
4
 
T2/DR4 cells loaded with 500 ng/ml of relevant peptide resulted in 446 spots whereas line 
#9251 had only 304 spots at the same peptide concentration. Peptide concentration of  
50 ng/ml or lower was not sufficient in stimulating either T cell line (Figure 23B). Additionally, 
varying numbers of T cells were tested on 5x10
4
 T2/DR4 cells loaded with 1 µg/ml of the 
cognate peptide. Th line #8862 was more sensitive than line #9251 at cell numbers lower 
than 2.5x104 cells/well and 1.25x104 #8862 cells resulted in a mean spot number of 417 
compared to 316 average spots for equal number of #9251 T cells used (Figure 23B). The 
dose dependent dilution of secreted IFNγ was observed in both T cell lines however, 1.5x103 
cells of Th line #8862 resulted in an average of 150 spots whereas the same number of 
#9251 cells resulted in barely detectible IFNγ response. 
 
 
Table 31. NY-BR-1 specific CD4
+
 T cell epitopes 
 
HLA RESTRICTION
PUBLISHED NAME    
(Gardyan et al)
DESIGNATION IN 
THESIS SEQUENCE POSTION SYFPEITHI score
HLA-DRB1*0301 BR1-88 peptide #8797 VVTFLVDRKCQLDVL 88-102 34
HLA-DRB1*0301 BR1-1238 peptide #9017 DVSSTIYNNEVLHQP 1238-1252 15
HLA-DRB1*0301 BR1-1347 peptide #8756 KSKITIDIHFLERKM 1347-1361 22
HLA-DRB1*0401 BR1-537 peptide #8862 AFELKNEQTLRADPM 537-551 26
HLA-DRB1*0401 BR1-1242 peptide #9251 TIYNNEVLHQPLSEA 1242-1256 18
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Figure 23. Characterization of NY-BR-1-specific, HLA-DR3- and -DR4-restricted murine CD4
+
 T 
cell lines 
HLA-DR3- restricted CD4
+
 T cell lines #8756 and #8797 and HLA-DR4- restricted CD4
+
 T cell lines 
#8862 and #9251 were tested for HLA-restriction, specificity and affinity in an ELISPOT assay. (A) 
1x10
5
 effector cells were incubated overnight with 5x10
4
 target cells alone or loaded with 1 µg/ml 
peptide and secreted IFNγ was measured by ELISPOT assay. T2, T2/DR3 or T2/DR4 cells were used 
as target cells and were loaded with an unmatched 15 mer peptide (irrelevant peptide), CLIP peptide 
or the matched synthetic peptide (relevant peptide). Bars show mean of IFNγ spots per well and error 
bars show SEM of triplicates. (B) The HLA-DRB1*0401-restricted T cell lines #8862 and #9251 were 
also tested for their peptide affinity and the minimum number of T cells required for effective 
recognition in an ELISPOT assay. For testing the peptide affinity, 1x10
5
 T cells were incubated with 
5x10
4
 T2/DR4 cells along with decreasing concentration of the relevant peptide. The peptide was 
diluted 10 fold starting from 5 µg/ml to 5 pg/ml (gray bars) and 0 pg/ml (blue bars). In order to test the 
minimum number of T cells required for effective recognition, the number of T cells was decreased by 
performing 2 fold serial dilution starting with 1x10
5
 cells/well to 781 cells/well (indicated by gray). The 
number of target T2/DR4 cells and peptide concentration used was kept constant at 5x10
4
 cells/well 
and 1 µg/ml, respectively. Bars show mean of IFNγ spots per well and error bars show SEM of 
triplicates. 
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5.3.2 Testing of NY-BR-1-specific HLA-DR3 and HLA-DR4 tetramers  
 
Figure 24. Testing of NY-BR-1-specific HLA-DR3 and HLA-DR4 tetramers  
The NY-BR-1 specific CD4
+
 helper T cell lines were incubated with the tetramer and counterstained 
with anti-CD4 antibody for FACS analysis. (A) T cells were incubated with tetramers (diluted 1:50) at 
37°C for 2.5 hours and counterstained with anti-CD4 antibody. Representative dot plot shows the 
fraction of tetramer positive cells among CD4
+ 
T cells stained with the control CLIP tetramer (top row) 
or the corresponding NY-BR-1 specific tetramer (bottom row). (B) Other staining conditions for the 
tetramers were tested including incubation at 4°C for 2 hours, 37°C for 45 minutes or 37°C for 2 hours 
with tetramer dilution of 1:50 or 1:100. This was followed by surface staining with anti -CD4 antibody. 
Frequency of tetramer labeled cells among CD4
+
 T cells is depicted as bar graphs.  
 
In order to be able to detect NY-BR-1 specific CD4+ T cells specific for the HLA-DR3- and 
HLA-DR4-restricted epitopes (described in the previous section) among tumor infiltrating 
lymphocytes, we wanted to use HLA-DR3 and HLA-DR4 tetramers loaded with NY-BR-1 
epitopes which were obtained from NIH tetramer facility. They were tested on the various 
NY-BR-1 specific CD4+ T cell lines available to test their specificity and binding capacity and 
to optimize the staining protocol. Thus, the CD4+ T cells were incubated with the specific 
tetramer diluted 1:50 along with anti-CD4 antibody to evaluate the presence of antigen 
specific T cells. Only the T cell line #8797 was labeled by the specific tetramer and not by the 
unspecific HLA-DR3 tetramer loaded with the CLIP peptide (Figure 24A). All the remaining T 
cell lines did not bind the specific tetramer at a rate higher than the CLIP-loaded tetramer 
(Figure 24B). Since the HLA-DR3-restricted T cell lines did not contain functional CD4+ T 
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cells which could be activated by the cognate peptide present on the context of HLA-DR3 
(Figure 23A) and did not expand effectively in vitro, the HLA-DR4-restricted CD4+ T cell lines 
were used for further optimization of the tetramer staining. Tetramer binding did not improve 
when they were incubated at 4 °C for 2 hour, or 37 °C for 45 minutes or for 2 hours (Figure 
24B).  
 
Figure 24 (contd.) Testing of NY-BR-1-specific HLA-DR3 and HLA-DR4 tetramers  
HLA-DR4 tetramer loaded with the peptide #9251 (from Immunitrack) was tested for their binding to Th 
line #9251. (C) 1x10
6
 cells were incubated with the CLIP tetramer or the NY-BR-1 specific tetramer 
diluted 1:100 at room temperature for 1 hour followed by surface staining with anti-CD4 antibody for 45 
minutes at 4 °C. Fraction of tetramer labeled CD4
+
 T cells present in the T cell line #9251 or #8862 is 
depicted as dot plots. (D) Percentage of tetramer bound CD4
+
 T cells in the T cell line #9251 after 
incubation with tetramer (diluted 1:10) in the presence of 5 nM dasatinib either at room temperature 
(RT) or at 37 °C for 1.5 hours is depicted.  
 
Additionally, HLA-DR4 tetramer loaded with peptide #9251 kindly provided by Immunitrack 
was tested at room temperature (dilution 1:100) followed by surface staining of CD4 
molecules. Th line #8862 was included as a biological negative control. There was no 
specific tetramer staining observed (Figure 24C). Dasatinib is a protein tyrosine kinase 
inhibitor which is known to stabilize the TCR on the cell surface following TCR engagement 
and has been demonstrated to enhance tetramer binding to TCR (235). Thus, the CD4+ T 
cell line #9251 was incubated with the tetramer in the presence of 5 nM Dasatinib for 1.5 
hours at room temperature or at 37°C, followed by surface staining. The co-incubation with 
Dasatinib failed to enhance binding of the tetramer to the TCR of CD4+ T cell line #9251 
irrespective of the temperature of incubation (Figure 24D). 
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5.4 Interaction between NY-BR-1 expressing tumors and the immune system 
5.4.1 Analysis of NY-BR-1 specific immune response in spleens of tumor 
bearing mice 
 
Figure 25. NY-BR-1 specific CD8
+
 and CD4
+
 T cells are induced after EONY tumor injection 
HLA-DR4tg mice (n=10) were injected with 2x10
5
 EO771 cells, EONY#9 cells or EONY#17 cells s.c. 
and the splenocytes were isolated from the tumor bearing mice after 20 days and incubated with 
various NY-BR-1 epitopes. The activation of NY-BR-1 specific T cells in response to the peptides was 
detected by IFNγ catch assay. (A) Gating scheme for analysis of IFNγ secreting cells among 
splenocytes. (B) The percentage of IFNγ
+
CD8
+
 (upper row) and IFNγ
+
CD4
+ 
cells (lower row) among 
splenocytes is shown as dot plots. (Mann Whitney test, * p≤ 0.05; ** p≤0.01; *** p≤0.001; **** 
p≤0.0001). 
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As mentioned earlier, NY-BR-1 could act as a xeno-antigen in HLA-DR4tg mice resulting in 
an anti-NY-BR-1 immune response. This might explain why EONY #9 and EONY#17 cells 
gave rise to tumors at a slower rate compared to the parental EO771 cells (Section 5.1.2.3, 
Figure 14A). In order to detect NY-BR-1 specific immune responses in mice transplanted 
with NY-BR-1 expressing tumors, splenocytes were isolated from tumor bearing mice and 
NY-BR-1 specific CD4+ and CD8+ T cells which were activated to secreted IFNγ in response 
to soluble peptides representing NY-BR-1 epitopes were detected using IFNγ catch assay. 
Exemplary gating scheme is depicted in Figure 25A. IFNγ secreting CD4+ and CD8+ T cells 
could be detected in mice bearing EONY#9 and EONY#17 tumors compared to those 
bearing EO771 tumor (Figure 25B) at significantly higher frequencies suggesting that NY-
BR-1 expression in tumors is maintained and elicits an NY-BR-1 specific T cell response. 
The mean frequency of CD8+ T cells specific for H2-Db restricted NY-BR-1 epitope peptide 
#6 among splenocytes was 0.044% and 0.034% in mice transplanted with EONY#9 and 
EONY#17 cells, respectively compared to significantly lower mean frequency of 0.00625% in 
mice bearing EO771 tumors (Figure 25B). Besides CD8+ T cells, NY-BR-1 specific CD4+ T 
cells were also induced in mice which had NY-BR-1 expressing tumors. In mice bearing 
EONY#9 tumors, 0.064 % and 0.0294 % of splenocytes comprised of HLA-DR4-restricted 
CD4+ T cells specific for peptide #8862 and peptide #9251, respectively whereas in mice 
transplanted with EONY#17 tumors the frequencies were 0.0287% and 0.023%, respectively. 
In contrast, the frequency of CD4+ T cells reactive to peptide#8862 and peptide #9251 were 
0.00726% and 0.015% in mice with parental EO771 tumors lacking NY-BR-1 expression 
(Figure 25B). Surprisingly, H2-Db-restricted CD8+ T cell epitope peptide #6 also activated 
CD4+ T cells to secrete IFNγ and HLA-DR4- restricted CD4+ T cell epitopes, peptide #8862 
and #9251 induced IFNγ response from CD8+ T cells when supplied as soluble peptides 
(Figure 25B). This cross-activation was significantly stronger in mice with EONY#9 or 
EONY#17 derived tumors compared to those with EO771 derived tumors (Figure 25B).  
5.4.2 Characterization of tumor infiltrating leukocytes 
We could detect NY-BR-1 specific CD4
+
 and CD8
+
 T cells in the spleens of mice transplanted 
with NY-BR-1 expressing tumors (Figure 25B). Therefore we wanted to investigate whether T 
cells and macrophages infiltrate the tumors as well. Tumors were resected 20 days after 
inoculation and a single cell suspension was obtained by applying a combination of 
mechanical disruption and enzymatic digestion. The leukocyte fraction was then enriched by 
using Ficoll density gradient centrifugation, followed by staining for surface markers. The 
gating scheme employed is shown in Figure 26A. Briefly, cells were gated based on their 
forward and side scatter characteristics followed by exclusion of doublets. The dead cells 
were then excluded based on dead cell stain followed by gating on CD45+ cells to include all 
leukocytes. CD45+ cells were then characterized as CD4+ T cells, CD8+ T cells and 
CD11b+F4/80+ macrophages. The proportion of CD4+ T cells among CD45+ cells infiltrating 
EONY#9 and EONY#17 tumors was 13% and 14%, respectively which was lower in 
comparison to 21% CD4+ T cells in tumors arising from EO771 transplantation (Figure 26B). 
The other cell populations showed the reverse trend and tumors expressing NY-BR-1 were 
infiltrated with more CD8+ T cells and CD11b+F4/80+ macrophages. However, the difference 
was significant for both EONY clones compared to EO771 tumors only in the case of 
macrophages as the fraction of TAMs in EONY#9 derived and EONY#17 derived tumors was 
1.5 times and 1.46 times more than that of EO771 tumors, respectively (Figure 26B. left 
panel). Interestingly, macrophages comprised the most abundant cell population among the 
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leukocytes, with CD11b+F4/0+ comprising more than 70% of all leukocytes in some tumors 
(Figure 26B. left panel).  
 
Figure 26. Characterization of tumor infiltrating leukocytes 
2x10
5
 EO771 cells, EONY#9 cells or EONY#17 cells were injected s.c. into the right flank of HLA-
DRB1*0401tg mice (n=10). Tumors were resected and digested with Collagenase D and single cell 
suspension was obtained by passing them through a 70 µm mesh. Immune cells were isolated by 
performing gradient centrifugation using Lympholyte-M and collecting the interphase. Immune cells 
were then characterized by flow cytometry. (A) Gating scheme for analysis of tumor infiltrating CD4
+
 T 
cells, CD8
+
 T cells and CD11b
+
F4/80
+
 macrophages. (B) Percentage of CD4
+
 T cells, CD8
+
 T cells 
and CD11b
+
F4/80
+
 macrophages within CD45
+
 cells is shown. (Mann Whitney test, * p≤ 0.05; ** 
p≤0.01; *** p≤0.001). 
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5.4.3 Establishment of macrophage associated markers on in vitro polarized 
peritoneal exudate cells (PECs) 
 
Figure 27. In vitro polarization of PECs 
PECs isolated from HLA-DR4 mice after thioglycollate treatment for 4 days were stained for various 
M1- and M2- associated markers. (A) Gating scheme for analysis of expression of iNOS, CD11C, 
HLA-DR4 and CD206 on peritoneal macrophages. (B) Expression of various markers on untreated 
macrophages or those treated with IFNγ and LPS or IL-4 for 24 hours is shown in a representative dot 
plot. 
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Figure 27 (contd). In vitro polarization of PECs 
(C) Histograms depict the expression of CD11c, CD206, HLA-DR4 and iNOS on peritoneal 
macrophages treated with IFNγ and LPS or IL-4 for 24, 48 or 72 hours. 
 
Having observed a significant increase in TAMs within NY-BR-1-expresssing tumors in 
comparison to parental EO771 tumors, we intended to analyze this myeloid infiltrate in more 
detail, particularly with respect to their differentiation status. In order to establish macrophage 
differentiation markers that would allow discrimination between M1-like and M2-like 
macrophages, we first made use of peritoneal exudate cells (PECs) as surrogate for tumor 
associated macrophages. Mouse peritoneal cavity contains quiescent macrophages which 
can be harvested easily, however the administration of thioglycollate broth is known to elicit 
macrophages (236). Since PECs from these mice are comprised of mostly macrophages, 
they are suitable for in vitro characterization of macrophages markers. 
PECs were isolated on 4 days after thioglycollate administration and they were allowed to 
attach for 2 hours. The non-adherent cells were washed away with PBS. The attached 
macrophages were then polarized in vitro into M1-like or M2-like macrophages as described 
in section 4.2. The cells were then analyzed for M1- and M2-associated markers by flow 
cytometry. The gating scheme employed is depicted in Figure 27A. Briefly, cells were first 
gated based on their forward and side scatter characteristics followed by exclusion of 
doublets and dead cells. Then, macrophages which can be identified as CD45+CD11+F4/80+ 
cells were analyzed for expression of the following markers: CD11c, iNOS, HLA-DR and 
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CD206. M1-like markers iNOS and HLA-DR are upregulated on M(IFNγ+LPS) macrophages 
compared to untreated and M(IL-4) macrophages by 24 hours of polarization (Figure 27B). 
On the other hand M(IL-4) cells upregulate CD11c in 66% cells in addition to CD206 in 
34.89% cells after 24 hour stimulation (Figure 27B). However, CD11c is usually associated 
with M1-like macrophages, especially in adipose tissue macrophages (219). While CD11c 
was upregulated on M(IL-4) cells as early as 24 hours and expression increased further after 
48 and 72 hours, CD206 could be detected on the surface of M(IL-4) cells only after 72 hours 
(Figure 27C). On the other hand, both M1-associated markers HLA-DR4 and iNOS are 
upregulated on IFNγ+LPS treated macrophages within 24 hours and their level of expression 
continue to increase with time (Figure 27C). 
 
 
Figure 27 (contd). In vitro polarization of PECs 
(D) RNA was isolated from PECs polarized in vitro for 24 hours with IFNγ and LPS or with IL-4 and the 
expression of various M1-associated genes (upper panel) or M2-associated genes (lower panel) were 
analyzed by qRT-PCR. The expression data has been depicted as the log2(fold change) of the gene 
relative to house-keeping gene normalized to untreated sample. 
 
Additionally, RNA was isolated from PECs polarized for 24 hours and the expression of 
various M1- and M2- associated genes was analyzed by qRT-PCR. As expected genes 
known to be expressed in M1- like macrophages like Il6, Cxcl10, Il12, IL1β, Stat1, Cd86 and 
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Cd80 were upregulated in PECs polarized with IFNγ and LPS compared to IL-4 treated 
PECs (Figure 27D, upper panel). Conversely, IL-4 treatment induced genes associated with 
M2-like macrophages, e.g. Ym1, Fizz1, Arg1, Mrc1, Cd206, Cd11c, Il10, Cd163, Stat6, 
Pparg1 (Figure 27D, lower panel). Vegfa was surprisingly upregulated in PECs cultured in 
the presence of IFNγ and LPS, as detected by two different primer pairs (designated by 
Vegfa and Vegf, Figure 27D, lower panel). Thus, FACS antibodies for HLA-DR, iNOS and 
CD206 were shown to detect the respective M1- or M2- associated markers on in vitro 
polarized PECs. Additional genes associated with M1- or M2- like macrophages could be 
detected with specific primer pairs by qRT-PCR. 
5.4.4 Phenotypic analysis of M1/M2-like tumor associated macrophages 
Next the expression of M1- and M2- associated markers on TAMs was analyzed by flow 
cytometry. The proportion of HLA-DR4+ macrophages was significantly lower in EONY#9 
derived tumors but the level of expression of M1-associated marker HLA-DR was higher in 
EONY#17 TAMs compared to EO771 tumors (Figure 28A). iNOS expressing TAMs were 
more abundant and had higher levels of iNOS in NY-BR-1 expressing tumors (Figure 28A). 
CD206 showed reverse tendency in terms of frequency of positive cells and the expression 
levels. EONY tumors were infiltrated by more CD206+ macrophages but the level of 
expression was more in EO771 TAMs (Figure 28A). In order to assess if the difference in the 
frequencies of infiltrating T cells and macrophages could be due to differences in tumor size, 
the frequencies of various population of infiltrating cells were plotted against tumor size 
(Figure 28B). The low values of coefficient of regression (R2) suggest that the extent of 
infiltration by various immune cells does not correlate to tumor size. The only exception was 
that high iNOS expressing macrophages were more abundant in smaller tumors. 
In order to evaluate the sensitivity of various primer pairs available for detection of various 
M1- and M2- associated markers in tumor associated macrophages, CD11b+ cells were 
isolated from EO771 or EONY#17 derived tumors by labeling with magnetic beads and RNA 
was isolated from them. The expression of various genes was normalized to the respective 
house-keeping gene. The relative expression gives us an idea which genes could be used 
for later experiments based on expression levels, as low expressed gene would be difficult to 
detect in sorted TAMs due to low cell numbers available. Representative dot plot shows that 
post magnetic sorting the proportion of CD11b+F4/80+ cells increased from 54.4% to 83.7% 
(Figure 28C). Gene expression analysis on these cells for a variety of M1- and M2- like 
makers by qRT-PCR showed that M2-associated markers Il-10, Stat6 and Pparg1 are higher 
expressed on TAMs from EO771 tumors compared to EONY#17 tumors while Fizz1, Arg1 
and Il-6 showed the reverse trend (Figure 28D, upper panel). On the other hand, genes 
described to be upregulated in M1-like macrophages such as Il-1b, Stat1, Cxcl9 and Nos2 
were detected in lower amounts in EO771 TAMs compared to EONY#17 TAMs (Figure 28D, 
lower panel). This hints that macrophages infiltrating EONY tumors could resemble less 
immunosuppressive phenotype. 
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Figure 28. Characterization of tumor associated macrophages in EO771 and EONY tumors 
(A) Fraction of macrophages expressing HLA-DR, iNOS and CD206 macrophages (upper panel) and 
the level of expression (MFI) (lower panel) for the same markers is shown. (Mann Wh itney test, * p≤ 
0.05; ** p≤0.01; *** p≤0.001). (B) Frequencies of tumor infiltrating CD4
+
 T cells, CD8
+
 T cells and 
macrophages and of different macrophage populations are plotted against corresponding tumor 
weight for linear regression analysis. R2 values indicate coefficient of regression. 
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Figure 28 (contd.) Characterization of tumor associated macrophages in EO771 and EONY 
tumors 
(C) Tumor infiltrating leukocytes isolated from EO771 and EONY#17 tumors by a combination of 
enzymatic and mechanical digestion followed by a density gradient centrifugation were enriched for 
CD11b
+
 cells using anti-CD11b microbeads. Representative dot plot depicts the relative abundance 
of CD11b
+
F4/80
+
 macrophages among CD45
+
 cells before magnetic enrichment (pre-MACS) and 
after positive selection in the unlabeled fraction (flow-through) and in the fraction labeled with beads 
(column fraction). (D) The expression of various genes associated with M2-like (upper panel) or M1-
like (lower panel) macrophages, was analyzed in the isolated CD11b
+
 cells by qRT-PCR. Log fold 
change for gene normalized to the house-keeping gene is shown. (Student‘s t test, * p≤ 0.05; ** 
p≤0.01; *** p≤0.001) 
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5.4.5 Impact of Ad.NY-BR-1 immunization on tumor development in HLA-
DRB1*0401 transgenic mice 
We could confirm the induction of NY-BR-1 specific CD8+ and CD4+ T cells in mice 
transplanted with NY-BR-1 expressing tumors. Additionally, we also observed that these 
tumors are infiltrated with higher frequencies of macrophages that express higher level of 
M1-associated markers compared to TAMs infiltrating parental tumors. We hypothesized that 
this could be due to NY-BR-1 specific T cells induced after tumor transplantation. Thus, 
immunization against NY-BR-1 to induce stronger immune responses should enhance the 
M1-like phenotype of the tumor infiltrating macrophages. We had already shown that 
immunization with the NY-BR-1 expressing Ad5.NY-BR-1 resulted in strong NY-BR-1 specific 
immune responses, including CD4+ and CD8+ T cell responses.  
 
Figure 29. Immunization with NY-BR-1 encoding adenovirus delays tumor growth 
HLA-DRB1*0401tg mice were immunized i.p. either with 5x10
8
 pfu Ad.NY-BR-1 (n=10) or with 5x10
8
 
pfu Ad.Control (n=10) and 2x10
5
 EONY#17 cells were injected s.c. into the right flank 14 days post 
immunization. The tumor growth was monitored for 30 days after injection and then the tumors were 
harvested and tumor weight was measured. (A) Tumor area and (B) tumor weight were measured as 
described earlier. Error bars represent SEM (n=10) and statistical analysis was performed using Mann 
Whitney test (*, p<0.5; **p<0.01, ***, p<0.001; ****, p<0.0001).  
 
 
HLA-DR4tg mice were immunized with the NY-BR-1 expressing Ad5.NY-BR-1 or the empty 
virus Ad5.Control and EONY#17 cells were injected subcutaneously 14 days post 
immunization and tumor growth was monitored for 30 days following tumor inoculation. The 
immunization induced anti-NY-BR-1 immunity translated into delayed tumor growth as well 
and transplanted EONY#17 cells gave rise to tumors at a slower rate in mice immunized with 
Ad5.NY-BR-1 compared to those immunized with Ad5.Control (Figure 29A). The first 
palpable tumors appeared already after 9 days of tumor inoculation in both groups of mice, 
but the difference in the tumor size became apparent within 15 days post tumor injection. 
The average size and weight of tumors in the control group was 168 mm2 and 0.83 g, 
respectively compared to 96 mm2 and 0.47 g in the group which received Ad.NY-BR-1 
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(Figure 29A). Thus, immunization with an adenoviral encoding NY-BR-1 had a suppressive 
effect on growth of EONY tumors. 
5.4.6 Impact of Ad.NY-BR-1 immunization on phenotype of TAMs 
We hypothesized that NY-BR-1 specific CD4+ T cells could affect the phenotype of TAMs 
polarizing them towards an M1-like phenotype. Therefore, we investigated the phenotype of 
TAMs in mice immunized with Ad5.NY-BR-1 or Ad5.Control and subsequently transplanted 
with EONY#17 tumor cells. The fraction of macrophages among tumor infiltrating immune 
cells increased from an average of 36% to 61.6 % after immunization against NY-BR-1 
(Figure 30A, left panel). HLA-DR expression is known to be higher on M1-like macrophages 
and we could demonstrate the same in in vitro polarized PECs isolated from HLA-DR4tg 
mice. Thus, the percentage of HLA-DR4+ cells among TAMs was analyzed. Although there 
was no significant difference between the frequency of HLA-DR4+ TAMs after Ad.NY-BR-1 
administration (Figure 30A, middle panel), there was an increment of 1.3 times in the level of 
HLA-DR4 expression on the TAMs (Figure 30A, right panel) suggesting a more M1-like 
phenotype. However, the gene expression data obtained by qRT-PCR showed that M1-like 
markers, Cxcl10 and Stat1 was expressed to lower extent in the TAMs (Figure 30B, lower 
panel) whereas immunization with Ad.NY-BR-1 did not significantly alter the expression of 
M2-associated genes in TAMs (Figure 30B, upper panel). 
 
Figure 30. Characterization of TAMs following immunization with NY-BR-1 encoding 
adenovirus 
HLA-DRB1*0401tg mice were immunized i.p. either with 5x10
8
 pfu Ad.NY-BR-1 (n=10) or with 5x10
8
 
pfu Ad.Control (n=10) and 2x10
5
 EONY#17 cells were injected s.c. onto the right flank 14 days post 
immunization. On day 30 the tumors were harvested and tumor-infiltrating immune cells were isolated 
as described earlier. CD45
+
CD11b
+
F4/80
+
 macrophages were FACS sorted and RNA was isolated for 
gene expression analysis. (A) The frequency of CD11b
+
F4/80
+
 macrophages among CD45
+
 cells, 
HLA-DR
+
 cells among macrophages, and the level of HLA-DR on macrophages is depicted.  
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Figure  30 (contd). Characterization of TAMs following immunization with NY-BR-1 encoding 
adenovirus 
(B) Expression of M2- (upper panel) and M1-assoclated genes (lower panel) in the TAMs was 
quantified by qRT-PCR. Log fold change for gene normalized to the house-keeping gene is shown 
(Student‘s t test, * p≤ 0.05; ** p≤0.01; *** p≤0.001).  
 
5.5 Interaction of CD4+ T cells and macrophages 
It has been shown that antigen specific CD4+ T cells can be stimulated by macrophages 
which present antigenic epitopes in the context of MHC II molecule. The macrophages in the 
tumor microenvironment can take up secreted tumor antigen and process it and 
subsequently present it on the cell surface as a peptide-MHC II complex (209). CD4+ T cells 
specific for the epitope secrete IFNγ upon activation which can re-polarize the tumor-
infiltrating macrophages into an M1-like phenotype. 
5.5.1 Tumor derived peptide loaded CD11b+ cells stimulate specific CD4+ T 
cells ex vivo 
Previous experiments demonstrated that EO771 and EONY#17 derived tumors were heavily 
infiltrated by macrophages and over 50% of all CD45+ cells were macrophages (Figure 26B) 
and CD11b+F4/80+ macrophages comprised more than 80% of all CD45+ cells (Figure 28C) 
after enrichment with magnetic beads coupled to anti-CD11b antibody. Thus, tumor-
infiltrating CD11b+ cells isolated from EO771, EONY#9 or EONY#17 derived tumors were co-
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cultured overnight with HLA-DR4-restricted CD4+ T cell lines specific for NY-BR-1 epitopes 
#8862 and #9251. 
Tumor infiltrating macrophages from NY-BR-1 expressing tumors (EONY#9 and EONY#17) 
failed to stimulate CD4+ T cells to secrete IFNγ when compared to TAMs isolated from 
parental EO771 tumors (Figure 31, green bars). T2/DR4 cells which express HLA-DR4 
molecule were loaded with the relevant peptide and used as a positive control and could 
strongly activate both CD4+ T cell lines. However, CD4+ T cell line #8862 could recognize 
TAMs loaded externally with the peptide #8862 (Figure 31, red bars) indicating that the HLA-
DR4 expression on the TAMs was enough for the TCR on CD4+ T cells to engage with the 
peptide-MHC II complex. On the other hand, the CD4+ T cell line specific for the NY-BR-1 
epitope #9251 failed to recognize CD11b+ cells loaded with the relevant peptide (Figure 31, 
red bars, right panel). 
 
Figure 31. Peptide pulsed TAMs are recognized by NY-BR-1-specific CD4
+
 T cell line #8862  
Tumor infiltrating leukocytes isolated from EO771, EONY#9 and EONY#17 tumors by a combination of 
enzymatic and mechanical digestion followed by a density gradient centrifugation were enriched for 
CD11b
+
 cells using anti-CD11b microbeads. The isolated cells were then used as target cells in an 
ELISPOT assay either alone or loaded with 1 µg/ml peptide with NY-BR-1 specific CD4
+
 T cells. 1x10
5
 
effector cells (CD4
+
 T cells line #8862 or #9251) were incubated overnight with 5x10
4
 target cells and 
IFNγ secretion was measured by ELISPOT assay. Mean number of IFNγ spots is represented as bar 
graphs and error bars depict SEM of triplicates in ELISPOT assay (Mann Whitney test, * p≤ 0.05; ** 
p≤0.01; *** p≤0.001). 
 
5.5.2 NY-BR-1 specific CD4+ T cells can repolarize in vitro polarized M2-like 
macrophages towards M1-like macrophages 
We demonstrated that we could successfully isolate and polarize peritoneal macrophages 
into M1-like and M2-like phenotype. In order to investigate if NY-BR-1 specific CD4+ T cells 
are capable of reducing the immunosuppressive phenotype of M2-like macrophages, PECs 
were polarized to M2-like macrophages using IL-4 and then co-cultured with NY-BR-1 
specific CD4+ T cells in the presence of the relevant peptide or tumor lysates for 48 hours. 
The activation of the CD4+ T cells in response to their cognate epitope was measured by the  
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Figure 32. NY-BR-1-specific CD4
+
 T cell lines #8862 and #9251 re-polarize M2-like macrophages  
PECs isolated from HLA-DR4tg mice were polarized to M2-like macrophages for 48 hours using  
10 ng/ml IL-4. 1.8 x10
6
 polarized PECs were co-cultured with 1x10
6
 CD4
+
 T cells and 5 µg/ml synthetic 
peptide or with protein lysates from tumor cells containing 50 µg total protein. Supernatant and PECs 
were harvested after 48 hours for analysis. (A) Bar graph shows the quantity of secreted IFNγ in the 
supernatant as measured by ELISA and error bars depict SEM of duplicates in the ELISA. (B) 
Representative dot plots show gating scheme for the analysis of HLA-DR4 and iNOS expression on 
the PECs following co-culture with the CD4
+
 T cells. (C) Bar graphs show the percentage of HLA-DR4
+
 
and iNOS
+
 macrophages and the level of expression as median fluorescence intensities (MFI) after 48 
hours of co-culture.  
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secreted IFNγ present in the supernatant. IFNγ response could only be detected when the 
CD4+ T cell lines #8862 and #9251 were co-cultured with the PECs in the presence of the 
corresponding peptide in the soluble form (Figure 32A, bars 5 and 12). T cells did not secrete 
detectible levels of IFNγ when co-cultured with the PECs alone (Figure 32A, bars 3 and 10) 
or in the presence of an irrelevant peptide (Figure 32A, bars 4 and 11). PECs loaded with 
lysates from EO771, EONY#9 and EONY#17 tumor cells also failed to elicit an IFNγ 
response that could be detected in the supernatant after 48 hours of co-culture (Figure 32A,  
bars 6, 7, 8, 13, 14 and 15).   
The harvested PECs were then characterized for the expression of various M1- and M2- 
associated markers by flow cytometry or qRT-PCR. The gating scheme employed is depicted 
in Figure 32B. Briefly, cells were gated based on their forward and side scatter 
characteristics, followed by exclusion of doublets and cells positive for dead cell stain. The 
live cells were gated on CD45
+
 events which comprised 99% of all live cells. Within the 
CD45+ leukocytes, 98% of the cells were determined to be macrophages based on the 
expression of CD11b and F4/80. These CD11b
+
F4/80
+
 cells were then analyzed for the 
expression of M1-associated markers, HLA-DR4 on the cell surface or intracellular iNOS. 
Forty eight percent of the PECS treated with IL-4 for 48 hours expressed HLA-DR4 molecule 
on their surface. The proportion of HLA-DR4+ PECs increases slightly to 62% when IL-4 
containing medium is replaced with fresh medium without IL-4 (Figure 32C, upper left panel, 
medium only). Soluble peptide representing HLA-DR4-restricted CD4+ T cell epitopes does 
not result in further increase of HLA-DR4 expression levels on the surface of PECs.  
Addition of CD4+ T cells alone or in combination with irrelevant peptide results in the 
approximately 14% increase in HLA-DR4 surface expression compared to medium alone. 
However, the strongest increase in HLA-DR4 expression on PECs is observed when PECs 
are co-cultured with NY-BR-1 specific CD4+ T cell lines in the presence of the specific 
peptide in the soluble form (Figure 32C, upper left panel). The proportion of macrophages 
positive for HLA-DR4 on the cell surface increased from 71.9% to 96.2% and 72% to 99.1% 
when co-cultured with the CD4+ T cell lines #8862 and #9251 and their corresponding 
epitopes, respectively compared to CD4+ T cells with irrelevant peptide. Similar tendency is 
observed in the level of HLA-DR4 expression measured by the median fluorescence intensity 
(MFI) values (Figure 32C, lower left panel). The baseline iNOS expression in M2 polarized 
PECs is almost negligible and is not induced by addition of T cells alone or with the irrelevant 
peptide (Figure 32C, upper right panel). However, interaction of the CD4+ T cell lines #8862 
or #9251 with PECs loaded with the relevant peptide resulted in the induction of iNOS 
expression in 47.8% and 33.6% of the PECs, respectively (Figure 32C, upper right panel). 
This increase in iNOS levels was reflected in the MFI values which showed 15.58 and 9.09 
fold increase when compared to PECs loaded with irrelevant peptide and co-cultured with 
#8862 and #9251 T cells, respectively (Figure 32C, lower right panel). PECs loaded with 
lysates from NY-BR-1 expressing EO771 derived clones, EONY #9 and EONY #17 failed to 
upregulate of HLA-DR or iNOS post co-culture with NY-BR-1 specific CD4+ T cells (Figure 
32C, blue bars). 
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Figure 32 (contd.) NY-BR-1-specific CD4
+
 T cell lines #8862 and #9251 re-polarize M2-like 
macrophages  
(D) Expression of M1-assoclated genes in the PECs after co-culture was quantified by qRT-PCR. Log 
fold change for gene normalized to the house-keeping gene is shown. (Student‘s t test, * p≤ 0.05; ** 
p≤0.01; *** p≤0.001) 
 
 
Additional M1- and M2-associated genes were analyzed by qRT-PCR to further characterize 
the change in the phenotype of the PECs following the co-culture. Co-incubation of the CD4+ 
T cells with M2-polarized PECs loaded with their cognate peptide significantly enhanced the 
expression of M1-associated genes Cd80, Cd86 and IL-1b compared to PECs loaded with 
an irrelevant peptide (Figure 32D, red bars). Interestingly, PECs loaded with lysates from 
NY-BR-1 expressing tumor cells expressed higher levels of Il-1b, Cd80 and Cd86 compared 
to PECs loaded with EO771 tumor cell lysates when co-cultured with NY-BR-1 specific CD4+ 
T cells (Figure 32D, blue bars). Surprisingly, Cxcl10 expression showed the reverse trend 
when Th line #9251 was used.  M2-associated genes Fizz1 and Pparg1 were both 
downregulated in PECs following antigen specific interaction between both CD4+ T cells and 
M2-polarized PECs (Figure 32E, red bars). Remarkably, other M2-associated markers Tgfb1 
and Ym1 were also downregulated in the case of CD4+ T cell line #9251 but showed the 
reverse trend in the group with T cell line #8862. Fizz1, Pparg1 and Ym1 levels are reduced 
under the influence of NY-BR-1 specific CD4+ T cell activity in presence of tumor cell lysate 
containing NY-BR-1 compared to parental cell lysate. Unexpectedly, Arg1 expression was 
increased in PECs co-cultured with both CD4+ T cell lines in the presence of the relevant 
peptide or EONY lysate. However, one important fact to keep in mind is that Arg1 was also 
detected in M1-polarized macrophages (Figure 28D), albeit to lower levels compared to M2-
polarized macrophages. Taken together, the FACS data and qRT-PCR data suggest that the 
interaction of NY-BR-1 specific CD4
+
 T cell lines #8862 and #9251 with M2-polarized PECs 
which present the cognate peptide can result in the polarization of the PECs towards and 
M1-like phenotype.  
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Figure  32 (contd). NY-BR-1-specific CD4
+
 T cell lines #8862 and #9251 re-polarize M2-like 
macrophages  
(E) Expression of M2-assoclated genes in the PECs after co-culture was quantified by qRT-PCR. Log 
fold change for gene normalized to the house-keeping gene is shown. (Student‘s t test, * p≤ 0.05; ** 
p≤0.01; *** p≤0.001) 
 
5.5.3 Depletion of CD4+ T cells resulted in delayed tumor growth and switch in 
macrophage polarization 
The immunization of HLA-DR4tg mice with Ad.NY-BR-1 induced strong NY-BR-1 specific T 
cell response and had a suppressive effect on the growth of EONY#17 tumors. Additionally, 
EONY tumors induced CD8+ and CD4+ T cell responses against NY-BR-1 and were 
infiltrated with macrophages that resembled M1-like phenotype. Since Ad.NY-BR-1 
immunization resulted in higher expression of HLA-DR4 molecules on tumor infiltrating 
macrophages and NY-BR-1 specific CD4+ T cells could repolarize macrophages to M1-like 
phenotype in vitro, we hypothesized that adenovirus immunization induced NY-BR-1 CD4+ T 
cells could also repolarize TAMs towards less immunosuppressive M1-like macrophages in 
vivo. In order to test our hypothesis, we immunized mice against NY-BR-1 using the 
adenovirus with the objective of inducing CD4+ and CD8+ T cells against NY-BR-1. This was 
followed by depletion of CD4+ T cells using the GK1.5 antibody shortly before tumor 
Results Page 119 
 
inoculation to investigate the role of the CD4+ T cells on macrophage polarization as depicted 
in the scheme Figure 33A.  
 
Figure 33. Depletion of endogenous CD4
+
 T cells results in less immunosuppressive TAMs 
within EONY#17 tumors 
HLA-DR4tg mice were immunized with 5x10
8
 pfu Ad.NY-BR-1 or Ad.control i.p. followed by s.c. 
injection of 2x10
5
 EONY#17 cells onto the right flank. This was combined with the depletion of CD4
+
 T 
cells and 100 µg of depleting antibody, GK1.5 or the isotype control was administered i.p. in each 
dose. (A) Schematic representation of the experiment indicates the timeline of various treatments. (B) 
Tumor growth curve shows the tumor area measured on various days for 17 days after tumor injection. 
(C) Weight of tumors harvested after day 17 is depicted as dot plots. Error bars represent SEM and 
statistical analysis done by Mann Whitney test. ( * p≤ 0.5; ** p≤0.01; *** p≤0.001) 
 
Immunization of mice with Ad.NY-BR-1 resulted in delayed growth of inoculated EONY#17 
tumors which reached a mean size of 49 mm2, 17 days after tumor injection (Figure 33B, 
closed blue squares) compared to mice immunized with the control virus which had tumors 
with the average size of 92 mm2 (Figure 33B, closed black circles). This recapitulated what 
was observed in previous experiments. Surprisingly, antibody mediated depletion of CD4+ T 
cells in mice immunized with the control virus (Figure 33B, open black circles) had protective 
effect on the mice and inhibited tumor outgrowth with the average size of tumors being 57% 
smaller than in the group that received the isotype (Figure 33B, closed black circles). 
Interestingly, the anti-tumor effect that accompanied the depletion of CD4+ T cells became 
apparent around day 13 after tumor transplantation. Depletion of CD4+ T cells following 
Ad.NY-BR-1 immunzation did not further reduce the tumor growth rate (Figure 33B, open 
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blue squares). The tumors were excised 17 days after inoculation and the weight of the 
harvested tumors confirmed the results obtained by tumor measurements (Figure 33C).  
The EONY#17 tumors comprised of approximately 16.8% CD4+ T cells, 8.25% CD8+ T cells 
and 54.5% CD11b+F4/80+ macrophages within CD45+ leukocytes present in the tumor 
(Figure 33D, black closed circles). The immunization of HLA-DR4tg mice with Ad.NY-BR-1 
did not significantly alter the proportion of tumor infiltrating CD4+ T cells, CD8+ T cells and 
CD11b+F4/80+ cells (Figure 33D, blue closed squares). The administration of the GK1.5 
antibody successfully depleted the CD4+ T cell population in the tumor (Figure 33D, open 
symbols). Absence of CD4+ T cells changed the relative abundance of infiltrating CD8+ T 
cells and macrophages as expected. Among the EONY#17 TAMs, 47.1% and 45% cells 
expressed HLA-DR4 molecules in control immunized and NY-BR-1 immunized mice, 
respectively (Figure 33D, lower panel).  However, CD4+ T cell depletion resulted in more than 
1.3 fold increase in the fraction of HLA-DR4
+
 macrophages in both groups. There was no 
difference in the frequency of HLA-DR4 expressing macrophages infiltrating EONY#17 
tumors between the mice immunized with the control virus or the NY-BR-1 expressing virus 
but the level of HLA-DR4 surface expression was higher on the macrophages after 
immunization with the Ad.NY-BR-1, as indicated by 1.7 fold increase in the MFI value (Figure 
33D, lower panel).  
 
Figure 33 (contd.) Depletion of endogenous CD4
+
 T cells results in less immunosuppressive 
TAMs within EONY#17 tumors 
(D) The frequency of CD4
+
 T cells, CD8
+
 T cells and CD11b
+
F4/80
+
 macrophages among CD45
+
 cells, 
HLA-DR
+
 cells among macrophages, and the level of HLA-DR4 on macrophages is depicted. 
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Figure 33 (contd.) Depletion of endogenous CD4
+
 T cells results in less immunosuppressive 
TAMs within EONY#17 tumors 
(E) Expression of M2- (upper two panels) and M1-assoclated genes (lower two panels) in sorted 
TAMs was quantified by qRT-PCR. Log fold change for gene normalized to the house-keeping gene 
is shown (Student‘s t test, * p≤ 0.05; ** p≤0.01; *** p≤0.001). 
 
 
The macrophages were sorted and expression of M1- and M-2 associated genes was 
analyzed by real time PCR. Mice immunized with the Ad.NY-BR-1 had significantly lower 
levels of Arg1 and Cd206 expression in the TAMs compared to those immunized with the 
control virus (Figure 33E) but there was no significant difference in the expression of other 
genes. Remarkably, the depletion of CD4+ T cells in the control group was accompanied by 
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repolarization of the TAMs towards an M1-like phenotype as indicated by the reduced 
expression of M2-associated genes like Ym1, Arg1 and Cd206 (Figure 33E, black bars). The 
same trend was observed in the group immunized with Ad.NY-BR-1 and Ym1, Fizz1 and 
Cd206 (not statistically significant for Cd206, p=0.1246) expression in macrophages was 
reduced after depletion of CD4+ T cells. Additionally, tumor infiltrating macrophages 
upregulated genes like Il-1b, Stat1 and Cxcl10 in response to CD4+ T cell depletion in the 
mice immunized with Ad.NY-BR-1 suggesting a shift towards an M1-like phenotype (Figure 
33E, blue bars). Thus, CD4+ T cell depletion alone seems to re-polarize the TAMs towards a 
less immunosuppressive phenotype in EONY#17 tumors. 
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6 Discussion 
6.1 Transplantable tumor model expressing breast cancer associated tumor 
antigen NY-BR-1 
6.1.1 EO771/NY-BR-1 transfectants were immunogenic 
NY-BR-1 is a breast cancer associated differentiation antigen which is highly overexpressed 
in breast cancer (94) making it an ideal target for immunotherapy. We established NY-BR-1 
transfectant clones of C57BL/6 derived mammary adenocarcinoma cell line EO771. Since, 
NY-BR-1 is not expressed in mice and there are no known homologs; it induced an immune 
response when NY-BR-1 expressing EO771 transfectant clones EONY #9 and EONY #17 
were inoculated into HLA-DR4tg mice. Both EONY #9 and EONY#17 gave rise tumors at a 
slower rate compared to parental EO771 cells (Figure 14A) even though there were no 
differences in their viability in vitro (Figure 11A). The NY-BR-1 expression was higher in 
EONY #9 cells than in EONY #17 cells (Figure 11B). This difference in expression levels was 
reflected in the growth kinetics in vivo and EONY #9 derived tumors had a slower growth rate 
than tumors arising from EONY #17 cells (Figure 14A). When splenocytes isolated from mice 
bearing NY-BR-1 expressing tumors were stimulated by synthetic peptides representing 
HLA-DR4- and H2-Db-restricted NY-BR-1 epitopes, the NY-BR-1 specific T cells that had 
been induced following tumor transplantation could be stimulated to secrete IFNγ (Figure 
25B). This confirms the induction of anti-NY-BR-1 immune responses against EO771/NY-
BR-1 transfectants and thus, the delayed tumor growth can be attributed to anti-NY-BR-1 
immune responses. Since the EONY tumors are not rejected, the model can still be used to 
answer the questions that we had raised.  
Various tumor models that have been established rely on exogenous antigens which are not 
expressed by the recipient mice. An example being the chicken ovalbumin protein (OVA) 
which is extensively used as a model antigen in diverse murine tumor models of melanoma 
(237), lymphoma (238) and breast carcinoma (239) to name a few . Both CD8
+ 
(240) and 
CD4+ T cell epitopes (241) of OVA have been identified facilitating the generation of TCR 
transgenic mice for both CD8+ (242) and CD4+ (243) T cells which makes it an attractive 
model antigen to study anti-tumor immune responses (244), the role of the tumor 
microenvironment (239, 245) and mechanisms of action of immune checkpoint blockade 
(245, 246) in detail. However, it has also shown immunogenicity like NY-BR-1 in our model 
and OVA expressing transfectants had delayed tumor growth compared to the parental 
tumor cell line in vivo (247, 248). We observed that high NY-BR-1 expressing clone EONY#9 
led to slower developing tumors compared to EONY#17 which had intermediate expression 
(Figure14A). Interestingly, similar results have been reported for OVA expressing colon 
carcinoma cell line MC38 and transplantation of high OVA expressing transfectants resulted 
in tumor rejection (David Esiel, 249) whereas MC38-OVA transfectants with lower OVA 
expression gave rise to progressively growing tumors in vivo (248). On the other hand, other 
tumor models where the growth rate of cells expressing OVA was not affected significantly 
compared to parental cell lines have also been described (250). Irrespective of these 
differences in the growth behavior of OVA expressing tumor cell lines, tumor models 
expressing OVA have been valuable for investigating mechanisms involved in anti-tumor 
immunity. Thus, clone EONY #17 with intermediate NY-BR-1 expression which could give 
rise to tumors and was not highly suppressed as the EONY#9 clone was suitable for 
transplantation experiments.  
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6.1.2 Loss of NY-BR-1 expression in vivo and in vitro 
NY-BR-1 expression could be detected in lysates from only 50% of resected D8P3 tumors by 
Western blot and qRT-PCR (Figure 9B, C). Inhibition of the proteasome revealed that D8P3 
cells have a high turnover of NY-BR-1 which results in low amounts of detectable protein 
(Figure 9D). It has been demonstrated that tumor antigen can be processed and CTL 
epitopes derived thereof are presented despite lack of detectable protein (251). Therefore, 
even though NY-BR-1 protein could not be detected in EL4/NY-BR-1 transfectant clone 
D8P3 derived tumors due to rapid turnover as demonstrated by enhanced NY-BR-1 
detection following proteasome inhibition (Figure 9D); it does not necessarily mean that NY-
BR-1 expression is lost. 
Besides, tumors are known to be infiltrated with various immune cells (70) and stromal cells 
(252, 253) and can form a significant proportion of the tumor. For example, T cell and 
myeloid cell infiltration in EL4 tumors have been studied (254). Thus, lysates from resected 
tumors which contain many other cell types might have had low amount of NY-BR-1 among 
the total protein which made its detection challenging. However, it is possible that NY-BR-1 
expression was lost in vivo as it is well known that antigen loss variants can arise due to 
mutations in tumors (255) or due to the selection pressure exerted by the immune system 
(256, 257). Antigen negative tumor cells can outgrow antigen positive cells as they are not 
susceptible to T cell mediated killing which relies on antigenic epitopes being presented in 
the context of MHC molecules. Immune cells like tumoricidal macrophages which cannot 
distinguish between antigen positive and antigen negative tumors in vitro fail to control the 
outgrowth of antigen loss variants in vivo (258). Additionally, inflammatory factors like TNFα 
present in the tumor microenvironment can induce dedifferentiation of melanoma cells 
resulting in transient loss of tumor antigens (259). Since NY-BR-1 is also a differentiation 
antigen, it might be similarly regulated in patients. However, it is unlikely that NY-BR-1 
expression was lost in vivo as a result of similar mechanisms as it was expressed under the 
control of a constitutive promoter in our model. 
EONY#19 lost its expression after prolonged in vitro culture. The loss of gene expression in 
transfectant clones is not uncommon and has been attributed to a variety of factors including 
epigenetic downregulation of genes encoded by exogenous transcription units (260). For 
example, neomycin resistance gene can silence transgenes under the specific viral 
promoters like SV40 and MPVS promoters (261). We used linearized pcDNA3.1(-) plasmid in 
which CMV promoter drives the expression of NY-BR-1 and Zeocin resistance gene. Thus, 
similar mechanisms might be responsible in the silencing of NY-BR-1 expression in 
EONY#19 clone. Since, the site of integration might play a role as well and transfected DNA 
can integrate at any genetic locus (262), other clones might not have been affected.   
6.1.3 Dominance of NY-BR-1-specific CD4+ T cells in vitro 
Upon peptide immunization of HLA-DR3tg mice with the 15 mer HLA-DR3-restricted epitope 
#9017, both NY-BR-1 specific CD8+ T and CD4+ T cell responses could be detected 
(Gardyan, unpublished). This led us to hypothesis that a H2-Db- or H2-Kb-restricted epitope 
was contained within the HLA-DR3 restricted epitope. Using the SYFPEITHI data base for in 
silico predictions, we could predict a 9 mer H2-Db- restricted epitope (peptide#6) contained 
within the 15 mer. It was later confirmed as H2-Db-restricted epitope by in vitro experiments. 
In order to generate a CTL line for this epitope, splenocytes from HLA-DR3 mice immunized 
with the synthetic peptide were restimulated with irradiated EL4/NY-BR-1 transfectant clone 
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D8P3 along with irradiated syngeneic feeder cells. EL4/NY-BR-1 transfectant clone D8P3 
should have been ideal for restimulation of CD8+ T cells as they do not express MHC II (even 
under IFNγ stimulation). Still, this restimulation protocol resulted in selective expansion of 
CD4+ T cells (Figure 18C) which was unexpected. A possible explanation could be that 
irradiated D8P3 which were added as stimulator cells released NY-BR-1 specific processed 
CD4+ T cell epitopes while they died and this was binding to the HLA-DR3 molecules of the 
feeder cells. Since peptide #6 is contained within an HLA-DR3 epitope (peptide #9017); 
peptide #6 might represent the core sequence of #9017 and could bind to HLA-DR3 on 
remaining feeder cells and stimulate the CD4+ T cells to secrete IFNγ (Figure 18C, D). The 
MHC II molecules binds peptides with a length of approx. 15 amino acids that associate 
through a core sequence of about nine residues with the allele specific peptide binding 
groove (59, 62). Surprisingly, CD8+ T cells labeled with the NY- NR-1specifc H2-Db-
dextramer that were sorted still developed into a mixed culture of CD8+ and CD4+ T cells. 
These cell lines were obtained from C57BL/6 mice immunized with Ad.NY-BR-1 and 
stimulated with feeder cells from C57BL/6 mice and irradiated D8P3 cells and it was not 
expected that CD4
+
 T cells could be stimulated by the 9 mer core sequence presented on I-
Ab molecule. Therefore, it can be assumed that peptide #6 binds not only the HLA-DR3 
molecule, but also to the I-Ab molecule. T cell epitopes that are restricted by various MHC 
molecules and are thus called promiscuous T cell epitopes have been described previously 
for both MHC I (263) and MHC II (264, 265) molecules. Promiscuous T cell epitopes can also 
bind different MHC molecules from different species as demonstrated by the identification of 
a Trp2 epitope which is restricted by both, the human HLA-A*0201 and the murine H2-Kb 
molecule (263). Similar cross-species MHC II binding epitopes have been identified for 
malarial parasite derived protein (266). Promiscuous CD4+ T cell epitopes (267) are frequent 
among HLA-DR restricted epitopes because the allele specific binding motifs of MHC II 
molecules are more degenerated compared to that of the MHC I system (59, 62). Thus, 
passively released epitopes from irradiated D8P3 cells might have been presented in the 
context of I-Ab by irradiated feeder cells, thereby predominantly stimulating CD4+ T cells 
among the responding splenocytes. Regarding the CTL responses against peptide #6, 
binding affinity of this peptide had been determined in peptide binding assays to be quite 
high (Figure 20A) meaning that even small amounts of passively released epitopes could 
have been mutually presented by H2Db- molecules expressed on CTLs and feeder cells 
possibly resulting in overstimulation of the antigen specific CD8
+
 T cells and finally in their 
activation induced cell death (AICD) (268, 269). 
6.1.4 First NY-BR-1 expressing tumor model 
We successfully established what is to our best knowledge, the first NY-BR-1 expressing 
tumor model. We could demonstrate that NY-BR-1 expressing tumors could elicit an immune 
response against already published HLA-DR4- restricted CD4+ T cell epitopes and the newly 
identified H2-Db-resctricted CD8+ T cells epitopes (Figure 25). Thus, this model would allow 
the investigation of NY-BR-1 as a candidate for therapeutic vaccination approaches like DC 
vaccination, peptide vaccination or adenovirus immunization. We already demonstrated that 
immunization with Ad.NY-BR-1 successfully induced anti-tumor immunity and was able to 
suppress tumor growth when immunization was performed before tumor inoculation (Figure 
29). Our model can also be used to ascertain the efficacy of adenovirus immunization 
against NY-BR-1 in mice with pre-existing tumors. The success of such therapeutic 
immunization has clinical implications as recombinant adenoviral vectors have been safely 
Discussion Page 126 
 
used as vaccines against prostate cancer (270, 271) and tuberculosis (272) and this would 
pave the way for the trial of adenoviral vaccines against breast cancer.  
We also established EONY MHC I KO cells which could act as parental lines for transfection 
of human MHC I molecules. For example, these cells transfected to express the HLA-A2 
molecule could be used to transplant HLA-transgenic mice which co-express HLA-A2 and 
HLA-DR4 (273) and the effect of peptide vaccination using previously identified HLA-A2 
restricted CD8+ T cell epitopes (101) and HLA-DR4 restricted CD4+ T cell epitopes (102) 
could be investigated. This would not only allow us to evaluate the potential of peptide 
vaccination strategies in NY-BR-1 positive patients but also allow us to study the synergistic 
effect of NY-BR-1 specific CD8+ and CD4+ T cells in controlling NY-BR-1 expressing tumors. 
Peptide vaccination studies using synthetic long peptides which induce both CD4+ and CD8+ 
T cell response have been shown to perform better than short peptide vaccines which only 
induce CTL response (119) as CD4
+
 T cell derived IL-2 might break tolerance against self-
antigen, allowing enhanced anti-tumor effect of CD8+ T cells (210). CD4+ T cells not only 
support CD8
+
 T cell function by facilitating secondary expansion and memory formation (103, 
274), but also are capable of mediating tumor rejection by mechanisms independent of CD8+ 
T cell function (275, 276). Besides T cells, NK cells also demonstrate cytotoxic effects on 
tumor cells as MHC I downregulation is a commonly observed phenomena in malignant cells 
of various tumor types including melanoma, colorectal carcinoma, cervical carcinoma and 
small cell lung carcinoma which allows them to evade T cell mediated destruction (277, 278) 
but make them susceptible to NK cells (226). The MHC I knockout cells we generated were 
also susceptible to NK cell recognition (Figure 16B, C) thereby allowing us to use this model 
for studying the role of NK cell mediated response in breast cancer. EO771 cells have been 
used for orthotopic transplantation of breast cancer (279, 280). However, we were unable to 
establish an orthotopic mouse model due to the development of necrosis. Thus, we adopted 
subcutaneous injection in the right flank as a lot of other tumor models including those for 
pancreatic cancer and colorectal cancer also rely on non-orthotopic tumor transplantation. 
6.2 Modulation of macrophages by CD4+ T cells 
6.2.1 EONY tumors are highly infiltrated by TAMs 
Breast cancer is known to be highly infiltrated with macrophages which generally correlated 
with poor prognosis (191, 193-195, 281). In our model we saw similar results and 
macrophages were the most abundant population among tumor-infiltrating leukocytes. We 
observed that more than 40% of all CD45+ cells within the tumor were in fact CD11b+F4/80+ 
macrophages and in some cases the percentage was as high as 70% (Figure 26B). Similar 
infiltration levels have been reported in transplanted 4T1 tumor cells which are of BALB/c 
origin and CD11b+ cells constituted up to 86% of tumor infiltrating leukocytes (282). This was 
in contrast to another study which showed that TAMs make about 33% of CD45+ cells in 
EO771 tumors; although it is important to keep in mind they defined macrophages by another 
set of markers (283). Whereas the proportion of macrophages in the spontaneous model of 
breast cancer MMTV PYMT was reported to be 80% of CD45+ cells (283) which again is in 
contrast to the reported proportion of TAMs in large PyMT tumors which are infiltrated with 
approximately 40% TAMs (284) which is again using another set of markers. 
It appears interesting that the EONY tumors had a higher frequency of infiltrating 
macrophages compared to EO771 tumors (Figure 26B). The percentage of infiltrating TAMs 
have been shown to increase with increasing tumor size in the MMTV-PyMT tumor model 
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(284); however, we saw the reverse trend as smaller EONY tumors had larger proportions of 
infiltrating TAMs (Figure 26B), even though we could not find a significant correlation 
between tumor size and percentage of TAMs. EONY tumors were not only immunogenic and 
induced antigen specific CD8+ T cell response (Figure 25) but also recruited more 
macrophages into the tumor (Figure 26B). Interestingly, successful vaccination using SLP 
against HPV 16 derived E7 induced regression of TC-1 tumors and was accompanied by 
enhanced infiltration of antigen specific CTLs and macrophages (285). The increased 
macrophage recruitment into the shrinking tumors was dependent on CD8+ T cells and could 
be abrogated by depleting the CD8+ T cells with antibody (285). Another vaccination 
approach in the same tumor model showed increased macrophage infiltration following 
vaccination and demonstrated that T cell infiltration follows myeloid cells (286). Both studies 
highlighted the importance of the recruited macrophages in mediating tumor regression as 
disruption of CSF-1R signaling abolished the efficacy of the vaccine (285, 286). In our model 
as well, immunization with adenovirus not only suppressed tumor growth but also induced an 
M1-like phenotype among TAMs and resulted in upregulation of HLA-DR4 expression levels 
on intratumoral macrophages (Figure 30A). Antigen specific CD4
+
 T cells were also induced 
in NY-BR-1 expressing tumor bearing mice and they have been reported to activate TAMs in 
the tumor microenvironment to upregulate MHC II (209, 215) which might explain why the 
TAMs in the EONY tumors resembled a more M1-like phenotype compared to those from 
parental TAMs (Figure 30A, B).   
6.2.2 Modulation of macrophages by NY-BR-1 specific CD4+ T cells 
As mentioned earlier, intratumoral accumulation of TAMs is associated with bad prognosis; 
hence TAMs have emerged as a target for anti-cancer therapies (287). Therapeutic targeting 
of TAMs relies on blockage of their recruitment into the tumor as well as their elimination, or 
on their re-polarization towards a less immunosuppressive phenotype (287). It has been 
shown in a myeloma model that tumor infiltrating macrophages isolated from murine multiple 
myeloma cell line (MOPC) derived tumors could activate proliferation of CD4+ T cells when 
co-cultured with tumor antigen specific CD4
+
 T cells. These results indicate that the TAMs 
had taken up the tumor antigen in vivo and could present tumor antigen derived epitopes to 
the CD4+ T cells in the context of MHC II (209, 214). The tumor antigen in this model was the 
idiotype specific (Id) peptide from the secreted immunoglobulin (Ig) L chain V region. The 
activated CD4
+
 T cells secreted IFNγ which in turn activated the macrophages resulting in 
upregulation of MHC II on the TAMs (214) thereby enhancing their tumor-suppressive 
properties (209). 
In our model we wanted to investigate if NY-BR-1 specific CD4+ T cells would also recognize 
NY-BR-1 antigen derived epitopes presented in the context of MHC II molecules on the 
surface of TAMs isolated from NY-BR-1 expressing tumors. However, in our model, CD11b
+
 
cells isolated from NY-BR-1 expressing EONY #17 tumors did not stimulate NY-BR-1 
specific CD4+ T cells to a higher extent compared to those derived from parental tumors 
devoid of NY-BR-1 expression (Figure 31). This was not due to the lack of sufficient HLA-
DR4 expression on cell surface, as the addition of the peptide to the co-culture effectively 
stimulated the CD4+ T cells to secrete IFNγ (Figure 31). This does not necessarily mean that 
NY-BR-1 was not taken up by the TAMs, processed and presented on their cell surface. The 
half-life of peptide-MHC II complex can vary a lot and it has been reported that the half-life of 
HLA-DR*0401 binding to various HLA-DR4*0401- restricted epitopes varied between 1 hour 
to several days (288, 289). Importantly, immune-dominant peptide/HLA-DR4 complexes are 
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described to have a dissociation half-life varying between 1 hour to several days, whereas 
non-immunodominant ones showed a dissociation half-life of less than 30 minutes at 37°C 
(288, 289). The prediction algorithm NetMHCII (290, 291) generates predicted IC50 values (in 
nM) as a measure of binding affinities of peptides to different MHC molecules. IC50 is the 
concentration of the query peptide (in this case the epitope) which inhibits 50% of a 
reference peptide binding. Peptides with binding affinities of less than 50nM are considered 
to be strong binding peptides (292) since those peptides are more likely to remain bound to 
the MHC molecule. Using the NetMHCII algorithm, the binding affinities of the CD4+ T cell 
epitopes for peptides #8862 and #9251 to the HLA-DR*0401 molecule were predicted to be 
1200 nM and 340 nM, respectively (290, 291) indicating that the half-lives of these peptide-
MHC complexes were likely to be short as well. In our model the sample preparation 
included enzymatic digestion of 1 hour followed by mechanical disruption, Ficoll gradient 
density centrifugation and MACS isolation which summed up to approximately 3-4 hours. 
Thus, the TAMs were not in contact with the dying tumor cells during the final 2-3 hours of 
sample preparation and there were no peptides to replace the ones exiting the pMHC 
complex. Since empty MHC molecules (MHC molecules not bound to peptides) are known to 
be internalized quickly (293), one possible explanation might be that the empty MHC II 
molecule was internalized during sample preparation. 
Another reason for lack of TAM recognition by NY-BR-1 specific CD4
+
 T cells could be that 
the density of HLA-DR4 molecules presenting the antigenic epitope was too low. 
Furthermore, the affinity of the CD4+ T cell lines employed might have been insufficient. We 
showed for both CD4+ T cell lines tested, that peptide concentration below 50 ng/ml was 
insufficient to induce an IFNγ response (Figure 23B). It has been shown that secreted 
antigen is better than non-secreted antigen for antigen uptake by TAMs resulting in activation 
of CD4+ T cells (215) as high concentration of the tumor specific antigen facilitates its uptake. 
If NY-BR-1 expression was indeed lost in vivo and antigen negative breast cancer cells 
dominated the tumor, the local concentration of NY-BR-1 would not have been enough for 
TAMs to take it up.  
To circumvent the aforementioned issues, we used in vitro polarized PECs loaded with 
synthetic peptide or tumor cell lysates as a surrogate for tumor infiltrating TAMs to study the 
effect of antigen specific interaction with CD4+ T cells. We demonstrated that interaction of 
M2-polarized macrophages co-cultured with NY-BR-1 specific CD4+ T cells could re-polarize 
these macrophages towards an M1 like phenotype in vitro (Figure 32). This is in agreement 
with published reports which show that human M2 polarized macrophages loaded with 
synthetic peptide in vitro (213) or murine tumor infiltrating macrophages which have taken up 
antigen in vivo (214, 215) can be instructed by antigen specific CD4+ T cells to become less 
immunosuppressive as a result of IFNγ secretion by CD4+ T cells. It is important to keep in 
mind that only when soluble peptide was loaded onto the PECs, detectible levels of IFNγ 
were secreted by our CD4+ T cell lines resulting in upregulation HLA-DR4 expression and 
enhanced iNOS production, as detected by FACS (Figure 32 A,C). However, when tumor 
lysates were used; neither IFNγ secretion nor any increase in surface expression of HLA-
DR4 or iNOS production could be detected (Figure32 A, C). Changes in macrophage 
polarization upon incubation with tumor lysates could only be seen at the transcriptional 
level. Tumor lysates comprise of other cellular proteins and the effective concentration of NY-
BR-1-specific CD4+ T cell epitopes within the lysates might have been below the detection 
limit of 50 ng/ml required for recognition by the NY-BR-1 specific CD4+ T cell lines (Figure 
23B). 
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Insufficient tumor uptake by macrophages can be overcome by the use of CD47 blocking 
antibody since CD47 which is also known as the ‗don‘t eat me signal‘ allows tumors to evade 
phagocytosis (294). The downside of using this antibody is that, in spite of enhanced 
phagocytosis of tumor cells, macrophages did not prime CD4+ T cells in the colon cancer 
model which was tested (294). Thus their capacity to present NY-BR-1 derived epitopes to 
CD4+ T cells would need to be established in our model. However, switch in polarization of 
TAMs loaded with EONY#17 lysates following interaction with CD4+ T cell lines #8862 and 
#9251 highlights two aspects, first the two epitopes are naturally processed in the EONY 
tumor cells or in the PECs after they had taken up the NY-BR-1 protein contained within the 
tumor lysates. Second, effective tumor lysis in vivo resulting in passive release of tumor 
antigen, might allow TAMs to take up and process NY-BR-1 protein and present epitopes to 
CD4+ T cells stimulating them to secrete IFNγ which in turn could start their repolarization 
process towards an M1-like phenotype. Thus, it might be necessary to increase local levels 
of antigen within the tumor for TAMs to take it up. For example, chemotherapy and radiation 
therapy has been shown to result in immunogenic cell death (295) which augments uptake of 
dying cells by antigen presenting cells (296). It has been demonstrated that low dose 
irradiation can also induce CTL against tumor antigens and when combined with Th1 therapy 
it had synergistic effects in controlling tumor growth (297). Hence it would be interesting to 
combine low dose irradiation and antigen specific CD4+ T cell therapy and study changes in 
TAM polarization. However, it should be kept in mind that low dose irradiation can reprogram 
TAMs towards an M1-like phenotype (150); thus, it would be necessary to delineate the 
contribution of irradiation and the antigen specific CD4+ T cells on the polarization of TAMs. 
Repolarization of TAMs using antigen specific CD4+ T cells might be interesting to study in a 
clinical setting as it might be superior to other approaches used for therapeutic targeting of 
TAMs. For example, blocking macrophage recruitment into the tumors using a CCL2 
blocking antibody was beneficial in the beginning and delayed tumor progression but resulted 
in aggressive metastasis following cessation of therapy (298) and did not show clinical 
benefit (201). Also, CSF1R antibody is known to deplete macrophages and was shown to be 
effective (199, 299). However, it has some undesirable side-effects like accumulation of pro-
tumorigenic neutrophils (300, 301).  Thus, it is better to re-program the macrophages than to 
just block their recruitment or deplete them completely and antigen specific CD4+ T cells 
might be able to do so. 
6.2.3 Depletion of CD4+ T cells 
We could show that peptide/tumor lysate loaded M2-polarized PECs could be re-polarized in 
vitro upon interaction with NY-BR-1 specific CD4+ T cells and there are published reports 
documenting the role of antigen specific CD4+ T cells in repolarizing TAMs (209, 214). Thus 
we hypothesized that antigen specific CD4
+
 T cells induced by immunization were 
responsible for the shift in polarization towards M1 like TAMs and that depleting them should 
counteract the positive effect of adenovirus immunization (Figure 30). However, we observed 
that depletion of CD4+ T cells in mice immunized with Ad.NY-BR-1 prior to tumor cell 
injection, resulted in an even less immunosuppressive TAM phenotype. This was unexpected 
because in our model we saw that immunization with adenovirus resulted in antigen specific 
response including NY-BR-1 specific CD4+ effector T cells (Figure 20F), which was 
accompanied by upregulation of M1-associated markers (Figure 33 D,E). However tumor 
derived factors like VEGFA, IL-10 and PGE2 can induce the expression of FasL on tumor 
endothelium which results in the selective killing of T effector cells but not of Tregs (302). 
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This prevents infiltration of effector T cells in the tumor while Tregs preferentially accumulate 
in the tumor (302). The strong tumor-suppressive effects of CD4+ T cell depletion in our study 
suggests that majority of the CD4+ T cells in our model might have had tumor-promoting 
properties. Thus, failure of immunization induced CD4+ T cells to infiltrate the tumor might 
explain why CD4+ T cell depletion inhibited tumor progression irrespective of successful 
immunization. Besides Tregs, Th2 cells have been described to have tumor promoting 
activity as well. For example, the mammary tumors of MMTV-PyMT mice were shown to be 
infiltrated with IL-4 producing Th2 cells which can induce M2-like phenotype in the TAMs 
thereby promoting metastasis (303). Antibody mediated elimination of CD4+ T cells in a 
melanoma model resulted in abolishment of Th2 cytokines but not Th1 cytokines in the tumor 
and was accompanied by enhanced anti-tumor immunity (304). Additionally, anti-CD4 
antibody can also deplete immunosuppressive CD4 expressing regulatory T cells which can 
be recruited by CCL22 and result in poor prognosis (305). Antibody mediated depletion of 
CD4
+
CD25
+
Foxp3
+
 Tregs and a subset of pDCs which is known to have immunosuppressive 
phenotype has been reported to result in delayed tumor growth (306). In this case however, 
the anti-tumor effect was mediated by CD8
+
 T cells (306). Depletion of intratumoral 
CD4+CD25+ T cells during effector phase can cause tumor regression possibly via depletion 
of IL-10 and TGF-β in the tumor (307). Another study underscoring the immunosuppressive 
role CD4+ T cells in breast cancer showed that inhibiting the recruitment of naïve CD4+ T 
cells which eventually differentiate into Tregs resulted in delayed tumor growth (308).Taken 
together, it can be concluded that CD4+ T cells infiltrating EONY tumors have 
immunosuppressive properties. 
The impact of CD4+ T cell infiltration on breast cancer prognosis depends on their phenotype. 
Th1 cells which can produce Th1 cytokines like IFNγ are normally associated with successful 
anti-tumor immunity by enhancing the performance of CD8+ T cells (309) or by directly 
suppressing tumor cell growth (310). In breast cancer, high Treg infiltration usually correlates 
with poor prognosis (83, 305, 311, 312) due to their immunosuppressive phenotype. There 
are exceptions where high infiltration of Foxp3+ Tregs in breast cancer specimen was 
accompanied by elevated number of CD8+ TILs and correlated with good prognosis (84). Th2 
cells have an immunosuppressive phenotype and promote tumor metastasis by inducing M2-
like TAMs (303). However, a recent study showed that adoptively transferred Th2 cells can 
lead to tumor regression (313). Thus, detailed characterization of CD4+ T cell phenotype and 
their function in tumor progression needs to be done before targeting CD4+ T cells for 
depletion as a strategy for cancer therapy. In our model, the endogenous T cells seemed to 
have tumor promoting Th2 like phenotype as their abrogation resulted in less aggressive 
tumor growth and the infiltrating macrophages resembled M1-like macrophages. 
6.3 Summary and outlook 
To summarize, we could successfully generate the first NY-BR-1 expressing transplantable 
tumor model in which we could validate the newly identified CD8+ T cell epitopes and the 
already known CD4+ T cells. We also generated MHC I knockout cell lines which would allow 
us to study NK cells mediated immune responses and the synergism between CD4+ and 
CD8+ T cells following peptide vaccination. We showed the efficacy of adenovirus 
immunization in generating a CD8
+
 and CD4
+
 T cell response, in controlling tumor growth 
and in repolarizing TAMs. In vitro studies with PECs showed that CD4+ T cells can re-
polarize M2-like macrophages loaded with the cognate peptide but we could not demonstrate 
the same effect in vivo. 
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